ID,SMILES,pIC50,bioactivity,bioactivity1,TARGET,ASSAY_DESCRIPTION,YEAR
CHEMBL101907,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cc(C)cc(Br)c1)Oc1ccccc1-3,5.91,group4-ia,ia,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL101914,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccccc1)Oc1ccccc1-3,6.13,group3-int,int,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL102403,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(C)cc1)Oc1ccccc1-3,5.91,group4-ia,ia,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL102541,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cc(Cl)cc(Cl)c1)Oc1ccccc1-3,5.96,group4-ia,ia,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL102720,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)c(C)c1)Oc1ccccc1-3,5.85,group4-ia,ia,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL102754,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)c(F)c1)Oc1ccccc1-3,5.66,group4-ia,ia,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL103,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,7.86,group2-a,a,Androgen Receptor,Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay,2019
CHEMBL103092,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(C)c(F)c1)Oc1ccccc1-3,5.91,group4-ia,ia,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL103232,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Br)cc1)Oc1ccccc1-3,6.32,group3-int,int,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL10560,CC#C[C@@]1(O)CC[C@@]2(CC)c3ccc(O)cc3CC[C@@H]2C1,6.38,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2009
CHEMBL1082407,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,6.67,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL1082780,O=S(=O)(Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1)c1ccsc1,5.6,group4-ia,ia,Androgen Receptor,Binding affinity to AR,2010
CHEMBL1083783,O=S(=O)(Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1)c1ccccc1,5.2,group4-ia,ia,Androgen Receptor,Binding affinity to AR,2010
CHEMBL1084013,COc1cccc(S(=O)(=O)Nc2ccc(-c3ccc4c(cnn4-c4ccc(F)cc4)c3)c(C(F)(F)F)c2)c1,5.5,group4-ia,ia,Androgen Receptor,Binding affinity to AR,2010
CHEMBL1084014,O=S(=O)(Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1)c1cccc(C(F)(F)F)c1,5.4,group4-ia,ia,Androgen Receptor,Binding affinity to AR,2010
CHEMBL1084360,CS(=O)(=O)Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,5.3,group4-ia,ia,Androgen Receptor,Binding affinity to AR,2010
CHEMBL1084632,CCCS(=O)(=O)Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,5.5,group4-ia,ia,Androgen Receptor,Binding affinity to AR,2010
CHEMBL1084843,CSc1ccc(CN2CC(C)(C)[C@@H](Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)cc1,6.5,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human AR expressed in baculovirus Sf9 cells system by scintillation counting,2010
CHEMBL1085380,CCCNS(=O)(=O)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,5.2,group4-ia,ia,Androgen Receptor,Binding affinity to AR,2010
CHEMBL1085381,CC(C)CNS(=O)(=O)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,5.2,group4-ia,ia,Androgen Receptor,Binding affinity to AR,2010
CHEMBL1085593,CC1(C)CN(Cc2ccccc2)C(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,7,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human AR expressed in baculovirus Sf9 cells system by scintillation counting,2010
CHEMBL1085594,N#Cc1ccc(Oc2ccc(F)cc2F)cc1C(F)(F)F,7.22,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells coexpressing MMTV-ARE reporter gene assessed as inhibition of DHT-induced response,2010
CHEMBL1085625,CCS(=O)(=O)Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,5.3,group4-ia,ia,Androgen Receptor,Binding affinity to AR,2010
CHEMBL1085819,CC1(C)CN(Cc2ccccc2F)C(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,7.36,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells coexpressing MMTV-ARE reporter gene assessed as inhibition of DHT-induced response,2010
CHEMBL1085853,CCNS(=O)(=O)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,5.5,group4-ia,ia,Androgen Receptor,Binding affinity to AR,2010
CHEMBL1085883,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccccc1,6.7,group3-int,int,Androgen Receptor,Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay,2010
CHEMBL1086086,O=S(=O)(NCCO)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,5,group4-ia,ia,Androgen Receptor,Binding affinity to AR,2010
CHEMBL1094797,CCCC1=C(C(=O)OCC)[C@H](c2ccnc3ccccc23)C(C#N)=C(C)N1,6.14,group3-int,int,Androgen Receptor,Inhibition of androgen receptor,2010
CHEMBL1095223,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1CCCNC(N)=O,6.1,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting,2010
CHEMBL1095224,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1CCCNS(N)(=O)=O,7.05,group2-a,a,Androgen Receptor,Antagonist activity at AR in bicalutamide-resistant human LNCAP cells assessed as effect on cell proliferation after 6 days,2010
CHEMBL1095862,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1CCCS(N)(=O)=O,6.4,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting,2010
CHEMBL1095863,CNS(=O)(=O)CCCN1C(=S)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)C1(C)C,6.72,group3-int,int,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as effect on cell proliferation after 6 days,2010
CHEMBL1095864,CN(C)S(=O)(=O)CCCN1C(=S)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)C1(C)C,5.43,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as effect on cell proliferation after 6 days,2010
CHEMBL1097751,CC1=C(C#N)[C@@H](c2ccc(F)cc2Cl)C(C(=O)OC(C)(C)C)=C(C)N1,6.61,group3-int,int,Androgen Receptor,Inhibition of androgen receptor,2010
CHEMBL1097855,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1CCS(N)(=O)=O,7.1,group2-a,a,Androgen Receptor,Antagonist activity at AR in bicalutamide-resistant human LNCAP cells assessed as effect on cell proliferation after 6 days,2010
CHEMBL1098171,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1CCCCS(N)(=O)=O,6.96,group3-int,int,Androgen Receptor,Antagonist activity at AR in bicalutamide-resistant human LNCAP cells assessed as effect on cell proliferation after 6 days,2010
CHEMBL1098173,Cc1cc(N2C(=O)C(C)(C)N(CCCS(N)(=O)=O)C2=S)ccc1C#N,6.52,group3-int,int,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as effect on cell proliferation after 6 days,2010
CHEMBL1098174,COc1cc(N2C(=O)C(C)(C)N(CCCS(N)(=O)=O)C2=S)ccc1C#N,5.72,group4-ia,ia,Androgen Receptor,Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting,2010
CHEMBL1099083,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)C)[C@@H]1c1cccc([N+](=O)[O-])c1,5.9,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor,2010
CHEMBL1099086,CC1(C)C(=O)N(c2ccc(C#N)c(Cl)c2)C(=S)N1CCCS(N)(=O)=O,7.92,group2-a,a,Androgen Receptor,Antagonist activity at AR in bicalutamide-resistant human LNCAP cells assessed as effect on cell proliferation after 6 days,2010
CHEMBL1099087,Cc1c(N2C(=O)C(C)(C)N(CCCS(N)(=O)=O)C2=S)ccc(C#N)c1C(F)(F)F,6.58,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting,2010
CHEMBL1099140,CN1C(=S)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)C1(C)C,7.82,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting,2010
CHEMBL1099141,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1CCCC(=O)O,6.4,group3-int,int,Androgen Receptor,Antagonist activity at AR in bicalutamide-resistant human LNCAP cells assessed as effect on cell proliferation after 6 days,2010
CHEMBL1099142,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1CCCC(N)=O,6.32,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting,2010
CHEMBL113332,COc1ccc(C=C2c3ccccc3C(=O)c3ccccc32)c(O)c1,6.63,group3-int,int,Androgen Receptor,Inhibition of R1881-induced full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct after 72 hrs by fluorescence assay,2018
CHEMBL1163598,Cc1ccc(C(=O)CC(Nc2ccc([N+](=O)[O-])cc2)c2cccc(F)c2)cc1,6.85,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc by luciferase reporter gene assay,2010
CHEMBL1163630,O=C(CC(Nc1ccc([N+](=O)[O-])cc1)c1ccco1)c1ccc(Cl)cc1,8.54,group1-p,p,Androgen Receptor,Binding affinity to androgen receptor,2010
CHEMBL1170,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,7.75,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting analysis,2013
CHEMBL117465,CC1=CC(C)(C)Nc2ccc(-c3cc(F)cc(C#N)c3)cc21,6.68,group3-int,int,Androgen Receptor,Cross-reactivity as binding to human androgen receptor (hAR),2000
CHEMBL1208805,C[C@]12CN(S(=O)(=O)c3ccc(F)cc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.27,group2-a,a,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1208812,C[C@]12CNC[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,6.89,group3-int,int,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1209236,Cn1c(C#N)ccc1-c1ccc(C(=O)C(C)(C)C)cc1,7,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor ligand binding domain by two hybrid assay,2010
CHEMBL1209298,Cn1c(C#N)ccc1-c1ccc(/C(=N\O)C(C)(C)C)cc1,6.78,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor ligand binding domain by two hybrid assay,2010
CHEMBL1209903,CCCN1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.85,group2-a,a,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1209904,CCC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,6.89,group3-int,int,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1209905,CC(C)C(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,5.79,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1209906,C[C@]12CN(C(=O)C3CC3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.16,group2-a,a,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1209970,C[C@]12CN(C(=O)c3ccccc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.27,group2-a,a,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1209971,CC(C)NC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,5.34,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1209972,C[C@]12CN(C(=O)Nc3ccccc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,6.91,group3-int,int,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1209973,CCOC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.19,group2-a,a,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1210033,CCCOC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.27,group2-a,a,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1210034,C[C@]12CN(C(=O)Nc3ccc(F)cc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,6.98,group3-int,int,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1210035,C[C@]12CN(S(C)(=O)=O)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,6.69,group3-int,int,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1210036,CCS(=O)(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.07,group2-a,a,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1210090,C[C@]12CN(S(=O)(=O)c3ccccc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7,group2-a,a,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1210091,C[C@]12CN(S(=O)(=O)c3ccccn3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,5.91,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1210150,C[C@]12CN(c3cccc(S(N)(=O)=O)c3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,6.47,group3-int,int,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1210151,C[C@]12CN(c3cccc(S(C)(=O)=O)c3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,6.82,group3-int,int,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1210152,C[C@]12CN(c3cc(Cl)ncn3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,6.98,group3-int,int,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1210214,C[C@]12CN(c3ncccn3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,6.42,group3-int,int,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1210783,C[C@]12CN(c3cccc(C(N)=O)c3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,8.13,group1-p,p,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1210840,CN1C(=O)[C@@]2(C)O[C@@](C)(C1=O)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,5.67,group4-ia,ia,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1210841,C[C@@]12O[C@@](C)(C(=O)N(CC3CC3)C1=O)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,5.48,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1210842,CC(C)OC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.92,group2-a,a,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1210843,CC(C)[N+]1([O-])C(=O)[C@@]2(C)O[C@@](C)(C1=O)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,5.3,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1210876,COc1ccc(C=C2c3cccc(Cl)c3C(=O)c3c(Cl)cccc32)cc1O,5,group4-ia,ia,Androgen Receptor,Inhibition of R1881-induced transcriptional activity of human AR V7 truncated mutant expressed in human PC3 cells harboring pGL3-ARR3tk-NLuc after 24 hrs by luciferase reporter gene assay,2018
CHEMBL1210878,COc1cccc(C=C2c3cccc(Cl)c3C(=O)c3c(Cl)cccc32)c1O,5,group4-ia,ia,Androgen Receptor,Inhibition of R1881-induced transcriptional activity of human AR V7 truncated mutant expressed in human PC3 cells harboring pGL3-ARR3tk-NLuc after 24 hrs by luciferase reporter gene assay,2018
CHEMBL1210907,CCNC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,6.5,group3-int,int,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1210908,CC(C)N1C(=O)[C@@]2(C)O[C@@](C)(C1=O)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.5,group2-a,a,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1210909,C[C@]12CN(O)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,6.74,group3-int,int,Androgen Receptor,Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay,2010
CHEMBL1210910,CON1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,6.75,group3-int,int,Androgen Receptor,Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay,2010
CHEMBL1210959,COc1ccc(C=C2c3cccc(Cl)c3C(=O)c3c(Cl)cccc32)c(OC)c1O,6.77,group3-int,int,Androgen Receptor,Inhibition of full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct assessed as reduction in R1881-induced secreted PSA level after 72 hrs by fluorescence assay,2018
CHEMBL1215403,COC(=O)C1=C(C)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,6.52,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,2010
CHEMBL1215406,CCCC1=C(C(=O)OC)C(c2ccccc2Cl)C(C#N)=C(C)N1,6.52,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,2010
CHEMBL1215480,CCCCC1=C(C(=O)OC)C(c2ccccc2Cl)C(C#N)=C(C)N1,6.05,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,2010
CHEMBL1215549,CCCC1=C(C(=O)OC)C(c2ccc(F)cc2Cl)C(C#N)=C(C)N1,7,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,2010
CHEMBL1215550,COC(=O)C1=C(C(F)(F)F)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,6.1,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,2010
CHEMBL1215552,COC(=O)C1=C(Cn2ccnc2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,5.41,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,2010
CHEMBL1215620,COC(=O)C1=C(Cn2cccn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,6.1,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,2010
CHEMBL1215621,COC(=O)C1=C(Cn2cncn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,5.34,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,2010
CHEMBL1215622,COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,5.57,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,2010
CHEMBL1215623,COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)[C@H]1c1ccc(F)cc1Cl,6.52,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,2010
CHEMBL121626,Cc1c(Cl)cccc1Nc1ccccc1C(=O)O,4.33,group4-ia,ia,Androgen Receptor,Activity at androgen receptor ligand binding domain assessed as inhibition of SRC2-3 interaction after 2 hrs by fluorescence polarization assay,2007
CHEMBL1253831,C[C@@]1([C@H]2CC[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@@]32C)CC=CC(=O)N1,5.52,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay,2010
CHEMBL1253832,C[C@@]1([C@H]2CC[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@H]4CC[C@@]32C)CC=CC(=O)N1,6.3,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay,2010
CHEMBL1254922,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC[C@@H]2[C@@]1(C)CC=CC(=O)N1,5.7,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay,2010
CHEMBL1255008,C[C@]12CC[C@H]3[C@@H](CC=C4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2[C@@]1(C)CC=CC(=O)N1,5.7,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay,2010
CHEMBL1274,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,8.05,group1-p,p,Androgen Receptor,Inhibition of [3H]mibolerone binding to human Androgen receptor of PC3/AR Cell Lysate,2004
CHEMBL1276308,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,7.64,group2-a,a,Androgen Receptor,Inhibition of human lymph node carcinoma of prostate (LNCaP) cell proliferation,2004
CHEMBL1288321,OC1(C(F)(F)F)CCCc2c1[nH]c1cc(Cl)c(Cl)cc21,7.57,group2-a,a,Androgen Receptor,Binding affinity to androgen receptor by fluorescence binding assay,2010
CHEMBL1288322,OC1(C(F)(F)F)CCCc2c1[nH]c1ccc(Cl)c(Cl)c21,7.02,group2-a,a,Androgen Receptor,Binding affinity to androgen receptor by fluorescence binding assay,2010
CHEMBL1288323,OC1(C(F)(F)F)CCc2c1[nH]c1c(Cl)cc(Cl)cc21,7.89,group2-a,a,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL1288956,Oc1cccc2c1[nH]c1ccc(Br)cc12,5.85,group4-ia,ia,Androgen Receptor,Binding affinity to androgen receptor by fluorescence binding assay,2010
CHEMBL1288957,N#Cc1ccc2[nH]c3c(O)cccc3c2c1,5.34,group4-ia,ia,Androgen Receptor,Binding affinity to androgen receptor by fluorescence binding assay,2010
CHEMBL1288958,Oc1c(Br)ccc2c1[nH]c1cc(Cl)c(Cl)cc12,7.47,group2-a,a,Androgen Receptor,Binding affinity to androgen receptor by fluorescence binding assay,2010
CHEMBL1288959,Oc1cccc2c1[nH]c1ccc(Cl)c(Cl)c12,7.82,group2-a,a,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL1288979,OC1(C(F)(F)F)CCCc2c1[nH]c1c(Cl)cc(Cl)cc21,7.47,group2-a,a,Androgen Receptor,Binding affinity to androgen receptor by fluorescence binding assay,2010
CHEMBL1288980,OC1(C(F)(F)F)CCCc2c1[nH]c1c(Cl)ccc(Cl)c21,7.07,group2-a,a,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL1288981,OC1(C(F)(F)F)CCCc2c1[nH]c1c(Cl)cc(F)cc21,7.05,group2-a,a,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL1289012,CC1(O)CCCc2c1[nH]c1ccc(C#N)cc21,5.04,group4-ia,ia,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL1289013,N#Cc1ccc2[nH]c3c(c2c1)CCCC3(O)C(F)(F)F,6.32,group3-int,int,Androgen Receptor,Binding affinity to androgen receptor by fluorescence binding assay,2010
CHEMBL1289887,CC1(C)C(=O)N(c2ccc(C#N)c(Cl)c2)C(=S)N1c1cccc(S(N)(=O)=O)c1,6.4,group3-int,int,Androgen Receptor,Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay,2010
CHEMBL1289999,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1cccc(S(N)(=O)=O)c1,7,group2-a,a,Androgen Receptor,Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days,2010
CHEMBL1290000,CC1(C)C(=O)N(c2ccc(C#N)c(Cl)c2)C(=S)N1c1cccc(S(N)(=O)=O)n1,6.22,group3-int,int,Androgen Receptor,Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay,2010
CHEMBL1290098,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1cccc(S(N)(=O)=O)n1,6.16,group3-int,int,Androgen Receptor,Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay,2010
CHEMBL1290099,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccnc(S(N)(=O)=O)c1,6,group3-int,int,Androgen Receptor,Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay,2010
CHEMBL1290206,CC1(C)C(=O)N(c2ccc(C#N)c(Cl)c2)C(=S)N1c1cncc(S(N)(=O)=O)c1,5.7,group4-ia,ia,Androgen Receptor,Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay,2010
CHEMBL1290207,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1cncc(S(N)(=O)=O)c1,7.52,group2-a,a,Androgen Receptor,Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days,2010
CHEMBL1290632,OC1(C(F)(F)F)CCCCc2c1[nH]c1c(Cl)cc(Cl)cc21,6.22,group3-int,int,Androgen Receptor,Binding affinity to androgen receptor by fluorescence binding assay,2010
CHEMBL1290633,OC1(C(F)(F)C(F)(F)F)CCCc2c1[nH]c1cc(Cl)c(Cl)cc21,7.47,group2-a,a,Androgen Receptor,Binding affinity to androgen receptor by fluorescence binding assay,2010
CHEMBL1290751,OC1(C(F)(F)F)c2[nH]c3c(Cl)cc(Cl)cc3c2CCC1(F)F,7,group2-a,a,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL1302748,COc1cc(C2Nc3cccc4cccc(c34)N2)ccc1O,4.48,group4-ia,ia,Androgen Receptor,Displacement of SRC2-3 peptide from human AR ligand binding site expressed in Escherichia coli BL21 by AF2 FP assay,2011
CHEMBL131,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,4.47,group4-ia,ia,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human LNCaP cells after 1440 mins by scintillation counting method,2018
CHEMBL131681,CC1(C)Nc2ccc(-c3csc(C#N)c3)cc2C(C)(C)C1=O,5.96,group4-ia,ia,Androgen Receptor,Cross-reactivity as binding to human androgen receptor (hAR),2000
CHEMBL131855,CC1=CC(C)(C)Nc2ccc(-c3sc(C#N)cc3C)cc21,6.7,group3-int,int,Androgen Receptor,Cross-reactivity as binding to human androgen receptor (hAR),2000
CHEMBL131963,Cc1c2c(cc3c(C(F)(F)F)cc(Cl)nc13)C(C)CC(C)(C)N2,6.17,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL132193,CC1=CC(C)(C)Nc2ccc(-c3ccc(C#N)s3)cc21,5.96,group4-ia,ia,Androgen Receptor,Cross-reactivity as binding to human androgen receptor (hAR),2000
CHEMBL132205,CC1(C)CCc2cc3c(C(F)(F)F)cc(C(F)(F)F)nc3cc2N1,6.33,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL132295,CCCC[S+]([O-])c1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,6.47,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL132354,CC1(C)CCc2cc3c(C(F)(F)F)cc(SCC(F)(F)F)nc3cc2N1,6.05,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL132363,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ncccc1C)Oc1ccc(F)cc1-3,6.69,group3-int,int,Androgen Receptor,Inhibition of human androgen receptor at 10e-12 to 10e-5 M,2003
CHEMBL132427,CN1c2cc3nc(C#N)cc(C(F)(F)F)c3cc2CCC1(C)C,7.35,group2-a,a,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL132516,CC1=CC(C)(C)N(C)c2cc3nc(Cl)cc(C(F)(F)F)c3cc21,6.47,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL132609,CN1c2cc3nccc(C(F)(F)F)c3cc2CCC1(C)C,6.14,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL132635,CC1(C)CCc2cc3c(C(F)(F)F)cc(S(C)(=O)=O)nc3cc2N1,6.32,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL132803,CC1=CC(C)(C)Nc2cc3nc(F)cc(C(F)(F)F)c3cc21,7.51,group2-a,a,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL132889,Cc1cc(C#N)sc1-c1ccc2c(c1)C(C)(C)C(=O)C(C)(C)N2,6.82,group3-int,int,Androgen Receptor,Cross-reactivity as binding to human androgen receptor (hAR),2000
CHEMBL133054,Cc1c2c(cc3c(C(F)(F)F)ccnc13)C(C)CC(C)(C)N2,6.61,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL133167,CN1c2cc3nc(Br)cc(C(F)(F)F)c3cc2CCC1(C)C,7.14,group2-a,a,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL133289,CN1c2cc3nc(Cl)cc(C(F)(F)F)c3cc2CCC1(C)C,6.6,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL133329,CC1(C)CCc2cc3c(C(F)(F)F)cc(N)nc3cc2N1,5.94,group4-ia,ia,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL133331,CC1=CC(C)(C)Nc2cc3nc(Cl)cc(C(F)(F)F)c3cc21,7.52,group2-a,a,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL133465,CN1c2cc3nc(F)cc(C(F)(F)F)c3cc2CCC1(C)C,6.76,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL133503,CC1(C)CCc2cc3c(C(F)(F)F)cc(F)nc3cc2N1,7.66,group2-a,a,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL133656,CC1=CC(C)(C)Nc2ccc(-c3ccc([N+](=O)[O-])s3)cc21,5.84,group4-ia,ia,Androgen Receptor,Cross-reactivity as binding to human androgen receptor (hAR),2000
CHEMBL133715,CCCCSc1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,5.73,group4-ia,ia,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL133792,CC1(C)CCc2cc3c(C(F)(F)F)cc(Cl)nc3cc2N1,7.52,group2-a,a,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL133825,Cc1c2c(cc3c(C(F)(F)F)cc(F)nc13)C(C)CC(C)(C)N2,5.84,group4-ia,ia,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL134056,Cc1c2c(cc3c(C(F)(F)F)cc(Br)nc13)C(C)CC(C)(C)N2,6.11,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL134117,COc1ccc(CNc2cc(C(F)(F)F)c3cc4c(cc3n2)NC(C)(C)CC4)cc1,5.49,group4-ia,ia,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL134140,CC1(C)CCc2cc3c(C(F)(F)F)cc(Br)nc3cc2N1,7.14,group2-a,a,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL134180,CC1(C)CCc2cc3c(C(F)(F)F)cc(NS(C)(=O)=O)nc3cc2N1,6.3,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL134209,C[S+]([O-])c1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,7.2,group2-a,a,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL134242,CSc1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,6.12,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL134260,Cc1cc(C#N)sc1-c1ccc2c(c1)C(C)CC(C)(C)N2,7.35,group2-a,a,Androgen Receptor,Cross-reactivity as binding to human androgen receptor (hAR),2000
CHEMBL134277,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccsc1)Oc1ccc(F)cc1-3,6.67,group3-int,int,Androgen Receptor,Inhibition of human androgen receptor at 10e-12 to 10e-5 M,2003
CHEMBL134303,CC1(C)CCc2cc3c(C(F)(F)F)cc(N(S(C)(=O)=O)S(C)(=O)=O)nc3cc2N1,6.2,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL134421,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1ccccc1-3,6.19,group3-int,int,Androgen Receptor,Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells,1998
CHEMBL134602,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1ccc(F)cc1-3,6.19,group3-int,int,Androgen Receptor,Inhibition of human androgen receptor at 10e-12 to 10e-5 M,2003
CHEMBL135,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,7.72,group2-a,a,Androgen Receptor,Binding affinity to androgen receptor,2007
CHEMBL136322,CC1(C)OC(=O)Nc2ccc(-c3cc(F)cc(C#N)c3)cc21,5.89,group4-ia,ia,Androgen Receptor,Antagonist activity against the Androgen Receptor (AR),2002
CHEMBL137103,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cc(F)ccc1F)Oc1ccccc1-3,5.8,group4-ia,ia,Androgen Receptor,Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells,1998
CHEMBL1372017,Nc1nc(-c2ccc3ccccc3c2)cs1,5.04,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL138059,CC1(C)OC(=O)Nc2ccc(-c3coc(C#N)c3)cc21,6.89,group3-int,int,Androgen Receptor,Antagonist activity against the Androgen Receptor (AR),2002
CHEMBL1391700,Fc1ccc(-c2csc(N3CCOCC3)n2)cc1,6.19,group3-int,int,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL1393,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,6.28,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor,2010
CHEMBL139749,CC1(C)OC(=O)Nc2ccc(-c3csc(C#N)c3)cc21,6.55,group3-int,int,Androgen Receptor,Antagonist activity against the Androgen Receptor (AR),2002
CHEMBL139835,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,7.64,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL1403349,Fc1ccc(-c2csc(-c3ccncc3)n2)cc1,5.9,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL1416100,c1ccc(-c2csc(-c3ccncc3)n2)cc1,6.2,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL143978,COc1cccc2oc(-c3ccc(F)cc3)cc(=O)c12,5.79,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL146032,CC(=O)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C(F)(F)C(F)(F)F)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,7.27,group2-a,a,Androgen Receptor,In vitro antagonist potency in transactivation assay in CV-1 cells expressing androgen receptor,2000
CHEMBL146794,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)N1CCOCCOCc1ccc(O)c(C(N)=O)c1,7.11,group2-a,a,Androgen Receptor,Inhibition of 1.0 nM [3H]mibolerone binding to human androgen receptor of PC3/AR cell lysate,2003
CHEMBL146858,CC1(C)NC(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C1=O,8.22,group1-p,p,Androgen Receptor,Inhibition of [3H]mibolerone binding to human Androgen receptor of PC3/AR Cell Lysate,2004
CHEMBL1488607,Fc1ccc(-c2csc(N3CCSCC3)n2)cc1,5.8,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL150,O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,5.01,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,2009
CHEMBL1509,C[C@]12CC[C@H]3[C@H]([C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1C1=CC(=O)CC[C@@]13C,6.2,group3-int,int,Androgen Receptor,"Binding Assay: The test was carried out as in 1, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL151601,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)N1CC#CCOCc1ccc(O)c(C(N)=O)c1,7.31,group2-a,a,Androgen Receptor,Inhibition of 1.0 nM [3H]mibolerone binding to human androgen receptor of PC3/AR cell lysate,2003
CHEMBL1527972,Oc1ccc(C2Nc3cccc4cccc(c34)N2)cc1,4.51,group4-ia,ia,Androgen Receptor,Displacement of SRC2-3 peptide from human AR ligand binding site expressed in Escherichia coli BL21 by AF2 FP assay,2011
CHEMBL1549081,c1ccc(-c2csc(N3CCSCC3)n2)cc1,6.21,group3-int,int,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL156142,CC1CC(C)(C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,7.58,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL156278,CC1CC(C)(C)Nc2cc3c(cc21)c(C(F)(F)F)cc(=O)n3C,7.14,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL156312,CC12CCCN1c1cc3nc(O)cc(C(F)(F)F)c3cc1CC2,6.49,group3-int,int,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL1563710,c1ccc(OCCSc2nc3ccccc3[nH]2)cc1,5.37,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB assessed as reduction in PSA level after 3 days,2013
CHEMBL156641,C[C@H]1[C@@H](C)c2cc3c(C(F)(F)F)cc(O)nc3cc2NC1(C)C,6.79,group3-int,int,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL156751,CC(C)C1CC(C)(C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,6.8,group3-int,int,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL156806,CC1(C)Cc2cc3c(C(F)(F)F)cc(O)nc3cc2NC1(C)C,7.08,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL156982,CCC1CC(C)(C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,7.57,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL1572280,Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1,6.4,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL157344,CC1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC(C)(C)C1(C)C,7.24,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL157407,Cn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)N1CCCC1(C)CC3,7.57,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL157703,CC1=CC(C)(C)Nc2c1cc1c(C(F)(F)F)cc(O)nc1c2C,7.64,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL160230,CCC1(C)CCc2cc3c(C(F)(F)F)cc(=O)n(C)c3cc2N1C,7.62,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL160239,CCn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)NC(C)(C)C=C3C,6.16,group3-int,int,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL160250,CCC1(CC)CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,7.57,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL160257,C[C@@H]1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC(C)(C)[C@H]1C,5.15,group4-ia,ia,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL160386,CC1=CC(C)(C)Nc2cc3c(cc21)c(C(F)(F)F)cc(=O)n3C,7.47,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL160451,CC1=CC(C)(C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,7.55,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL160665,CC1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2NC1(C)C,7.52,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL160713,CCCC1(C)CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,7.38,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL160923,CC1=CC(C)(C)Nc2c1cc1c(C(F)(F)F)cc(=O)n(C)c1c2C,5.62,group4-ia,ia,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL161892,CN1c2cc3c(cc2[C@H]2CCCC[C@H]21)c(C(F)(F)F)cc(=O)n3C,7.44,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL161980,C[C@H]1CC[C@@H]2[C@H](C1)c1cc3c(C(F)(F)F)cc(=O)n(C)c3cc1N2C,7.27,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL162103,CN1CCc2cc3c(C(F)(F)F)cc(=O)n(C)c3cc21,6.71,group3-int,int,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL1623389,c1ccc(-c2csc(N3CCOCC3)n2)cc1,6.55,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL162368,CC1(C)CCC[C@@H]2c3cc4c(C(F)(F)F)cc(O)nc4cc3N[C@@H]21,7.58,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL162503,Cn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)NCC3,7.25,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL163142,CN1c2cc3c(cc2[C@H]2CCCC(C)(C)[C@H]21)c(C(F)(F)F)cc(=O)n3C,7.57,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL163143,CN1c2cc3c(cc2[C@@]2(C)CCCC[C@@H]12)c(C(F)(F)F)cc(=O)n3C,7.28,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL165219,C[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2C1(C)C,7.32,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL165803,C[C@H]1CC[C@H]2Nc3cc4c(cc3[C@H]2C1)c(C(F)(F)F)cc(=O)n4C,7.32,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL165912,CCCN1c2cc3c(cc2[C@H]2CCCC[C@H]21)c(C(F)(F)F)cc(=O)n3C,7.57,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL166323,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NCC3,7.64,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL166444,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3C=C[C@@]21C,9.52,group1-p,p,Androgen Receptor,Agonist activity at GAL4 DNA-binding domain fused androgen receptor (unknown origin) ligand binding domain expressed in UAS-bla GripTite 293 cells assessed as beta-lactamase transcriptional activation by FRET-based GeneBLAzer assay,2018
CHEMBL16685,COc1cccc2oc(-c3ccccc3)cc(=O)c12,5.06,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,2009
CHEMBL16807,O=c1cc(-c2ccccc2)oc2cccc(O)c12,6.08,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL16972,Cc1ccc(-c2cc(=O)c3c(O)cccc3o2)cc1,4.96,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL1738889,C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,8.42,group1-p,p,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL1738936,Cc1ccc(OCCn2c(SCCOc3ccccc3)nc3ccccc32)cc1,4.88,group4-ia,ia,Androgen Receptor,Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis,2011
CHEMBL1738937,Cc1ccc(OCCn2c(SCCC(=O)O)nc3ccccc32)cc1,4.3,group4-ia,ia,Androgen Receptor,Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis,2011
CHEMBL1782494,C[C@](O)(CS(=O)(=O)c1cccc2ccccc12)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,5.52,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor T877A mutant expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay,2011
CHEMBL1782495,C[C@](O)(CS(=O)(=O)c1ccccc1Cc1ccccc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,5.52,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor W741L mutant expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay,2011
CHEMBL1782496,C[C@](O)(CS(=O)(=O)c1ccccc1-c1ccccc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,5.52,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor T877A mutant expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay,2011
CHEMBL178333,O=C1[C@H]2C3CCC(C3)[C@H]2C(=O)N1c1ccc([N+](=O)[O-])c(C(F)(F)F)c1,7.92,group2-a,a,Androgen Receptor,Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay,2005
CHEMBL1783642,CC[Si](CC)(c1ccc(OCC(=O)C(C)(C)C)c(C)c1)c1ccc(OCC(=O)C(C)(C)C)c(C)c1,5.21,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay,2013
CHEMBL178469,O=C1[C@H]2C3C=CC(C3)[C@H]2C(=O)N1c1cccc(C(F)(F)F)c1,7.46,group2-a,a,Androgen Receptor,Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay,2005
CHEMBL178886,O=C1[C@H]2C3C=CC(C3)[C@H]2C(=O)N1c1cc(Cl)cc(Cl)c1,7.39,group2-a,a,Androgen Receptor,Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay,2005
CHEMBL178957,O=C1[C@H]2C3C=CC(C3)[C@H]2C(=O)N1c1cc(C(F)(F)F)cc(C(F)(F)F)c1,5.76,group4-ia,ia,Androgen Receptor,Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay,2005
CHEMBL1802077,COc1ccccc1C(=O)/C=C/c1ccccc1[N+](=O)[O-],6.12,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNCAP cells assessed as decrease in transmembrane protease serine 2 mRNA level after 20 hrs by real time RT-PCR analysis,2012
CHEMBL180681,Cc1cc(N2C(=O)[C@H]3C4C=CC(CC4)[C@H]3C2=O)ccc1Br,7.17,group2-a,a,Androgen Receptor,Inhibition of androgen receptor in human MDA-453 cells,2005
CHEMBL180859,O=C1[C@H]2C3C=CC(C3)[C@H]2C(=O)N1c1ccc(F)c(Cl)c1,7.48,group2-a,a,Androgen Receptor,Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay,2005
CHEMBL181674,O=C1[C@H]2C3C=CC(C3)[C@H]2C(=O)N1c1ccc2ccccc2c1,6.58,group3-int,int,Androgen Receptor,Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation,2005
CHEMBL181722,O=C1[C@H]2C3C=CC(C3)[C@H]2C(=O)N1c1ccc2cccnc2c1,5.98,group4-ia,ia,Androgen Receptor,Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay,2005
CHEMBL182186,O=C1[C@H]2C3C=CC(C3)[C@H]2C(=O)N1c1ccc([N+](=O)[O-])cc1,6.75,group3-int,int,Androgen Receptor,Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation,2005
CHEMBL1822155,COc1ccc(C2Nc3cccc4cccc(c34)N2)cc1O,5.09,group4-ia,ia,Androgen Receptor,Displacement of SRC2-3 peptide from human AR ligand binding site expressed in Escherichia coli BL21 by AF2 FP assay,2011
CHEMBL1822156,Oc1ccc(C2Nc3cccc4cccc(c34)N2)cc1O,4.51,group4-ia,ia,Androgen Receptor,Displacement of SRC2-3 peptide from human AR ligand binding site expressed in Escherichia coli BL21 by AF2 FP assay,2011
CHEMBL1822157,CC1=NN(c2ccccc2)C(=O)/C1=N\Nc1ccc(C(=O)O)c(O)c1,4.58,group4-ia,ia,Androgen Receptor,Displacement of SRC2-3 peptide from human AR ligand binding site expressed in Escherichia coli BL21 by AF2 FP assay,2011
CHEMBL182236,Cc1cc(N2C(=O)[C@H]3C4C=CC(C4)[C@H]3C2=O)ccc1Br,6.66,group3-int,int,Androgen Receptor,Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay,2005
CHEMBL182412,O=C1[C@H]2C3C=CC(CC3)[C@H]2C(=O)N1c1cccc(C(F)(F)F)c1,7.18,group2-a,a,Androgen Receptor,Inhibition of mutant T877A Androgen receptor in human LNCaP cells,2005
CHEMBL182593,O=C1[C@H]2C3C=CC(C3)[C@H]2C(=O)N1c1ccc(Cl)c(Cl)c1,7.39,group2-a,a,Androgen Receptor,Inhibition of mutant T877A Androgen receptor in human LNCaP cells,2005
CHEMBL182993,O=C1[C@H]2C3C=CC([C@@H]4C[C@H]34)[C@H]2C(=O)N1c1cccc(C(F)(F)F)c1,7.52,group2-a,a,Androgen Receptor,Inhibition of mutant T877A Androgen receptor in human LNCaP cells,2005
CHEMBL1830768,CC1(C)COC(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,6.95,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830769,CC1(C)COC(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,7.16,group2-a,a,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830770,CC1(C)COC(=O)[C@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,6,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor by cell based assay,2011
CHEMBL1830771,CC1(C)CNC(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,7.09,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor by cell based assay,2011
CHEMBL1830772,CN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,5.92,group4-ia,ia,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830773,CCN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,6.4,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830774,CCCN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,7.62,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor by cell based assay,2011
CHEMBL1830775,CCCCN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,8,group1-p,p,Androgen Receptor,Antagonist activity at human androgen receptor by cell based assay,2011
CHEMBL1830776,CCCCCN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,6.57,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830777,CCCCCCN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,6.12,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830778,CCCC(C)N1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,8.22,group1-p,p,Androgen Receptor,Antagonist activity at human androgen receptor by cell based assay,2011
CHEMBL1830779,CCC(C)N1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,7.5,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor by cell based assay,2011
CHEMBL1830780,CCC(CC)CN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,6.35,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830781,CC(C)CCCN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,6.1,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830782,COCN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,6.29,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830783,COCCN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,5.75,group4-ia,ia,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830784,CSCCN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,5.61,group4-ia,ia,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830785,CC1(C)CN(CCCO)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,6.28,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830786,COC(=O)CN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,6.52,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL1830787,CCOC(=O)CN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,5.45,group4-ia,ia,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830788,CCNC(=O)CN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,5.31,group4-ia,ia,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830789,CC1(C)CN(Cc2ccccc2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,7.96,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor by cell based assay,2011
CHEMBL1830937,COc1ccccc1CN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,6.53,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830938,COc1cccc(CN2CC(C)(C)C(Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)c1,6.96,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830939,COc1ccc(CN2CC(C)(C)C(Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)cc1,6.55,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830940,CC1(C)CN(Cc2ccccc2F)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,6.76,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830941,CC1(C)CN(Cc2cccc(F)c2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,7.21,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor by cell based assay,2011
CHEMBL1830942,CC1(C)CN(Cc2ccc(F)cc2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,6.84,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830943,CC1(C)CN(Cc2ccccc2O)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,7.77,group2-a,a,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830944,CC1(C)CN(Cc2cccc(O)c2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,7.96,group2-a,a,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830945,CC1(C)CN(Cc2ccc(O)cc2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,7.77,group2-a,a,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830946,CSc1ccc(CN2CC(C)(C)C(Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)cc1,7.29,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor by cell based assay,2011
CHEMBL1830947,CC1(C)CN(Cc2ccccn2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,6.12,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830948,CC1(C)CN(Cc2cccnc2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,6.06,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830949,CC1(C)CN(Cc2ccncc2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,6.89,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830950,CCOC(=O)c1ccc(CN2CC(C)(C)C(Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)o1,6.78,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830951,COC(=O)c1csc(CN2CC(C)(C)C(Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)n1,6.67,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830952,CC1(C)CN(Cc2nc3ccccc3s2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,7.29,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor by cell based assay,2011
CHEMBL1830953,Cc1nc(CN2CC(C)(C)C(Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)cs1,6.49,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2011
CHEMBL1830954,CC1(C)CN(Cc2noc(-c3ccccc3)n2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,7.4,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor by cell based assay,2011
CHEMBL1830955,CC1(C)CN(Cc2nc(-c3ccccc3)no2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,7.27,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor by cell based assay,2011
CHEMBL183173,CN1C(=O)C2C=CC1[C@@H]1C(=O)N(c3ccc([N+](=O)[O-])c4ccccc34)C(=O)[C@H]21,5.07,group4-ia,ia,Androgen Receptor,Inhibition of androgen dependent human prostate cancer cell MDA-MB-PCa2b proliferation,2005
CHEMBL1835807,CCN(CC)c1cc2oc(=O)ccc2cc1-c1ccccc1,5,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human recombinant androgen receptor-LBD expressed in Escherichia coli after 18 hrs by liquid scintillation counting,2011
CHEMBL1835832,CCN(CC)c1cc2oc(=O)ccc2cc1-c1cccs1,5.01,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human recombinant androgen receptor-LBD expressed in Escherichia coli after 18 hrs by liquid scintillation counting,2011
CHEMBL183882,O=C1[C@H]2C3CCCC(CC3)[C@H]2C(=O)N1c1cccc(C(F)(F)F)c1,6.18,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human MDA-453 cells,2005
CHEMBL184228,CC[C@H]1C[C@@]2(C)C(CC[C@@H]2O)C2CCC3=CC(=O)CCC3=C21,8.7,group1-p,p,Androgen Receptor,Inhibition of human androgen receptor expressed in Escherichia coli,2004
CHEMBL184313,CCCCC[C@H]1C[C@@]2(C)C(CC[C@@H]2O)C2CCC3=CC(=O)CCC3=C21,7.77,group2-a,a,Androgen Receptor,Inhibition of human lymph node carcinoma of prostate (LNCaP) cell proliferation,2004
CHEMBL184981,O=C1[C@H]2C3C=CC(CC3)[C@H]2C(=O)N1c1ccc(Cl)c(Cl)c1,6.82,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human MDA-453 cells,2005
CHEMBL185265,Cc1c(NS(C)(=O)=O)cccc1N(Cc1ccccc1)Cc1ccc(Oc2cccc(OCCCC(=O)NCCCC(=O)O)c2)cc1,5.8,group4-ia,ia,Androgen Receptor,Inhibition of human androgen receptor,2005
CHEMBL185880,O=C1[C@H]2[C@H]3CC[C@H](C3)N2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,5.89,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against androgen receptor of MDA-453 cells,2004
CHEMBL186254,CCCCCCCCCC[C@H]1C[C@@]2(C)C(CC[C@@H]2O)C2CCC3=CC(=O)CCC3=C21,7.77,group2-a,a,Androgen Receptor,Inhibition of human lymph node carcinoma of prostate (LNCaP) cell proliferation,2004
CHEMBL186467,CCCCCCCC[C@H]1C[C@@]2(C)C(CC[C@@H]2O)C2CCC3=CC(=O)CCC3=C21,7.77,group2-a,a,Androgen Receptor,Inhibition of human lymph node carcinoma of prostate (LNCaP) cell proliferation,2004
CHEMBL187605,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)N21,5.36,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against mutant androgen receptor of LNCap cells,2004
CHEMBL188129,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@@H]1C(=O)N(c3ccc([N+](=O)[O-])c4ccccc34)C(=O)N21,5.48,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against androgen receptor of MDA-453 cells,2004
CHEMBL188261,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@]1(C)C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)N21,6.11,group3-int,int,Androgen Receptor,In vitro antagonistic activity against androgen receptor of MDA-453 cells,2004
CHEMBL188297,O=C1[C@H]2[C@H]3CC[C@H](C3)[C@H]2C(=O)N1c1ccc([N+](=O)[O-])c(C(F)(F)F)c1,8,group1-p,p,Androgen Receptor,In vitro antagonistic activity against androgen receptor of MDA-453 cells,2004
CHEMBL188545,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@H]1C(=O)N(c3ccc([N+](=O)[O-])c4ccccc34)C(=O)N21,5.23,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against mutant androgen receptor of LNCap cells,2004
CHEMBL188803,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@@H]1C(=O)N(c3ccc(C#N)cc3)C(=O)N21,5.59,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against androgen receptor of MDA-453 cells,2004
CHEMBL188857,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@H]1C(=O)N(c3ccc(C#N)cc3)C(=O)N21,5.46,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against mutant androgen receptor of LNCap cells,2004
CHEMBL189306,CCCCCCCCCCCC[C@H]1C[C@@]2(C)C(CC[C@@H]2O)C2CCC3=CC(=O)CCC3=C21,9.7,group1-p,p,Androgen Receptor,Inhibition of human androgen receptor expressed in Escherichia coli,2004
CHEMBL189600,N#Cc1ccc(N2C(=O)[C@H]3[C@@H]4C[C@@H](CN4C(=O)c4ccccc4)N3C2=O)cc1C(F)(F)F,6.52,group3-int,int,Androgen Receptor,In vitro antagonistic activity against androgen receptor of MDA-453 cells,2004
CHEMBL190109,Cc1c(NS(C)(=O)=O)cccc1N(Cc1ccc(Oc2ccc(Cl)c(OCC(=O)O)c2)cc1)Cc1ccc(F)cc1F,5.44,group4-ia,ia,Androgen Receptor,Inhibition of human androgen receptor,2005
CHEMBL190225,Cc1c(NS(C)(=O)=O)cccc1N(Cc1ccccc1)Cc1ccc(Oc2ccc(OCC(=O)O)cc2)cc1,4.93,group4-ia,ia,Androgen Receptor,Inhibition of human androgen receptor,2005
CHEMBL1908373,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,6.57,group3-int,int,Androgen Receptor,Inhibitory activity against human Androgen receptor,1996
CHEMBL1914477,Cc1cc(C(=O)N[C@H]2C(C)(C)[C@H](Oc3ccc(C#N)c(Cl)c3)C2(C)C)nn1C,7.27,group2-a,a,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916236,CC(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)c(C#N)c2)C1(C)C,6.76,group3-int,int,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916237,CC(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)c(Cl)c2)C1(C)C,7.5,group2-a,a,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916238,CC(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)c(C)c2)C1(C)C,7.16,group2-a,a,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916239,CC(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)c(C(F)(F)F)c2)C1(C)C,6.9,group3-int,int,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916240,CC(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)cc2Cl)C1(C)C,6.79,group3-int,int,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916241,CC(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)c(C)n2)C1(C)C,6.29,group3-int,int,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916242,CC1(C)[C@H](NC(=O)c2cnccn2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,7.09,group2-a,a,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916243,CC1(C)[C@H](NC(=O)c2cc[nH]n2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,7.12,group2-a,a,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916244,CC1(C)[C@H](NC(=O)c2cn[nH]c2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,7.38,group2-a,a,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916245,Cn1cc(C(=O)N[C@H]2C(C)(C)[C@H](Oc3ccc(C#N)c(Cl)c3)C2(C)C)cn1,7.7,group2-a,a,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916246,Cc1nnc(C(=O)N[C@H]2C(C)(C)[C@H](Oc3ccc(C#N)c(Cl)c3)C2(C)C)o1,7.52,group2-a,a,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916247,CC1(C)[C@H](NC(=O)c2cnc3ncccn23)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,7.8,group2-a,a,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916248,Cc1nc2ncccn2c1C(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)c(Cl)c2)C1(C)C,7.16,group2-a,a,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916249,COCCn1ccc(C(=O)N[C@H]2C(C)(C)[C@H](Oc3ccc(C#N)c(Cl)c3)C2(C)C)n1,6.87,group3-int,int,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916250,CC1(C)[C@H](NC(=O)c2ccn(CCO)n2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,6.87,group3-int,int,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916251,CC1(C)[C@H](NC(=O)c2cnn(CCO)c2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,7.23,group2-a,a,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916252,CC1(C)[C@H](NC(=O)c2ccn(CCC#N)n2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,7.05,group2-a,a,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916253,CNC(=O)Cn1ccc(C(=O)N[C@H]2C(C)(C)[C@H](Oc3ccc(C#N)c(Cl)c3)C2(C)C)n1,6.79,group3-int,int,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916254,CN(C)C(=O)Cn1ccc(C(=O)N[C@H]2C(C)(C)[C@H](Oc3ccc(C#N)c(Cl)c3)C2(C)C)n1,6.76,group3-int,int,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1916412,Cc1nc(O[C@H]2C(C)(C)[C@H](NC(=O)c3cnc4ncccn34)C2(C)C)ccc1C#N,6.84,group3-int,int,Androgen Receptor,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,2011
CHEMBL1923999,O=C(O)c1cccc(CSc2ccc(Cl)cc2Cl)c1,4.3,group4-ia,ia,Androgen Receptor,Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis,2011
CHEMBL1924000,COC(=O)c1ccc([C@H]2Nc3ccc(C(C)=O)cc3[C@H]3C=CC[C@H]32)cc1,5.92,group4-ia,ia,Androgen Receptor,Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis,2011
CHEMBL1924001,CCOC(=O)c1ccc2c(c1)[C@H]1C=CC[C@@H]1[C@@H](c1ccccc1)N2,6.05,group3-int,int,Androgen Receptor,Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis,2011
CHEMBL1924002,NS(=O)(=O)c1ccc2c(c1)[C@@H]1C=CC[C@@H]1[C@@H](c1ccc(Br)cc1)N2,6.3,group3-int,int,Androgen Receptor,Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis,2011
CHEMBL1924003,Cc1cc(/C=C/C(=O)O)c(C)n1-c1ccc2c(c1)OCO2,4.3,group4-ia,ia,Androgen Receptor,Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis,2011
CHEMBL1928872,O=C1COc2ccc(C3=Nn4cnnc4SC3c3ccccc3)cc2N1,5.44,group4-ia,ia,Androgen Receptor,Displacement of [3H]testosterone from AR,2011
CHEMBL1928874,O=C1COc2ccc(C3=Nn4cnnc4SC3c3ccccc3F)cc2N1,5.23,group4-ia,ia,Androgen Receptor,Displacement of [3H]testosterone from AR,2011
CHEMBL1928875,O=C1COc2ccc(C3=Nn4cnnc4SC3c3cccc(F)c3)cc2N1,5.33,group4-ia,ia,Androgen Receptor,Displacement of [3H]testosterone from AR,2011
CHEMBL1928877,O=C1COc2ccc(C3=Nn4ccnc4SC3c3ccccc3)cc2N1,7.02,group2-a,a,Androgen Receptor,Displacement of [3H]testosterone from AR,2011
CHEMBL1928878,O=C1COc2ccc(C3=Nc4ccccc4SC3c3ccccc3)cc2N1,5.92,group4-ia,ia,Androgen Receptor,Displacement of [3H]testosterone from AR,2011
CHEMBL1929041,Cc1cc(F)ccc1-n1nc(C(F)(F)F)cc1-c1cc(Cl)c2c(c1)NC(=O)CO2,5.35,group4-ia,ia,Androgen Receptor,Displacement of [3H]testosterone from AR,2011
CHEMBL1933081,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(CCc2ccccc2)c1C,7.28,group2-a,a,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL1934427,CCOC(=O)c1c(C)[nH]c(C)c1-c1ccc([N+](=O)[O-])cc1,7.66,group2-a,a,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL1934428,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(C)c1C,5.21,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1934429,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(-c2ccccc2)c1C,5.37,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1934430,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(Cc2ccccc2)c1C,6.47,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1934431,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(CC2CCCCC2)c1C,5.43,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1934432,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(C(=O)c2ccccc2)c1C,6.82,group3-int,int,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL1934433,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(S(=O)(=O)c2ccccc2)c1C,6.89,group3-int,int,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL1934434,COC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(Cc2ccccc2)c1C,6.13,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1934435,Cc1c(C(=O)O)c(-c2ccc([N+](=O)[O-])cc2)c(C)n1Cc1ccccc1,6.72,group3-int,int,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL1934436,Cc1c(CO)c(-c2ccc([N+](=O)[O-])cc2)c(C)n1Cc1ccccc1,6.52,group3-int,int,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL1934437,CC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(Cc2ccccc2)c1C,6.89,group3-int,int,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL1934438,Cc1cc(-c2ccc([N+](=O)[O-])cc2)c(C)n1Cc1ccccc1,5.51,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1934439,COC(=O)c1c(-c2ccccc2)c(C)n(Cc2ccccc2)c1C,7.19,group2-a,a,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL1934440,COC(=O)c1c(-c2ccc(C#N)cc2)c(C)n(Cc2ccccc2)c1C,7.57,group2-a,a,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL1934441,COC(=O)c1c(-c2ccc(C#N)c(C(F)(F)F)c2)c(C)n(Cc2ccccc2)c1C,8.33,group1-p,p,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL1934442,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1ccccc1,8.52,group1-p,p,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL1934443,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1cccnc1,7.19,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1934444,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1ccc(Cl)nc1,8.05,group1-p,p,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL1934445,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1cncc(CO)c1,7,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1934446,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1cnc(Cl)c(CO)c1,6.55,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1934447,Cc1c(-c2ccc(C#N)cc2)c(C#N)cn1Cc1cnc(Cl)c(CO)c1,5.85,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1934448,Cc1c(C#N)c(-c2ccc(C#N)cc2)cn1Cc1cnc(Cl)c(CO)c1,6.04,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1946622,CC1(C)CNC(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,6.98,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL1946805,CC(=O)CN1CC(C)(C)[C@@H](Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,6.58,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL1946806,Cc1nnc(CN2CC(C)(C)[C@@H](Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)o1,6.2,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL1946807,CC(c1nnc(-c2cccc(F)c2)o1)N1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,7.11,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL1946809,CC1(C)CN(Cc2nnc(-c3ccccc3)o2)C(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,7.15,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL1946811,CC1(C)CN(CCC#N)C(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,6.88,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL1946812,CC1(C)CN(CCO)C(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,6.58,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL1947177,CC(CO)N1CC(C)(C)[C@@H](Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,6.47,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL1947178,CC1(C)CN(C(C)(C)CO)C(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,6.12,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL1947179,CC(O)CN1CC(C)(C)[C@@H](Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,6.01,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL1947183,CC(CO)CN1CC(C)(C)[C@@H](Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,6.43,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL1947185,CC1(C)CN(CCC#N)C(=O)[C@@H]1Oc1ccc(C#N)c(Cl)c1,7.17,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,2012
CHEMBL195033,O=C1CC(c2ccccc2)Oc2ccc(O)cc21,5.48,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,2009
CHEMBL1957607,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(C(=O)NC(C)(C)C)cc1,6.96,group3-int,int,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957608,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(C(=O)NCC(C)(C)O)cc1,6.47,group3-int,int,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957609,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(C(=O)N2CCOCC2)cc1,6.29,group3-int,int,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957610,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Oc1ccc(C(=O)NCC(C)(C)O)cc1,5.75,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1957611,Cc1nn(-c2ccc(C#N)cc2)c(C)c1Cc1ccc(F)cc1,6.16,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1957612,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(F)cc1,9.33,group1-p,p,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957613,Cc1nn(-c2ccc(C#N)c(C(F)(F)F)c2)c(C)c1Cc1ccc(F)cc1,6.96,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1957614,Cc1nn(-c2ccc(C#N)cc2Cl)c(C)c1Cc1ccc(F)cc1,5.82,group4-ia,ia,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957615,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Oc1ccc(F)cc1,6.96,group3-int,int,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957616,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1-c1ccc(F)cc1,6.57,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1957617,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1CCc1ccc(F)cc1,7.28,group2-a,a,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957618,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1C(O)c1ccc(F)cc1,7.58,group2-a,a,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957619,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccccc1C(N)=O,5.38,group4-ia,ia,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957620,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1cccc(C(N)=O)c1,5.72,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1957621,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(C(N)=O)cc1,6.85,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1957622,CNC(=O)c1ccc(Cc2c(C)nn(-c3ccc(C#N)c(Cl)c3)c2C)cc1,7.57,group2-a,a,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957721,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(C(=O)N(C)C)cc1,6.04,group3-int,int,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957722,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(C(=O)NCCO)cc1,5.68,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1957723,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Oc1ccc(C(=O)N2CCOCC2)cc1,5.52,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL1957724,CC(=O)Nc1ccc(Oc2c(C)nn(-c3ccc(C#N)c(Cl)c3)c2C)nc1,5.27,group4-ia,ia,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957725,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Oc1ccc(NC(=O)C(C)(C)C)cn1,5.37,group4-ia,ia,Androgen Receptor,Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs,2012
CHEMBL1957726,CC(=O)Nc1ccc(Oc2c(C)nn(-c3ccc(C#N)c(Cl)c3)c2C)cn1,6.46,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay,2012
CHEMBL196374,Cc1noc(=O)c2ccc(NC(=O)C(O)(CC(C)(C)c3cc(F)ccc3O)C(F)(F)F)cc12,6.8,group3-int,int,Androgen Receptor,Binding affinity to human recombinant androgen receptor expressed in baculovirus infected Sf9 cells,2010
CHEMBL197595,C[C@H]1CN(C(=O)Nc2ccc(C(F)(F)F)nc2)[C@H](C)CN1c1ccc(C#N)c(C(F)(F)F)c1,6.96,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL197648,COc1ccncc1NC(=O)N1C[C@H](C)N(c2ccc(C#N)c(C(F)(F)F)c2)C[C@H]1C,5.92,group4-ia,ia,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL1981815,O=C(/C=C/c1ccc(O)cc1)c1cc(Cl)ccc1O,5.23,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL199284,Cc1ncccc1NC(=O)N1C[C@H](C)N(c2ccc(C#N)c(C(F)(F)F)c2)C[C@H]1C,6.17,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL199899,C[C@H]1CN(C(=O)Nc2ccncc2)[C@H](C)CN1c1ccc(C#N)c(C(F)(F)F)c1,6.85,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL200973,C[C@H]1CN(C(=O)Nc2ccc(C#N)nc2)[C@H](C)CN1c1ccc(C#N)c(C(F)(F)F)c1,6.7,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL201069,CSc1ccc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)cn1,6.66,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL201077,COc1ncccc1NC(=O)N1C[C@H](C)N(c2ccc(C#N)c(C(F)(F)F)c2)C[C@H]1C,6.72,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL2011362,N#Cc1ccc(-n2c(=O)n(Cc3ccccc3)c3ccccc32)cc1C(F)(F)F,6.77,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL2011367,CC(C)n1c(=O)n(-c2ccc(C#N)c(C(F)(F)F)c2)c2ccccc21,6.43,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL2011369,CCn1c(=O)n(-c2ccc(C#N)c(C(F)(F)F)c2)c2ccccc21,6.53,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL2011371,N#Cc1ccc(-n2c(=O)n(Cc3ccccc3)c3cccnc32)cc1C(F)(F)F,7.22,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL2011372,N#Cc1ccc(-n2c(=O)n(Cc3ccccc3)c3ncccc32)cc1C(F)(F)F,6.23,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL2011373,N#Cc1ccc(-n2c(=O)n(Cc3ccccn3)c3ccccc32)cc1C(F)(F)F,6.52,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL2011374,N#Cc1ccc(-n2c(=O)n(Cc3cccnc3)c3ccccc32)cc1C(F)(F)F,6.41,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL2011376,CC(c1ccccc1)n1c(=O)n(-c2ccc(C#N)c(C(F)(F)F)c2)c2ccccc21,6.44,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL2011377,N#Cc1ccc(-n2c(=O)n(Cc3nc(-c4ccccn4)no3)c3ccccc32)cc1Cl,6.9,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL2011378,CC(c1nc(-c2ccccn2)no1)n1c(=O)n(-c2ccc(C#N)c(Cl)c2)c2ccccc21,6.75,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL2011379,CNC(=O)c1ccc(-c2ccc3c(c2)C(C)(C)C(=O)N3c2ccc(C#N)c(C(F)(F)F)c2)cc1F,6.71,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL2011380,CNC(=O)c1ccc(-c2ccc3c(c2)C(C)(C)C(=O)N3c2ccc(C#N)c(OC)c2)cc1F,6.78,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL2011381,COc1cc(N2C(=O)C(C)(C)c3cc(-c4cccnc4OC)ccc32)ccc1C#N,7.1,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,2012
CHEMBL201167,C[C@H]1CN(C(=O)Nc2ccccn2)[C@H](C)CN1c1ccc(C#N)c(C(F)(F)F)c1,5.11,group4-ia,ia,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL201242,Cc1ccc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)cn1,6.89,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL201327,COC(=O)c1ccc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)cn1,6.33,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL201517,CCC[C@]12CC[C@H](O)CC1=CCC1C3CC[C@H](O)[C@@]3(C)CCC12,5.75,group4-ia,ia,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL201569,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43/C=C\Cl)C1CC[C@@H]2O,6.76,group3-int,int,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL201757,Cc1ccncc1NC(=O)N1C[C@H](C)N(c2ccc(C#N)c(C(F)(F)F)c2)C[C@H]1C,6.48,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL201809,CC#C[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,5.43,group4-ia,ia,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL202007,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43/C=C\F)C1CC[C@@H]2O,7.96,group2-a,a,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL2023820,O=C(O)c1cccc(Nc2ccc([N+](=O)[O-])c3ccccc23)c1,5.33,group4-ia,ia,Androgen Receptor,Antagonistic activity at AR in human 22Rv1 cells assessed as reduction in cell number by CCK8 assay,2020
CHEMBL202400,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43/C=C/F)C1CC[C@@H]2O,7.07,group2-a,a,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL202415,C/C=C/[C@]12CC[C@H](O)CC1=CCC1C3CC[C@H](O)[C@@]3(C)CCC12,6.07,group3-int,int,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL202660,CC1CN(c2ccc(C#N)c(C(F)(F)F)c2)C(C)CN1C(=O)Nc1ccc(C(F)(F)F)nc1,6.68,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL202710,C[C@H]1CN(C(=O)Nc2ccc(Cl)nc2)[C@H](C)CN1c1ccc(C#N)c(C(F)(F)F)c1,6.14,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL202990,C[C@H]1CN(C(=O)Nc2ccc(F)cc2F)[C@H](C)CN1c1ccc(C#N)c(C(F)(F)F)c1,6.7,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL2030817,O=C(/C=C/c1ccccc1)c1cc(Cl)ccc1O,5.82,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL203085,C[C@H]1CN(C(=O)Nc2ccncn2)[C@H](C)CN1c1ccc(C#N)c(C(F)(F)F)c1,5.34,group4-ia,ia,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL203423,C[C@H]1CN(C(=O)Nc2cncnc2)[C@H](C)CN1c1ccc(C#N)c(C(F)(F)F)c1,6,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL203561,C#CC[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,5.76,group4-ia,ia,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL203748,C=C[C@]12CCC(=O)C=C1CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,8.1,group1-p,p,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL204317,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43/C=C/Br)C1CC[C@@H]2O,6.92,group3-int,int,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL204389,CO/C=C/[C@]12CC[C@H](O)CC1=CCC1C3CC[C@H](O)[C@@]3(C)CCC12,5.34,group4-ia,ia,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL204642,C=C[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@]2(C)O,6.77,group3-int,int,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL2086964,COc1cc(/C=N/NC(=O)c2cc3c(ccc4ccccc43)o2)cc(OC)c1O,4.48,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR T877A mutant LBD assessed as inhibition of DHT-induced fluorescent labeled D11-FxxLF recruitment after 2 to 4 hrs by TR-FRET assay,2012
CHEMBL2086965,O=C(N/N=C/c1cc(Br)ccc1O)c1cc2ccccc2cc1O,4.91,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR T877A mutant LBD assessed as inhibition of DHT-induced fluorescent labeled D11-FxxLF recruitment after 2 to 4 hrs by TR-FRET assay,2012
CHEMBL2086966,O=C(N/N=C/c1cc2ccccc2cc1O)c1cc2ccccc2cc1O,4.8,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR LBD assessed as inhibition of DHT-induced fluorescent labeled D11-FxxLF recruitment after 2 to 4 hrs by TR-FRET assay,2012
CHEMBL2086967,CCCOc1ccc(/C=N/NC(=O)c2cc3c(ccc4ccccc43)o2)cc1,4.75,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR LBD assessed as inhibition of DHT-induced fluorescent labeled D11-FxxLF recruitment after 2 to 4 hrs by TR-FRET assay,2012
CHEMBL2112216,CC[C@H]1C[C@@H](C)Nc2cc3oc(=O)cc(C(F)(F)F)c3cc21,7.92,group2-a,a,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL2112311,CC[C@H]1c2cc3c(C(F)(F)F)cc(=O)oc3cc2NC[C@H]1C,8.7,group1-p,p,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL2112312,CC[C@@H]1c2cc3c(C(F)(F)F)cc(=O)oc3cc2NC[C@H]1C,9.52,group1-p,p,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL2112349,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1O,7.82,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL2112885,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3OC1C[C@H](NCNC(=O)c2cc(COCC#CCN3C(=O)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)C3(C)C)ccc2O)[C@H](O)[C@H](C)O1,7.05,group2-a,a,Androgen Receptor,Inhibition of 1.0 nM [3H]mibolerone binding to human androgen receptor of PC3/AR cell lysate,2003
CHEMBL2113032,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)N1OCCOCCOCCCc1ccc(O)c(C(N)=O)c1,6.48,group3-int,int,Androgen Receptor,Inhibition of [3H]mibolerone binding to human Androgen receptor of PC3/AR Cell Lysate,2004
CHEMBL2113034,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)N1OCCOCCCc1ccc(O)c(C(N)=O)c1,7.11,group2-a,a,Androgen Receptor,Inhibition of [3H]mibolerone binding to human Androgen receptor of PC3/AR Cell Lysate,2004
CHEMBL2113036,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)N1OCC#CCCc1ccc(O)c(C(N)=O)c1,7.31,group2-a,a,Androgen Receptor,Inhibition of [3H]mibolerone binding to human Androgen receptor of PC3/AR Cell Lysate,2004
CHEMBL2113247,C[C@@H]1CNc2cc3nc(O)cc(C(F)(F)F)c3cc2[C@@H]1CCC(F)(F)F,7.2,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,1999
CHEMBL2113248,CC(C)C[C@H]1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC[C@@H]1C,7.54,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,1999
CHEMBL2159539,N#Cc1ccc(C2=NOC3CCCCCC23)c(C(F)(F)F)c1,6,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159540,O=[N+]([O-])c1ccc(C2=NOC3CCCCCC23)cc1C(F)(F)F,6.98,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159541,O=[N+]([O-])c1ccc(C2=NO[C@@H]3CCCCC[C@H]23)c(C(F)(F)F)c1,6.51,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159542,O=[N+]([O-])c1ccc(C2=NO[C@H]3CCCCC[C@@H]23)c(C(F)(F)F)c1,6.41,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159543,Fc1ccc(C2=NOC3CCCCCC23)cc1C(F)(F)F,4.96,group4-ia,ia,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159544,Fc1ccc(C2=NOC3CCCCCC23)c(C(F)(F)F)c1,6.18,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159545,N#Cc1ccc(C2=NOC3CCCCCCC23)cc1C(F)(F)F,6.53,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159546,N#Cc1ccc(C2=NOC3CCCCCCC23)c(C(F)(F)F)c1,6.19,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159547,O=[N+]([O-])c1ccc(C2=NOC3CCCCCCC23)cc1C(F)(F)F,6.15,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159548,O=[N+]([O-])c1ccc(C2=NOC3CCCCCCC23)c(C(F)(F)F)c1,6.13,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159549,Fc1ccc(C2=NOC3CCCCCCC23)cc1C(F)(F)F,5.55,group4-ia,ia,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159550,Fc1ccc(C2=NOC3CCCCCCC23)c(C(F)(F)F)c1,4.88,group4-ia,ia,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159561,N#Cc1ccc(C2=NOC3CCCCCC23)cc1C(F)(F)F,7.36,group2-a,a,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159562,O=[N+]([O-])c1ccc(C2=NO[C@@H]3CCC[C@H]23)cc1C(F)(F)F,6.52,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159563,O=[N+]([O-])c1ccc(C2=NOC3CCCC23)c(C(F)(F)F)c1,6.57,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159564,Fc1ccc(C2=NOC3CCCC23)cc1C(F)(F)F,5.83,group4-ia,ia,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159565,Fc1ccc(C2=NOC3CCCC23)c(C(F)(F)F)c1,5.87,group4-ia,ia,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159566,N#Cc1ccc(C2=NOC3CCCCC23)cc1C(F)(F)F,7.56,group2-a,a,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159567,N#Cc1ccc(C2=NOC3CCCCC23)c(C(F)(F)F)c1,5.94,group4-ia,ia,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159568,N#Cc1cccc(C2=NOC3CCCCC23)c1C(F)(F)F,7.1,group2-a,a,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159569,O=[N+]([O-])c1ccc(C2=NOC3CCCCC23)cc1C(F)(F)F,6.92,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159570,O=[N+]([O-])c1ccc(C2=NO[C@@H]3CCCC[C@H]23)c(C(F)(F)F)c1,6.89,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159571,O=[N+]([O-])c1ccc(C2=NO[C@H]3CCCC[C@@H]23)c(C(F)(F)F)c1,6.58,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159572,Fc1ccc(C2=NOC3CCCCC23)cc1C(F)(F)F,5.96,group4-ia,ia,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159573,Fc1ccc(C2=NOC3CCCCC23)c(C(F)(F)F)c1,6.01,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159729,N#Cc1ccc(C2=NO[C@H]3CCC[C@@H]23)cc1C(F)(F)F,6.21,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159730,N#Cc1ccc(C2=NO[C@@H]3CCC[C@H]23)cc1C(F)(F)F,6.65,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159731,N#Cc1ccc(C2=NOC3CCCC23)c(C(F)(F)F)c1,6.35,group3-int,int,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL2159732,O=[N+]([O-])c1ccc(C2=NO[C@H]3CCC[C@@H]23)cc1C(F)(F)F,5.6,group4-ia,ia,Androgen Receptor,Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay,2012
CHEMBL216272,Cc1noc(=O)c2ccc(NC(=O)C(O)(CC(C)(C)c3cccc4c3OCC4)C(F)(F)F)cc12,6.2,group3-int,int,Androgen Receptor,Binding affinity to human recombinant androgen receptor expressed in baculovirus infected Sf9 cells,2010
CHEMBL216949,CCCCN(CCCC)c1ccc2nc(O)cc(C(F)(F)F)c2c1,7.53,group2-a,a,Androgen Receptor,Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay,2006
CHEMBL217168,CN(C)c1ccc2nc(O)cc(C(F)(F)F)c2c1,7.47,group2-a,a,Androgen Receptor,Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay,2006
CHEMBL217428,CC(C)Nc1ccc2nc(O)cc(C(F)(F)F)c2c1,7.78,group2-a,a,Androgen Receptor,Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay,2006
CHEMBL2177238,CN1C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)[C@@]1(C)c1ccc(O)cc1,8.02,group1-p,p,Androgen Receptor,Binding affinity to androgen receptor by competitive binding assay,2012
CHEMBL2181926,CCOC(=O)C1=C(C)NC(C)=C(C(C)=O)[C@H]1c1cccc2c(=O)cc(C)oc12,5.35,group4-ia,ia,Androgen Receptor,Antagonist activity against androgen receptor expressed in CHOK1 cells after 10 to 30 mins by luciferase reporter gene assay,2012
CHEMBL218490,CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,7.19,group2-a,a,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL2203836,CCS(=O)(=O)Nc1cc(F)c(-c2ccc(C#N)n2C)c(F)c1,7,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor by cellular reporter gene assay,2012
CHEMBL223355,CN(Cc1ccccc1)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,5.8,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL223813,CCCCN(C)C(=O)CCCCCCC[C@@H]1CC2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]21,6.55,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL224015,C[C@]12CCC(=O)CC1C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,5.54,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL224047,CCCCCCNC(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,5.18,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL224263,C[C@@H]1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,7.16,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,2008
CHEMBL224278,C[C@]12CCC(=O)CC1C[C@@H](CCCCCCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,5,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL224352,CCN(CC)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,6.52,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL224414,CC(C)N(C)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,6.37,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL224654,C[C@]12CC[C@H]3[C@@H](C(CCCCCCCC(=O)N4CCOCC4)C[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,5.89,group4-ia,ia,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL224707,C[C@]12CC[C@H]3[C@@H](C(CCCCCCCC(=O)N4CCCCC4)C[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,6.31,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL224733,C[C@]12CC[C@H]3[C@@H](C(CCCCCCCC(N)=O)C[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,6.35,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL224734,CCCNC(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,5.8,group4-ia,ia,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL224736,C[C@]12CCC(=O)CC1C[C@@H](CCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,5.17,group4-ia,ia,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL224770,CCCCN(C)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,6.55,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL224779,CCCCN(C)C(=O)CCCCCCCCC[C@@H]1CC2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]21,5.75,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL225147,CN(C)C(=O)CCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,6.96,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL227463,CCC1CN(C)c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2O1,7.17,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,2007
CHEMBL2297673,O=C(/C=C/c1ccccc1O)c1cc(Cl)ccc1O,5.43,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced cell growth treated for every 2 days for 4 days by hemocytometry,2018
CHEMBL2297680,COc1ccc(/C=C/C(=O)c2cc(Cl)ccc2O)cc1OC,5.28,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL2311179,C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O,9.7,group1-p,p,Androgen Receptor,Inhibition of human androgen receptor expressed in Escherichia coli,2004
CHEMBL2316535,c1ccc(CCCSc2nc3ccccc3[nH]2)cc1,4.92,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316538,c1ccc(CCSc2nc3ccccc3[nH]2)cc1,5.13,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316539,Cc1ccccc1OCCSc1nc2ccccc2[nH]1,4.72,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316540,Cc1cccc(OCCSc2nc3ccccc3[nH]2)c1,5.48,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB assessed as reduction in PSA level after 3 days,2013
CHEMBL2316541,Cc1ccc(OCCSc2nc3ccccc3[nH]2)cc1,5.16,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316542,Cc1cccc(C)c1OCCSc1nc2ccccc2[nH]1,5.17,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in enzalutamide-resistant human LNCAP cells assessed as reduction in PSA level after 3 days,2013
CHEMBL2316543,Clc1cccc(OCCSc2nc3ccccc3[nH]2)c1,5.3,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316544,Clc1ccc(OCCSc2nc3ccccc3[nH]2)cc1,5.4,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316545,NS(=O)(=O)c1ccc(OCCSc2nc3ccccc3[nH]2)cc1,4.21,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316546,c1ccc(OCCSc2cc3ccccc3[nH]2)cc1,5.27,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316547,NS(=O)(=O)c1cccc2cc(SCCOc3ccccc3)[nH]c12,5.19,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in enzalutamide-resistant human LNCAP cells assessed as reduction in PSA level after 3 days,2013
CHEMBL2316554,CCn1c(SCCOc2ccccc2)nc2ccccc21,4.92,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316559,Cc1ccc(OCCSc2nc3ccccc3n2CC(=O)OC(C)C)cc1,4.96,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316560,COCCn1c(SCCOc2ccc(C)cc2)nc2ccccc21,4.9,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316561,Cc1cccc(OCCSc2nc3ccccc3n2CC(=O)OC(C)C)c1,4.86,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316562,CCOC(=O)Cn1c(SCCOc2cccc(C)c2)nc2ccccc21,4.85,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316563,CCOc1cccc(OCCSc2nc3ccccc3n2CCOc2ccc(C)cc2)c1,4.64,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316564,COCCn1c(SCCOc2cccc(C)c2)nc2ccccc21,4.62,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316565,Cc1ccc(OCCSc2nc3ccccc3n2CC(=O)OC(C)C)cc1C,4.51,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316566,COC(=O)Cn1c(SCCOc2ccc(C)cc2)nc2ccccc21,4.48,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316567,CCn1c(SCCOc2cccc(C)c2)nc2ccccc21,4.46,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316568,CCOC(=O)Cn1c(SCCOc2ccc(C)c(C)c2)nc2ccccc21,4.39,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316569,Cc1cccc(OCCSc2nc3ccccc3n2C)c1,4.35,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2316570,CCOC(=O)Cn1c(SCCOc2cccc(CC)c2)nc2ccccc21,4.26,group4-ia,ia,Androgen Receptor,Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay,2013
CHEMBL2334339,CC[Si](CC)(c1ccc(OCC(O)CO)c(C)c1)c1ccc(OCC(O)C(C)(C)C)c(C)c1,5.17,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay,2013
CHEMBL2334342,CC[Si](CC)(c1ccc(OC[C@@H](O)CO)c(C)c1)c1ccc(OC[C@H](O)C(C)(C)C)c(C)c1,5.24,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay,2013
CHEMBL2334343,CC[Si](CC)(c1ccc(OC[C@@H](O)CO)c(C)c1)c1ccc(OC[C@@H](O)C(C)(C)C)c(C)c1,5.08,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay,2013
CHEMBL2334344,CC[Si](CC)(c1ccc(OC[C@H](O)CO)c(C)c1)c1ccc(OC[C@H](O)C(C)(C)C)c(C)c1,5.17,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay,2013
CHEMBL2334345,CC[Si](CC)(c1ccc(OC[C@@H](O)C(C)(C)C)c(C)c1)c1ccc(OC[C@H](O)CO)c(C)c1,5.13,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay,2013
CHEMBL2334724,CC[Si](CC)(c1ccc(OCC(=O)C(C)(C)C)c(C)c1)c1ccc(OC[C@H](O)CO)c(C)c1,5.4,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay,2013
CHEMBL2337505,N#Cc1ccc(N2CCC(O)(Cc3ccccc3)C2)cc1Cl,7.23,group2-a,a,Androgen Receptor,Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells,2013
CHEMBL2337506,N#Cc1ccc(N2CCC(O)C2)cc1Cl,7.09,group2-a,a,Androgen Receptor,Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay,2013
CHEMBL2337507,N#Cc1ccc(N2CCC(O)(c3ccccc3)C2)cc1Cl,6.42,group3-int,int,Androgen Receptor,Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay,2013
CHEMBL2337508,N#Cc1ccc(N2CCC(O)(c3ccc(F)cc3)C2)cc1Cl,6.75,group3-int,int,Androgen Receptor,Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells,2013
CHEMBL2337509,C[C@@H]1N(c2ccc(C#N)c(Cl)c2)CC[C@@]1(O)c1ccc(F)cc1,8.09,group1-p,p,Androgen Receptor,Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells,2013
CHEMBL2337510,C[C@@H]1N(c2ccc(C#N)c(Cl)c2)CC[C@@]1(O)c1ccc(C(N)=O)cc1,7.77,group2-a,a,Androgen Receptor,Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay,2013
CHEMBL2337511,CNC(=O)c1ccc([C@]2(O)CCN(c3ccc(C#N)c(Cl)c3)[C@H]2C)cc1,7.5,group2-a,a,Androgen Receptor,Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells,2013
CHEMBL2337512,CNC(=O)c1ccc([C@]2(O)CCN(c3ccc(C#N)c(Cl)c3)[C@H]2C)nc1,6.92,group3-int,int,Androgen Receptor,Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay,2013
CHEMBL2337513,CNC(=O)c1ccc([C@]2(O)CCN(c3ccc(C#N)c(Cl)c3)[C@H]2C)cn1,7,group2-a,a,Androgen Receptor,Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells,2013
CHEMBL2337514,C[C@@H]1N(c2ccc(C#N)c(Cl)c2)CC[C@@]1(O)c1ccc(C(=O)N(C)C)nc1,5.96,group4-ia,ia,Androgen Receptor,Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells,2013
CHEMBL2337515,CNC(=O)c1ccc([C@@]2(O)CCN(c3ccc(C#N)c(Cl)c3)[C@@H]2C)cn1,5.8,group4-ia,ia,Androgen Receptor,Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells,2013
CHEMBL2337516,C[C@@H]1N(c2ccc(C#N)c(Cl)c2)CC[C@@]1(O)c1ccc(N2CCCC2=O)nc1,6.8,group3-int,int,Androgen Receptor,Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay,2013
CHEMBL2337517,CNC(=O)c1ccc([C@]2(O)CCN(c3ccc(C#N)c(OC)c3)[C@H]2C)cn1,6.92,group3-int,int,Androgen Receptor,Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells,2013
CHEMBL2337518,CNC(=O)c1ccc([C@]2(O)CCN(c3ccc(C#N)cc3)[C@H]2C)cn1,5.12,group4-ia,ia,Androgen Receptor,Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells,2013
CHEMBL2337519,CNC(=O)c1ccc([C@]2(O)CCN(c3ccc(C#N)c(F)c3)[C@H]2C)cn1,5.77,group4-ia,ia,Androgen Receptor,Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay,2013
CHEMBL2346967,N#Cc1ccc(CN2CCN(c3ccc4nnc(C(F)(F)F)n4n3)CC2)cc1,5.82,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor-mediated cellular downregulation in human LNCAP cells assessed as decrease in nuclear receptor level after 20 to 22 hrs by laser-scanning fluorescence microplate cytometeric analysis,2013
CHEMBL2346968,Fc1ccc(CN2CCN(c3ccc4nnc(C(F)(F)F)n4n3)CC2)cc1,5.8,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor-mediated cellular downregulation in human LNCAP cells assessed as decrease in nuclear receptor level after 20 to 22 hrs by laser-scanning fluorescence microplate cytometeric analysis,2013
CHEMBL2346969,Fc1cccc(CN2CCN(c3ccc4nnc(C(F)(F)F)n4n3)CC2)c1F,5.68,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor-mediated cellular downregulation in human LNCAP cells assessed as decrease in nuclear receptor level after 20 to 22 hrs by laser-scanning fluorescence microplate cytometeric analysis,2013
CHEMBL2346970,OC1(c2ccc(F)cc2)CCN(c2ccc3nnc(C(F)(F)F)n3n2)CC1,5.43,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor-mediated cellular downregulation in human LNCAP cells assessed as decrease in nuclear receptor level after 20 to 22 hrs by laser-scanning fluorescence microplate cytometeric analysis,2013
CHEMBL2346971,OC1(c2cccnc2)CCN(c2ccc3nnc(C(F)(F)F)n3n2)CC1,4.97,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor-mediated cellular downregulation in human LNCAP cells assessed as decrease in nuclear receptor level after 20 to 22 hrs by laser-scanning fluorescence microplate cytometeric analysis,2013
CHEMBL2346972,Fc1ccc(CN2CCN(C3=Nn4c(nnc4C(F)(F)F)CC3)CC2)cc1,5.23,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor-mediated cellular downregulation in human LNCAP cells assessed as decrease in nuclear receptor level after 20 to 22 hrs by laser-scanning fluorescence microplate cytometeric analysis,2013
CHEMBL2346973,Cn1nccc1CCOc1ccc(C2CCN(c3ccc4nnc(C(F)(F)F)n4n3)CC2)cc1,6.63,group3-int,int,Androgen Receptor,Inhibition of androgen receptor-mediated cellular downregulation in human LNCAP cells assessed as decrease in nuclear receptor level after 20 to 22 hrs by laser-scanning fluorescence microplate cytometeric analysis,2013
CHEMBL2346974,CC(=O)N1CCN(CCOc2ccc(C3CCN(c4ccc5nnc(C(F)(F)F)n5n4)CC3)cc2)CC1,6.49,group3-int,int,Androgen Receptor,Inhibition of androgen receptor-mediated cellular downregulation in human LNCAP cells assessed as decrease in nuclear receptor level after 20 to 22 hrs by laser-scanning fluorescence microplate cytometeric analysis,2013
CHEMBL2346975,CC(=O)N1CCN(CCOc2ccc(C3(O)CCN(c4ccc5nnc(C(F)(F)F)n5n4)CC3)cc2)CC1,5.98,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor-mediated cellular downregulation in human LNCAP cells assessed as decrease in nuclear receptor level after 20 to 22 hrs by laser-scanning fluorescence microplate cytometeric analysis,2013
CHEMBL2346976,CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1,5.75,group4-ia,ia,Androgen Receptor,Induction of androgen receptor degradation in human LNCaP cells,2020
CHEMBL235003,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCC(=O)O)C[C@H]1CC(=O)CC[C@@]13C,6.14,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,2007
CHEMBL235126,O=c1cc(O)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,8.15,group1-p,p,Androgen Receptor,Antagonist activity at human AR,2007
CHEMBL235128,C[C@H](N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1)C(F)(F)F,7.7,group2-a,a,Androgen Receptor,Antagonist activity at human AR,2007
CHEMBL235159,COc1ccc(-c2ccc(C#N)c(C(F)(F)F)c2)cc1,9.1,group1-p,p,Androgen Receptor,Antagonist activity at human AR in MDA-MB453-MMTV-luci cells by functional assay,2007
CHEMBL235378,N#Cc1ccc(-c2ccc(O)cc2)cc1C(F)(F)F,7.92,group2-a,a,Androgen Receptor,Antagonist activity at human AR in MDA-MB453-MMTV-luci cells by functional assay,2007
CHEMBL235379,Cc1ccccc1-c1ccc(C#N)c(C(F)(F)F)c1,6.84,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL235445,C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CCC(=O)C=C1C[C@H]3CCCCc1ccc(OCCCCCC(=O)O)cc1,6.38,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,2007
CHEMBL235601,Cc1cccc(-c2ccc(C#N)c(C(F)(F)F)c2)c1,5.72,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL2356368,O=C1c2ccccc2C(=O)N1c1nc(-c2ccc(Cl)cc2)cs1,4.58,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL235661,C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CCC(=O)C=C1C[C@H]3CCCc1ccc(OCCC(=O)O)cc1,6.77,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,2007
CHEMBL2357456,O=C1c2ccccc2C(=O)N1c1nc(-c2ccc(F)cc2)cs1,4.54,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL235784,COC(=O)COc1ccccc1-c1ccc(C#N)c(C(F)(F)F)c1,5.88,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL235811,C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CCC(=O)C=C1C[C@H]3CCCCc1cccc(OCCCCC(=O)O)c1,6.48,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,2007
CHEMBL235871,C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CCC(=O)C=C1C[C@H]3CCCCc1cccc(OCCCC(=O)O)c1,6.17,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells,2007
CHEMBL235872,C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CCC(=O)C=C1C[C@H]3CCCCc1cccc(OCCCCCC(=O)O)c1,6.28,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,2007
CHEMBL236699,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC(CCCC(F)(F)C(F)(F)F)C(=O)O)C[C@H]1CC(=O)CC[C@@]13C,6.39,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells,2007
CHEMBL237971,C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CCC(=O)C=C1C[C@H]3CCCc1cccc(OCCCC(=O)O)c1,5.24,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,2007
CHEMBL237999,C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CCC(=O)C=C1C[C@H]3CCCc1ccc(OCCCCC(=O)O)cc1,6.18,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells,2007
CHEMBL238000,C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CCC(=O)C=C1C[C@H]3CCCCc1ccc(OCCCC(=O)O)cc1,6.07,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,2007
CHEMBL238001,C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CCC(=O)C=C1C[C@H]3CCCCc1ccc(OCCCCC(=O)O)cc1,6.6,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,2007
CHEMBL238124,CC(C)c1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,8.7,group1-p,p,Androgen Receptor,Antagonist activity at human AR,2007
CHEMBL238338,N#Cc1ccc(-c2ccccc2OCCO)cc1C(F)(F)F,5.81,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL238340,COCCOCCOc1ccccc1-c1ccc(C#N)c(C(F)(F)F)c1,5.09,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL238365,N#Cc1ccc(-c2ccccc2Cl)cc1C(F)(F)F,8.01,group1-p,p,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL238366,COc1ccccc1-c1ccc(C#N)c(C(F)(F)F)c1,7.7,group2-a,a,Androgen Receptor,Antagonist activity at human AR in MDA-MB453-MMTV-luci cells by functional assay,2007
CHEMBL2386392,O=c1cc(-c2ccc(C(F)(F)F)cc2)oc2cccc(O)c12,5.91,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL2386393,O=c1cc(-c2ccc(F)cc2)oc2cccc(O)c12,6.48,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL2386394,O=c1cc(-c2ccccc2)oc2cccc(F)c12,6.11,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL2386395,O=c1cc(-c2ccc([N+](=O)[O-])cc2)oc2cccc(O)c12,6.44,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL2386396,N#Cc1ccc(-c2cc(=O)c3c(O)cccc3o2)cc1,6.6,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL2386397,CN(C)c1ccc(-c2cc(=O)c3c(O)cccc3o2)cc1,6.07,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL2386399,Nc1ccc(-c2cc(=O)c3c(O)cccc3o2)cc1,5.7,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL2386401,CSc1ccc(-c2cc(=O)c3c(O)cccc3o2)cc1,5.97,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL2386404,O=c1cc(-c2ccc(Cl)cc2)oc2cccc(F)c12,6.44,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL2386405,O=c1cc(-c2ccc(F)cc2)oc2cccc(F)c12,6.72,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL2386406,N#Cc1ccc(-c2cc(=O)c3c(F)cccc3o2)cc1,5.92,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL2386408,NC(=O)c1ccc(-c2cc(=O)c3c(O)cccc3o2)cc1,5.45,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL2397333,CCS(=O)(=O)Nc1cccc(-c2cc(=O)n(-c3ccc(C#N)cc3)nc2C)c1,5.2,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay,2013
CHEMBL2397334,CCS(=O)(=O)Nc1cccc(-c2cc(=O)n(-c3ccc(Cl)c(Cl)c3)nc2C)c1,5.58,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay,2013
CHEMBL2397335,CCS(=O)(=O)Nc1cccc(-c2cc(=O)n(-c3cc(Cl)cc(Cl)c3)nc2C)c1,4.88,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay,2013
CHEMBL2397336,CCS(=O)(=O)Nc1cccc(-c2cc(=O)n(-c3ccc(F)c(Cl)c3)nc2C)c1,5.29,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay,2013
CHEMBL2397337,CCS(=O)(=O)Nc1cccc(-c2cc(=O)n(-c3ccc4ccccc4c3)nc2C)c1,5.01,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay,2013
CHEMBL239957,Cn1c(C#N)ccc1-c1ccc2[nH]c(=S)n(C3CCCC3)c2c1,6,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in A549 cells by HRE-tk luciferase assay,2007
CHEMBL240331,O=C(CSc1nc(O)c2ccccc2n1)c1ccc(O)c(O)c1,4.3,group4-ia,ia,Androgen Receptor,Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis,2011
CHEMBL2403348,CCC(CC)(c1ccc(N)c(C)c1)c1ccc(O)c(C)c1,5.27,group4-ia,ia,Androgen Receptor,Antagonist activity at human pSG5-AR assessed as inhibition of dihydrotestosterone-induced effect by reporter gene assay,2013
CHEMBL2403349,CC[Si](CC)(c1ccc(O)c(C)c1)c1ccc(O)c(C)c1,5.72,group4-ia,ia,Androgen Receptor,Antagonist activity at human pSG5-AR assessed as inhibition of dihydrotestosterone-induced effect by reporter gene assay,2013
CHEMBL2403350,CCCC[Si](CCCC)(c1ccc(O)c(C)c1)c1ccc(O)c(C)c1,5.09,group4-ia,ia,Androgen Receptor,Antagonist activity at human pSG5-AR assessed as inhibition of dihydrotestosterone-induced effect by reporter gene assay,2013
CHEMBL2403355,CCC(CC)(c1ccc(O)c(C)c1)c1ccc(O)c(C)c1,5.35,group4-ia,ia,Androgen Receptor,Antagonist activity at human pSG5-AR assessed as inhibition of dihydrotestosterone-induced effect by reporter gene assay,2013
CHEMBL2403356,CCCC(CCC)(c1ccc(O)c(C)c1)c1ccc(O)c(C)c1,4.6,group4-ia,ia,Androgen Receptor,Antagonist activity at human pSG5-AR assessed as inhibition of dihydrotestosterone-induced effect by reporter gene assay,2013
CHEMBL2407647,COc1cc(CNC(=O)[C@@]2(Cc3ccccc3)OC(=O)N([C@@H]3CCc4ccccc43)C2=O)cc(OC)c1,4.92,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) by NH Pro assay,2013
CHEMBL2440233,O=C(O[C@H]1C(=O)C=CN(C(=O)/C=C/c2ccccc2)[C@@H]1c1ccccc1)c1ccc(F)cc1C(F)(F)F,4.52,group4-ia,ia,Androgen Receptor,Displacement of Fluormone AL Green from androgen receptor ligand binding domain (unknown origin) after 4 hrs by fluorescence polarization assay,2013
CHEMBL2441092,COc1cccc(C(=O)Nc2cc(C)c(Oc3ccc(O)cc3)c(C)c2)c1,5.89,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor H874Y mutant (unknown origin) expressed in human 22Rv1 cells assessed as inhibition of DHT-induced cell growth after 3 days by WST-8 assay,2013
CHEMBL2441094,COc1cccc(C(=O)Nc2ccc(Oc3ccc(O)cc3)c(C)c2)c1,7.37,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor T877A mutant (unknown origin) expressed in human LNCAP cells assessed as inhibition of DHT-induced cell growth after 6 days by WST-8 assay,2013
CHEMBL2441107,COc1cccc(C(=O)Nc2ccc(Oc3ccc(O)cc3)cc2)c1,4.7,group4-ia,ia,Androgen Receptor,Displacement of [3H]-DHT from human GST-tagged androgen receptor LBD (627 to 919) expressed in Escherichia coli HB-101 after 15 hrs by liquid scintillation counting analysis,2013
CHEMBL245378,C[C@]12CC[C@H]3[C@@H](CC=C4[C@H]5CC[C@]43CC[C@@H]5O)[C@@H]1CC[C@@H]2O,5.86,group4-ia,ia,Androgen Receptor,Binding affinity to androgen receptor,2007
CHEMBL245575,C[C@]12CC[C@H]3[C@@H](CC=C4[C@H]5CC[C@]43CC[C@H]5O)[C@@H]1CC[C@@H]2O,5.95,group4-ia,ia,Androgen Receptor,Binding affinity to androgen receptor,2007
CHEMBL246007,C=CC(O)(c1nc2cc(Cl)c(Cl)cc2[nH]1)C(F)(F)F,8.15,group1-p,p,Androgen Receptor,Binding affinity at androgen receptor expressed in COS cells by whole cell binding assay,2007
CHEMBL246138,C=C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,7.48,group2-a,a,Androgen Receptor,Binding affinity at AR,2007
CHEMBL246139,C/C=C\[C@]12CC[C@H](O)CC1=CC[C@H]1[C@@H]3CC[C@H](O)[C@@]3(C)CC[C@@H]12,6.14,group3-int,int,Androgen Receptor,Binding affinity to androgen receptor,2007
CHEMBL246140,C=C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,8.1,group1-p,p,Androgen Receptor,Binding affinity at AR,2007
CHEMBL246341,C[C@]12CC[C@H]3[C@@H](CC=C4[C@H]5CC=C[C@]43CC[C@@H]5O)[C@@H]1CC[C@@H]2O,7.07,group2-a,a,Androgen Receptor,Binding affinity to androgen receptor,2007
CHEMBL246607,CC[C@@H]1COc2c(ccc3[nH]c(=O)cc(C(F)(F)F)c23)N1,7.08,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,2007
CHEMBL246800,CCSCC(O)(c1nc2cc(Cl)c(Cl)cc2[nH]1)C(F)(F)F,7.77,group2-a,a,Androgen Receptor,Binding affinity at androgen receptor expressed in COS cells by whole cell binding assay,2007
CHEMBL247453,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)N(CC(F)(F)F)[C@H](c1ccccc1)CO3,7.19,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,2007
CHEMBL247785,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)NCCO3,5.82,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,2007
CHEMBL247786,C[C@@H]1COc2c(ccc3[nH]c(=O)cc(C(F)(F)F)c23)N1,7.14,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,2007
CHEMBL248690,C[C@H](c1ccccc1)N(C)c1cc(C(F)(F)F)c(C#N)cn1,7.7,group2-a,a,Androgen Receptor,Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells,2007
CHEMBL248841,N#Cc1cnc(N2CCC3CCCCC3C2)cc1C(F)(F)F,6.58,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in MDA-MB-453 cells,2007
CHEMBL248868,CCCN(CCC)c1cc(C(F)(F)F)c(C#N)cn1,7.11,group2-a,a,Androgen Receptor,Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells,2007
CHEMBL248878,C[C@@H](Nc1cc(C(F)(F)F)c(C#N)cn1)c1ccccc1,5.31,group4-ia,ia,Androgen Receptor,Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells,2007
CHEMBL249070,CCC(C)N(C)c1cc(C(F)(F)F)c(C#N)cn1,8.15,group1-p,p,Androgen Receptor,Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells,2007
CHEMBL249071,CCCCN(C)c1cc(C(F)(F)F)c(C#N)cn1,8.42,group1-p,p,Androgen Receptor,Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells,2007
CHEMBL249072,CC1CCN(c2cc(C(F)(F)F)c(C#N)cn2)CC1,7.14,group2-a,a,Androgen Receptor,Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells,2007
CHEMBL249700,C=C1C=C2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1,7.4,group2-a,a,Androgen Receptor,Binding affinity at AR,2007
CHEMBL249903,C=C[C@]12CCC(CC)=CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,6.3,group3-int,int,Androgen Receptor,Binding affinity at AR,2007
CHEMBL249904,C#C[C@]1(O)CC[C@H]2[C@@H]3CC=C4C=C(C)CC[C@]4(C=C)[C@H]3CC[C@@]21C,5.79,group4-ia,ia,Androgen Receptor,Binding affinity at AR,2007
CHEMBL250083,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)N[C@H](c1ccccc1)CO3,5.83,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,2007
CHEMBL250084,CCC[C@@H]1COc2c(ccc3[nH]c(=O)cc(C(F)(F)F)c23)N1,6.95,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,2007
CHEMBL250104,O=C(O)CCc1cc(Br)c(OCc2cccc(Br)c2)c(Br)c1,5.11,group4-ia,ia,Androgen Receptor,Binding affinity at AR,2007
CHEMBL250109,C=C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,6.77,group3-int,int,Androgen Receptor,Binding affinity at AR,2007
CHEMBL250110,CC1=CC2=CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1,5.65,group4-ia,ia,Androgen Receptor,Binding affinity at AR,2007
CHEMBL251515,C=C[C@]12CC[C@@](C)(O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,5.58,group4-ia,ia,Androgen Receptor,Binding affinity at AR,2007
CHEMBL251552,N#Cc1ccc(OC2CCCCC2C#N)cc1C(F)(F)F,7.24,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from androgen receptor expressed in Sf9 cells,2007
CHEMBL253535,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)-c1c(O)cccc1OC3,8.96,group1-p,p,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL253744,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1C(C)O2,7.21,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay,2008
CHEMBL253746,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1C(OC)O2,6.95,group3-int,int,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL254798,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@@H](CF)N3CC(F)(F)F,6.7,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,2008
CHEMBL255157,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1cccc(C(F)(F)F)c1,4.94,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL255216,CC12CCC(C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)n4nccc34)C(=O)[C@@H]12,7.06,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL255331,CC12C[C@H](O)C(C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(I)c3)C(=O)[C@@H]12,8,group1-p,p,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL255367,Cc1cc(N2C(=O)[C@@H]3C4CCC(O4)[C@@H]3C2=O)ccc1Cl,6.3,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL255776,O=C1[C@H]2C3CCC(C3)N2C(=O)N1c1cccc(C(F)(F)F)c1,6.89,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL255918,CSCC1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,7.6,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,2008
CHEMBL256082,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@@H](Cc1ccccc1)N3CC(F)(F)F,7.29,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,2008
CHEMBL256329,Cc1ccc([C@H]2COc3cc4[nH]c(=O)cc(C(F)(F)F)c4cc3N2CC(F)(F)F)cc1,7.36,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,2008
CHEMBL256768,COc1c(OC(C)C)ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c12,8.55,group1-p,p,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL256769,COc1c(C(=O)OC(F)(F)F)ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c12,9.7,group1-p,p,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL256947,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1CO2,7.92,group2-a,a,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL256977,CCOc1ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c2c1OC,8,group1-p,p,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL257151,Cc1cc(=O)[nH]c2ccc3c(c12)COc1cccc(CO)c1-3,9.52,group1-p,p,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL257387,Cc1cccc([C@H]2COc3cc4[nH]c(=O)cc(C(F)(F)F)c4cc3N2CC(F)(F)F)c1,6.24,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,2008
CHEMBL257668,CC12CCC(C)(O1)[C@@H]1C(=O)N(c3cc(Cl)cc(Cl)c3)C(=O)[C@@H]12,7.8,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL257751,O=c1cc(C(F)(F)F)c2c(ccc3c2oc(=O)c2cccc(O)c23)[nH]1,7.66,group2-a,a,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL257988,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@@H](C(F)(F)F)N3CC(F)(F)F,7.47,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,2008
CHEMBL258190,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1C(O)O2,7.3,group2-a,a,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL258241,Cc1cc(=O)[nH]c2ccc3c4cc(F)ccc4oc(=O)c3c12,7.57,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay,2008
CHEMBL258384,C=CCC1Oc2cccc(OC)c2-c2ccc3[nH]c(=O)cc(C)c3c21,6.84,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay,2008
CHEMBL258397,COc1ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c2c1,7.32,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay,2008
CHEMBL263091,COc1ccc(F)cc1C(C)(C)CC(O)(C(=O)Nc1ccc2c(=O)onc(C)c2c1)C(F)(F)F,6.3,group3-int,int,Androgen Receptor,Binding affinity to human recombinant androgen receptor expressed in baculovirus infected Sf9 cells,2010
CHEMBL263660,O=C(CN1c2ccccc2Sc2ccc(C(F)(F)F)cc21)c1cccc2ccccc12,6.6,group3-int,int,Androgen Receptor,Inhibition of wild type androgen receptor expressed in CV1 cells assessed as dihydrotestosterone-stimulated transactivation by CAT reporter gene assay,2007
CHEMBL264131,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)CC3OC1C[C@H](NCNC(=O)c2cc(COCC#CCN3C(=O)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)C3(C)C)ccc2O)[C@H](O)[C@H](C)O1,7.05,group2-a,a,Androgen Receptor,Inhibition of [3H]mibolerone binding to human Androgen receptor of PC3/AR Cell Lysate,2004
CHEMBL266473,CCC1CCc2cc3c(C(F)(F)F)cc(=O)oc3cc2N1,9,group1-p,p,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL266491,COCCOc1ccccc1-c1ccc(C#N)c(C(F)(F)F)c1,5.65,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL266928,O=c1cc(C(F)(F)F)c2cc3c(cc2o1)NCCC3C(F)(F)C(F)(F)F,8.3,group1-p,p,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL267141,C[C@@H]1CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,7.72,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL267270,O=c1cc(C(F)(F)F)c2cc3c(cc2o1)NCCC3C(F)(F)F,8.7,group1-p,p,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL267431,COC[C@]1(OC)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(/C=N/O)cc3)C[C@@]21C,8.05,group1-p,p,Androgen Receptor,Antagonist activity at androgen receptor by cellular reporter gene assay,2012
CHEMBL267471,CC[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2CC1(CC)CC,7.32,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL267850,CC(C)[C@@H]1CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,7.6,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL267907,C[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2CC1(C)C,7.62,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL268098,O=c1cc(C(F)(F)F)c2cc3c(cc2o1)NCCC3,9,group1-p,p,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL268326,C[C@H]1C[C@@H](C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,7.82,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL268569,CCC[C@@H]1CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,7.5,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL269305,CCC1CC(C)c2cc3c(C(F)(F)F)cc(=O)oc3cc2N1,7.96,group2-a,a,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL270450,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1ccc(Cl)c(Cl)c1,6.32,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL270586,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1ccc(I)c(Cl)c1,6.46,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL271261,CC12CCC(C)(O1)[C@@H]1C(=O)N(c3c(N)ccc4nccn34)C(=O)[C@@H]12,7.16,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL271262,CC12CCC(C)(O1)[C@@H]1C(=O)N(c3c(N)ccc4ncsc34)C(=O)[C@@H]12,6.92,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL271924,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1ccc(Cl)c([N+](=O)[O-])c1,5.94,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL271925,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1ccc(Cl)c(C(F)(F)F)c1,5.48,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL272509,CSc1cc(N2C(=O)[C@H]3[C@@H](C2=O)C2(C)CCC3(C)O2)ccc1C#N,7.72,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL272510,CC12CCC(C)(O1)[C@@H]1C(=O)N(c3cccc(C(F)(F)F)c3)C(=O)[C@@H]12,7.44,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL272574,CC12C[C@@H](O)C(C)(O1)[C@H]1C(=O)N(c3ccc(C#N)c(I)c3)C(=O)[C@H]12,7.72,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL27297,CCC1CCNc2cc3c(cc21)c(C(F)(F)F)cc(=O)n3C,7.7,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,1999
CHEMBL27413,CCC1CCN(C)c2cc3c(cc21)c(C(F)(F)F)cc(=O)n3C,6.67,group3-int,int,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,1999
CHEMBL274318,O=C1CC(c2ccccc2)Oc2ccccc21,4.7,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,2009
CHEMBL274471,O=c1cc(-c2ccc(Cl)cc2)oc2cccc(O)c12,6.34,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL275638,O=c1cc(-c2ccccc2)oc2ccccc12,5.23,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,2009
CHEMBL276621,CCCCNC(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,5.2,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL27769,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,8.59,group1-p,p,Androgen Receptor,Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs,2012
CHEMBL28,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,5.28,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,2009
CHEMBL281028,CC1(C)CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,7.8,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,1999
CHEMBL281945,C[C@H]1CNc2cc3nc(O)cc(C(F)(F)F)c3cc2C1CCC(F)(F)F,7.21,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells was determined as a function of maximal inhibition of dihydrotestosterone using cotransfection assay,1999
CHEMBL282866,CCC1(CC)CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,7.14,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,1999
CHEMBL283449,CC1CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,6.59,group3-int,int,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,1999
CHEMBL285602,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NCCC3c1cc(C(F)(F)F)cc(C(F)(F)F)c1,6.6,group3-int,int,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,1999
CHEMBL286595,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)cc1)Oc1ccccc1-3,5.81,group4-ia,ia,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL286684,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NCCC3,7.92,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,1999
CHEMBL292284,CC(=O)C[C@]1(C(C)=O)CC[C@H]2C3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,8.21,group1-p,p,Androgen Receptor,Antagonist activity against Androgen receptor,2003
CHEMBL293409,CC1CC(C)(C)Nc2ccc3c(c21)COc1ccc([N+](=O)[O-])cc1-3,7.2,group2-a,a,Androgen Receptor,Inhibition of antagonist activity towards Androgen receptor,2003
CHEMBL294009,O=c1c(O)c(-c2ccccc2)oc2ccccc12,4.63,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,2009
CHEMBL302362,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1ccccc1-3,5.97,group4-ia,ia,Androgen Receptor,Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells,1998
CHEMBL3039217,CC(C)c1ccc2c(c1O)CC[C@H]1C3=C(CC[C@]21C)C(=O)OC3,6.32,group3-int,int,Androgen Receptor,Antagonist activity at AR F876L mutant (unknown origin) expressed in human PC3 cells assessed as inhibition of DHT-induced receptor transactivation after 24 hrs by PSA-luciferase reporter gene assay,2016
CHEMBL3084689,N#Cc1ccc(N2[C@H]3CC[C@@H]2C[C@H](O)C3)cc1Cl,7.5,group2-a,a,Androgen Receptor,Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition,2015
CHEMBL317921,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)c(Cl)c1)Oc1ccccc1-3,6.02,group3-int,int,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL3183409,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,7.8,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL318513,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cccc(C(F)(F)F)c1)Oc1ccccc1-3,6.5,group3-int,int,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL320690,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cccc(Cl)c1)Oc1ccccc1-3,6.6,group3-int,int,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL3221237,CN1C(=O)C(F)=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](C(=O)NCc5nc6cccnc6[nH]5)CC[C@H]4[C@@H]3CC[C@@H]12,6.71,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting analysis,2013
CHEMBL3233069,COc1ccc(OC[C@](C)(O)C(=O)N2CCc3c(C#N)cccc32)c(Cl)c1,8.46,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3233070,C[C@](O)(COc1ccc(Cl)cc1F)C(=O)N1CCc2c(C#N)cccc21,8.3,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3233071,C[C@](O)(COc1ccc(Cl)cc1Cl)C(=O)N1CCc2c(C#N)cccc21,8.04,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3233072,C[C@](O)(COc1ccc(Br)cc1F)C(=O)N1CCc2c(C#N)cccc21,7.43,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238273,C[C@](O)(COc1ccccc1)C(=O)N1CCc2c(C#N)cccc21,7,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238274,C[C@](O)(COc1ccc(F)cc1)C(=O)N1CCc2c(C#N)cccc21,7.9,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238275,C[C@](O)(COc1cccc(F)c1)C(=O)N1CCc2c(C#N)cccc21,7.47,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238276,C[C@](O)(COc1ccccc1F)C(=O)N1CCc2c(C#N)cccc21,8,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238277,C[C@](O)(COc1ccc(Cl)cc1)C(=O)N1CCc2c(C#N)cccc21,7.44,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238278,C[C@](O)(COc1cccc(Cl)c1)C(=O)N1CCc2c(C#N)cccc21,6.97,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238279,C[C@](O)(COc1ccccc1Cl)C(=O)N1CCc2c(C#N)cccc21,7.25,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238280,C[C@](O)(COc1ccc(Br)cc1)C(=O)N1CCc2c(C#N)cccc21,8.62,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238281,C[C@](O)(COc1ccc(C(F)(F)F)cc1)C(=O)N1CCc2c(C#N)cccc21,7.48,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238282,COc1ccc(OC[C@](C)(O)C(=O)N2CCc3c(C#N)cccc32)cc1,6.84,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238283,COC(=O)c1ccc(OC[C@](C)(O)C(=O)N2CCc3c(C#N)cccc32)cc1,6.88,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238284,C[C@](O)(COc1ccc(-c2cocn2)cc1)C(=O)N1CCc2c(C#N)cccc21,6.75,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238285,C[C@](O)(COc1ccc(C#N)cc1)C(=O)N1CCc2c(C#N)cccc21,7.79,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238286,C[C@](O)(COc1ccccc1C(F)(F)F)C(=O)N1CCc2c(C#N)cccc21,7.21,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238287,C[C@](O)(COc1ccccc1C#N)C(=O)N1CCc2c(C#N)cccc21,7.84,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238288,C[C@](O)(COc1ccc(F)cc1C#N)C(=O)N1CCc2c(C#N)cccc21,8.04,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238289,C[C@](O)(COc1ccc(F)cc1Br)C(=O)N1CCc2c(C#N)cccc21,7.94,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238290,Cc1cc(F)ccc1OC[C@](C)(O)C(=O)N1CCc2c(C#N)cccc21,7.97,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238291,C[C@](O)(COc1ccc(C#N)cc1Br)C(=O)N1CCc2c(C#N)cccc21,8.32,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238292,C[C@](O)(COc1ccc(C#N)cc1F)C(=O)N1CCc2c(C#N)cccc21,8.49,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238293,COc1cc(C#N)ccc1OC[C@](C)(O)C(=O)N1CCc2c(C#N)cccc21,7.79,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238294,COc1cc(Cl)ccc1OC[C@](C)(O)C(=O)N1CCc2c(C#N)cccc21,6.44,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3238295,COc1ccc(OC[C@](C)(O)C(=O)N2CCc3c(C#N)cccc32)c(F)c1,6.37,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from full length human AR expressed in COS cells after 3.5 hrs by liquid scintillation counting,2014
CHEMBL3262343,CC(C)(O)c1cn(-c2ccc(Cl)c(C(F)(F)F)c2)nn1,4.31,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human LNCAP cells assessed as inhibition of androgen-stimulated cell growth measured every 3 days,2014
CHEMBL3262347,CC(C)(O)c1cn(-c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)nn1,4.35,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human LNCAP cells assessed as inhibition of androgen-stimulated cell growth measured every 3 days,2014
CHEMBL3262348,CC(C)(O)c1cn(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nn1,4.4,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human LNCAP cells assessed as inhibition of androgen-stimulated cell growth measured every 3 days,2014
CHEMBL3263754,COc1nc(C2=NN(c3ccc(C#N)c(C)n3)[C@@H](C3CCCC3)C2)ccc1C(=O)O,5.04,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,2014
CHEMBL3263760,COc1nc(C2=NN(c3ccc(C#N)c(C)c3)[C@@H](C3CCCC3)C2)ccc1C(N)=O,5.49,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,2014
CHEMBL3263763,COc1nc(C2=NN(c3ccc(C#N)c(C)n3)[C@@H](C3CCCC3)C2)ccc1C(N)=O,5.11,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,2014
CHEMBL3263764,CNC(=O)c1ccc(C2=NN(c3ccc(C#N)c(C)n3)[C@@H](C3CCCC3)C2)nc1OC,5.07,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,2014
CHEMBL3263767,COc1nc(C2=NN(c3ccc(C#N)c(C)n3)[C@@H](C3CCCC3)C2)ccc1C(=O)NS(C)(=O)=O,5,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,2014
CHEMBL32812,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cccc(F)c1)Oc1ccccc1-3,6.1,group3-int,int,Androgen Receptor,Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells,1998
CHEMBL3317457,O=C(c1cc2ccc(F)cc2[nH]1)N(Cc1ccco1)Cc1ccco1,5.39,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days,2014
CHEMBL3318054,CN(Cc1ccc(Br)o1)C(=O)c1cc2ccc(F)cc2[nH]1,5.09,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay,2014
CHEMBL3318055,Cc1ccc(CN(C)C(=O)c2cc3cc(F)ccc3[nH]2)o1,5.03,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days,2014
CHEMBL3318056,N#CCCN(Cc1ccccc1)C(=O)c1cc2ccccc2[nH]1,5.12,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days,2014
CHEMBL3318057,COCCN(Cc1ccco1)C(=O)c1cc2cc(F)ccc2[nH]1,5.19,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days,2014
CHEMBL3318058,CC(C)N(Cc1ccco1)C(=O)c1cc2cc(C(F)(F)F)ccc2[nH]1,5.28,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay,2014
CHEMBL3318059,CN(Cc1ccc(Br)s1)C(=O)c1cc2ccc(F)cc2[nH]1,5.45,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days,2014
CHEMBL3318060,CN(Cc1cccs1)C(=O)c1cc2ccc(F)cc2[nH]1,5.47,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days,2014
CHEMBL3318061,Cc1ccc(CN(C(=O)c2cc3ccccc3[nH]2)C(C)C)o1,5.47,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay,2014
CHEMBL3318062,Cc1ccc2cc(C(=O)N(Cc3ccc(C)o3)C(C)C)[nH]c2c1,5.54,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days,2014
CHEMBL3318063,Cc1ccc2[nH]c(C(=O)N(Cc3ccc(C)o3)C(C)C)cc2c1,5.57,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days,2014
CHEMBL3318064,Cc1ccc2[nH]c(C(=O)N(Cc3ccco3)C(C)C)cc2c1,5.92,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay,2014
CHEMBL3318065,Cc1ccc(CN(C(=O)c2cc3cc(F)ccc3[nH]2)C(C)C)o1,5.86,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay,2014
CHEMBL3318066,Cc1ccc2cc(C(=O)N(Cc3ccco3)C(C)C)[nH]c2c1,6.07,group3-int,int,Androgen Receptor,Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay,2014
CHEMBL3318067,Cc1ccc(CN(C(=O)c2cc3cccc(F)c3[nH]2)C(C)C)o1,5.92,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay,2014
CHEMBL3318068,Cc1ccc(CN(C(=O)c2cc3ccc(F)cc3[nH]2)C(C)C)o1,5.66,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor binding function 3 in human enzalutamide-resistant MR49F cells assessed as reduction in PSA expression after 3 days by prostate surface antigen assay,2014
CHEMBL3318069,CC(C)N(Cc1ccco1)C(=O)c1cc2cc(F)ccc2[nH]1,6.22,group3-int,int,Androgen Receptor,Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days,2014
CHEMBL3318070,CC(C)N(Cc1ccco1)C(=O)c1cc2ccc(F)cc2[nH]1,6.28,group3-int,int,Androgen Receptor,Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay,2014
CHEMBL3323467,CNc1nc(-c2ccc3ccccc3c2)cs1,5.5,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323468,Oc1ccc2nc(N3CCOCC3)sc2c1,5.09,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323469,Oc1ccc(-c2ccc3ccccc3n2)cc1,5.01,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323470,c1ccc(-c2ccc(N3CCOCC3)s2)cc1,6.29,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323471,FC(F)(F)c1cccc(-c2csc(N3CCOCC3)n2)c1,6.21,group3-int,int,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323472,Cc1ccc(C)c(-c2csc(N3CCOCC3)n2)c1,6.21,group3-int,int,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323473,c1ccc(-c2csc(N3CCCCC3)n2)cc1,6.16,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323474,c1ccc(-c2cc(N3CCOCC3)cs2)cc1,6.08,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323475,Nc1ccccc1-c1csc(N2CCOCC2)n1,5.69,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323476,N#Cc1ccc(-c2ccc(N3CCOCC3)s2)cc1,5.84,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323477,FC(F)(F)[C@H]1CN(c2nc(-c3ccccc3)cs2)CCO1,6.8,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323478,Clc1ccc(-c2csc(N3CCOCC3)n2)c(Cl)c1,5.78,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323479,Clc1ccc(-c2csc(N3CCOCC3)n2)cc1Cl,5.53,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323480,OCc1sc(N2CCOCC2)nc1-c1ccccc1,5.3,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323481,Oc1ccc(-c2nc(-c3c[nH]c4ccccc34)cs2)cc1,5.19,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323482,CCc1sc(N2CCOCC2)nc1-c1ccccc1,5.07,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323483,Brc1ncn(-c2csc(N3CCOCC3)n2)c1Br,6.77,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323484,COc1c(-c2csc(N3CCOCC3)n2)ccc(F)c1F,6.75,group3-int,int,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323485,Cc1scc(-c2csc(N3CCOCC3)n2)c1C,6.6,group3-int,int,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323486,c1cc(-c2csc(N3CCOCC3)n2)cs1,6.66,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323487,Oc1c(F)cccc1-c1csc(N2CCOCC2)n1,6.57,group3-int,int,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323488,COc1cc(F)ccc1-c1csc(N2CCOCC2)n1,6.64,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323489,Clc1ncn(-c2csc(N3CCOCC3)n2)c1Br,6.48,group3-int,int,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323490,Clc1ncn(-c2csc(N3CCOCC3)n2)c1Cl,6.17,group3-int,int,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323491,Oc1c(-c2csc(N3CCOCC3)n2)ccc(F)c1F,6.1,group3-int,int,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323492,Clc1cn(-c2csc(N3CCOCC3)n2)cn1,6.14,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323493,Oc1cc(F)ccc1-c1csc(N2CCOCC2)n1,6.09,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323494,Clc1c(Br)ncn1-c1csc(N2CCOCC2)n1,5.89,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323495,Ic1ncn(-c2csc(N3CCOCC3)n2)c1I,5.74,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323496,c1ccc(-c2csc(N3CCOCC3)n2)nc1,5.59,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323497,Clc1ncn(-c2csc(N3CCOCC3)n2)c1I,5.58,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323498,Brc1cn(-c2csc(N3CCOCC3)n2)cn1,5.76,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,2014
CHEMBL3323499,c1cc(-c2csc(N3CCOCC3)n2)ccn1,5.53,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323500,COc1c(F)cc(O)cc1-c1csc(N2CCOCC2)n1,5.52,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323501,CS(=O)(=O)c1c(F)cccc1-c1csc(N2CCOCC2)n1,5.45,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323502,Cc1ncn(-c2csc(N3CCOCC3)n2)c1C,5.45,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3323503,Cc1sc(N2CCOCC2)nc1-c1ccccc1,5.84,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL3326454,CO[C@@H]1C(c2ccc(C#N)c(Cl)c2C)=NN2CC[C@H](O)[C@@H]12,9.15,group1-p,p,Androgen Receptor,Displacement of [3H]DHT from androgen receptor in human MDA-MB-435 cells after 30 mins,2014
CHEMBL3337731,Cc1nn(Cc2ccccc2)c(-c2ccc(F)cc2)c1-c1ccc2c(c1)NC(=O)CO2,5.25,group4-ia,ia,Androgen Receptor,Displacement of [3H]testosterone from androgen receptor (unknown origin) expressed in 293 cells after 16 hrs by scintillation counting,2014
CHEMBL3337823,CCCCn1nc(C)c(-c2ccc3c(c2)NC(=O)CO3)c1-c1ccc(F)cc1,5.44,group4-ia,ia,Androgen Receptor,Displacement of [3H]testosterone from androgen receptor (unknown origin) expressed in 293 cells after 16 hrs by scintillation counting,2014
CHEMBL3337824,Cc1nn(CC(C)C)c(-c2ccc(F)cc2)c1-c1ccc2c(c1)NC(=O)CO2,5.43,group4-ia,ia,Androgen Receptor,Displacement of [3H]testosterone from androgen receptor (unknown origin) expressed in 293 cells after 16 hrs by scintillation counting,2014
CHEMBL3337831,Cc1nn(CCC(C)(F)F)c(-c2ccc(F)cc2)c1-c1ccc2c(c1)NC(=O)CO2,5.04,group4-ia,ia,Androgen Receptor,Displacement of [3H]testosterone from androgen receptor (unknown origin) expressed in 293 cells after 16 hrs by scintillation counting,2014
CHEMBL3343778,CC(C)c1ccc2c(c1)C(=O)C[C@@H]1[C@]2(C)CCC[C@@]1(C)CNC(=O)c1ccccc1,4.08,group4-ia,ia,Androgen Receptor,Binding affinity to androgen receptor (unknown origin),2014
CHEMBL335316,CC1(C)CCc2cc3c(C(F)(F)F)cc(C#N)nc3cc2N1,8.05,group1-p,p,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL335992,CC1=CC(C)(C)Nc2ccc(-c3csc(C#N)c3)cc21,6.31,group3-int,int,Androgen Receptor,Cross-reactivity as binding to human androgen receptor (hAR),2000
CHEMBL336169,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccco1)Oc1ccc(F)cc1-3,6.59,group3-int,int,Androgen Receptor,Inhibition of human androgen receptor at 10e-12 to 10e-5 M,2003
CHEMBL336353,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1N(C)C)Oc1ccc(F)cc1-3,5.82,group4-ia,ia,Androgen Receptor,Inhibition of human androgen receptor at 10e-12 to 10e-5 M,2003
CHEMBL336736,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1ccc(F)cc1-3,6.09,group3-int,int,Androgen Receptor,Inhibition of human androgen receptor at 10e-12 to 10e-5 M,2003
CHEMBL338922,CC1(C)CCc2cc3c(C(F)(F)F)ccnc3cc2N1,6.67,group3-int,int,Androgen Receptor,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,2000
CHEMBL3402221,C[C@H]1CCCN1c1ccc(C#N)c2ccccc12,9.08,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3402222,C[C@@H]1CCCN1c1ccc(C#N)c2ccccc12,7.7,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3402223,CC1(C)CCCN1c1ccc(C#N)c2ccccc12,8.15,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3402224,CC[C@H]1CCCN1c1ccc(C#N)c2ccccc12,8.96,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3402225,CC(C)[C@H]1CCCN1c1ccc(C#N)c2ccccc12,8.85,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3402226,N#Cc1ccc(N2CCC[C@@H]2C(N)=O)c2ccccc12,7.47,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3402227,N#Cc1ccc(N2CCC[C@@H]2C#N)c2ccccc12,9,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3402228,C[C@H]1[C@@H](O)CCN1c1ccc(C#N)c2ccccc12,8.66,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3402229,C[C@H]1[C@H](O)CCN1c1ccc(C#N)c2ccccc12,8.62,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3402230,C[C@H]1C(=O)CCN1c1ccc(C#N)c2ccccc12,7.43,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3402231,C[C@H]1[C@@H](CO)CCN1c1ccc(C#N)c2ccccc12,8.39,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3402232,C[C@H]1[C@@H](C(C)(C)O)CCN1c1ccc(C#N)c2ccccc12,8.85,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3402233,COC(=O)[C@H]1CCN(c2ccc(C#N)c3ccccc23)[C@H]1C,8.12,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL3410850,N#Cc1ccc(N2[C@H]3CC[C@H]2CC(O)C3)cc1C(F)(F)F,7.4,group2-a,a,Androgen Receptor,Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition,2015
CHEMBL3410851,CC1(O)C[C@@H]2CC[C@@H](C1)N2c1ccc(C#N)c(C(F)(F)F)c1,7.53,group2-a,a,Androgen Receptor,Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition,2015
CHEMBL3410852,N#Cc1ccc(N2C3CCC2CC(=O)C3)cc1C(F)(F)F,7.18,group2-a,a,Androgen Receptor,Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition,2015
CHEMBL3410853,N#Cc1ccc(N2[C@H]3CC[C@H]2CC(NCc2ccccc2)C3)cc1C(F)(F)F,6.63,group3-int,int,Androgen Receptor,Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay,2015
CHEMBL3410854,CS(=O)(=O)NC1C[C@@H]2CC[C@@H](C1)N2c1ccc(C#N)c(C(F)(F)F)c1,5.58,group4-ia,ia,Androgen Receptor,Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition,2015
CHEMBL3410855,CCS(=O)(=O)NC1C[C@@H]2CC[C@@H](C1)N2c1ccc(C#N)c(C(F)(F)F)c1,5.69,group4-ia,ia,Androgen Receptor,Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition,2015
CHEMBL3410856,Cc1c(N2C3CCC2CC(C)(O)C3)ccc(C#N)c1Cl,8.68,group1-p,p,Androgen Receptor,Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition,2015
CHEMBL3421871,CC[C@@]12C[C@@](C)(O)[C@](O)(c3ccccc3)C[C@H]1CCc1cc(O)ccc12,6.52,group3-int,int,Androgen Receptor,Binding affinity to human AR,2015
CHEMBL3421892,Cc1noc(=O)c2ccc(NC(=O)C(O)(CC3(c4cc(F)ccc4Cl)CCC3)C(F)(F)F)cc12,7.4,group2-a,a,Androgen Receptor,Binding affinity to human AR,2015
CHEMBL342426,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccc(F)c(F)c1)Oc1ccccc1-3,6.04,group3-int,int,Androgen Receptor,Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells,1998
CHEMBL343306,CC1(C)OC(=O)Nc2ccc(-c3ccc(F)c(Cl)c3)cc21,6.68,group3-int,int,Androgen Receptor,Antagonist activity against the Androgen Receptor (AR),2002
CHEMBL345342,CC1=CC(C)(C)N(C)c2cc3c(cc21)c(C(F)(F)F)cc(=O)n3C,7.34,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL345854,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NC1(CCCCC1)CC3,7.46,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL346487,CC1=CC(C)(C)Nc2cc3nc(O)cc(C)c3cc21,7.44,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL346827,Cn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)NC(C)(C)CC3,7.44,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL347556,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)N1CCOCCN1CCN(CCOCc2ccc(O)c(C(N)=O)c2)CC1,6.46,group3-int,int,Androgen Receptor,Inhibition of 1.0 nM [3H]mibolerone binding to human androgen receptor of PC3/AR cell lysate,2003
CHEMBL347870,CC1=CC(C)(C)N(C)c2cc3nc(O)cc(C(F)(F)F)c3cc21,6.81,group3-int,int,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL347910,Cc1c2c(cc3c(C(F)(F)F)cc(O)nc13)C(C)CC(C)(C)N2,7.66,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL348495,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)N1CCOCCOCCOCc1ccc(O)c(C(N)=O)c1,6.48,group3-int,int,Androgen Receptor,Inhibition of 1.0 nM [3H]mibolerone binding to human androgen receptor of PC3/AR cell lysate,2003
CHEMBL348918,C[C@H]1Nc2cc3c(cc2[C@H]1C)c(C(F)(F)F)cc(=O)n3C,5.04,group4-ia,ia,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL349539,CC1=C(C)C(C)(C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,7.17,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL349631,C[C@H]1N(C)c2cc3c(cc2C1(C)C)c(C(F)(F)F)cc(=O)n3C,7.25,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL350465,CCC1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2NC1(C)C,7.34,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL350877,CC1(C)C=Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,7.57,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL351022,CC1(C)CNc2cc3nc(O)cc(C(F)(F)F)c3cc21,8,group1-p,p,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL351148,CCC1(C)CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,7.64,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL351465,C[C@@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,8.15,group1-p,p,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL351519,C[C@H]1Nc2cc3c(cc2C1(C)C)c(C(F)(F)F)cc(=O)n3C,7.66,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL352002,Cc1c2c(cc3c(C(F)(F)F)cc(=O)n(C)c13)C(C)CC(C)(C)N2,7.51,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL352456,CCn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)N[C@@H]1CCCC[C@H]31,6.64,group3-int,int,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL3576885,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3cc(-c4cc[nH]n4)ccc3[nH]2)C1=O,5.51,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,2015
CHEMBL3578271,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3cc(Cl)ccc3[nH]2)C1=O,5.51,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,2015
CHEMBL3578274,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3cc(C(F)(F)F)ccc3[nH]2)C1=O,5.52,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,2015
CHEMBL3578276,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3cc(NS(C)(=O)=O)ccc3[nH]2)C1=O,4.89,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,2015
CHEMBL3578284,Cc1nocc1-c1ccc2[nH]c([C@@]3(Cc4ccccc4)OC(=O)N([C@H](C)c4ccc(F)cc4)C3=O)nc2c1,5.47,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,2015
CHEMBL3578285,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3cc(N4CCOCC4)ccc3[nH]2)C1=O,5.11,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,2015
CHEMBL3578286,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3cc(-c4cccnc4)ccc3[nH]2)C1=O,5.43,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,2015
CHEMBL3578295,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3c(NS(C)(=O)=O)cccc3[nH]2)C1=O,4.96,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,2015
CHEMBL3590187,CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,7.3,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human prostate cancer cells,2014
CHEMBL359911,O=C1[C@H]2C3CCC(C3)[C@H]2C(=O)N1c1ccc2ccccc2c1,5.92,group4-ia,ia,Androgen Receptor,Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay,2005
CHEMBL3605560,CC(=O)OC[C@]12CC[C@H]3[C@@H](CC=C4C=CCC(=O)[C@@]43C)[C@]1(O)CC[C@@]2(O)[C@@](C)(O)[C@H]1CC(C)=C(C)C(=O)O1,5.45,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced KLK3 gene expression by Array Plate assay,2015
CHEMBL3605562,CC(=O)OC[C@]12CC[C@H]3[C@@H](CC=C4CC=CC(=O)[C@@]43C)[C@]1(O)[C@@H](OC(C)=O)C[C@@]2(O)[C@@](C)(O)[C@H]1CC(C)=C(C)C(=O)O1,5.57,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced SPDEF gene expression by Array Plate assay,2015
CHEMBL3605563,CC(=O)OC[C@]12CC[C@H]3[C@@H](CC=C4C=CCC(=O)[C@@]43C)[C@]1(O)[C@@H](OC(C)=O)C[C@@]2(O)[C@@](C)(O)[C@H]1CC(C)=C(C)C(=O)O1,5.92,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced SPDEF gene expression by Array Plate assay,2015
CHEMBL3605564,CC(=O)OC[C@]12CC[C@H]3[C@@H](CC=C4CC=CC(=O)[C@@]43C)[C@]1(O)CC[C@@]2(O)[C@@](C)(O)[C@H]1CC(C)=C(C)C(=O)O1,6.24,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced KLK2 gene expression by Array Plate assay,2015
CHEMBL361222,O=C1[C@H]2C3C=CC(C3)[C@H]2C(=O)N1c1ccc(Br)c(C(F)(F)F)c1,6.84,group3-int,int,Androgen Receptor,Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay,2005
CHEMBL361245,CC(=O)O[C@]1(C(C)=O)CCC2C3C=C(Cl)C4=CC(=O)[C@@H]5CC5[C@]4(C)C3CC[C@@]21C,7.21,group2-a,a,Androgen Receptor,Inhibition of human lymph node carcinoma of prostate (LNCaP) cell proliferation,2004
CHEMBL361445,O=C1[C@H]2C3C=CC(CC3)[C@H]2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,6.65,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human MDA-453 cells,2005
CHEMBL3622573,Cc1ccccc1Cc1n[nH]c(=O)c2ccccc12,5.02,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay,2015
CHEMBL3622574,COc1ccccc1Cc1n[nH]c(=O)c2ccccc12,5.02,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay,2015
CHEMBL3622575,O=c1[nH]nc(Cc2ccccc2F)c2ccccc12,4.98,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay,2015
CHEMBL3622576,O=c1[nH]nc(Cc2ccccc2C(F)(F)F)c2ccccc12,5.43,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay,2015
CHEMBL3622578,O=c1[nH]nc(Cc2ccccc2[N+](=O)[O-])c2ccccc12,5.84,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant expressed in human LNCaP cells assessed as inhibition of 10 nM DHT-stimulated cell proliferation after 6 days by WST-8 assay,2015
CHEMBL3622579,Nc1ccccc1Cc1n[nH]c(=O)c2ccccc12,4.34,group4-ia,ia,Androgen Receptor,Displacement of [3H]-DHT from human GST fused AR-LBD (627 to 919 amino acids) transfected in Escherichia coli HB 101 after 15 hrs by liquid scintillation counting assay,2015
CHEMBL3622581,O=C(Nc1ccccc1Cc1n[nH]c(=O)c2ccccc12)C(F)(F)F,6,group3-int,int,Androgen Receptor,Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay,2015
CHEMBL3622583,CCN(CC)c1ccccc1Cc1n[nH]c(=O)c2ccccc12,5.78,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay,2015
CHEMBL3622584,CCNc1ccccc1Cc1n[nH]c(=O)c2ccccc12,5.43,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay,2015
CHEMBL3622585,CN(C)c1ccccc1Cc1n[nH]c(=O)c2ccccc12,5.71,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay,2015
CHEMBL3622586,CNc1ccccc1Cc1n[nH]c(=O)c2ccccc12,5.04,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay,2015
CHEMBL3622587,Cc1cccc(C)c1Cc1n[nH]c(=O)c2ccccc12,5.86,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay,2015
CHEMBL3622588,O=c1[nH]nc(Cc2c(F)cccc2F)c2ccccc12,5.42,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay,2015
CHEMBL3622589,O=c1[nH]nc(Cc2c(Cl)cccc2Cl)c2ccccc12,4.96,group4-ia,ia,Androgen Receptor,Displacement of [3H]-DHT from human GST fused AR-LBD (627 to 919 amino acids) transfected in Escherichia coli HB 101 after 15 hrs by liquid scintillation counting assay,2015
CHEMBL3622590,O=c1[nH]nc(Cc2c(Cl)ccc(Cl)c2Cl)c2ccccc12,4.25,group4-ia,ia,Androgen Receptor,Displacement of [3H]-DHT from human GST fused AR-LBD (627 to 919 amino acids) transfected in Escherichia coli HB 101 after 15 hrs by liquid scintillation counting assay,2015
CHEMBL3623004,C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(/C=C/C(=O)O)cc2F)N1CC(C)(C)F,4.52,group4-ia,ia,Androgen Receptor,Binding affinity to androgen receptor (unknown origin),2015
CHEMBL3623114,C[C@@]12C[C@H](O)[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(I)c3)C(=O)[C@@H]12,8,group1-p,p,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL3623116,CC(C)OC(=O)[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.66,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL3623117,CN(C(=O)[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12)c1ccccc1,7.47,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL3623118,C[C@@]12C[C@@H](N)[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.22,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL3623119,CCC(=O)N[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.64,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL3623120,CNS(=O)(=O)N[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.47,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL3623121,CC(C)NC(=O)N[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.22,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL3623122,CN1CCN(OC(=O)N[C@@H]2C[C@]3(C)O[C@]2(C)[C@@H]2C(=O)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)[C@@H]23)CC1,8.22,group1-p,p,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL3623123,C[C@@]12C[C@@H](NS(C)(=O)=O)[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.7,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL3623124,C[C@@]12C[C@@H](NS(=O)(=O)c3ccccc3)[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,9,group1-p,p,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL3623125,C[C@@]12C[C@@H](NS(=O)(=O)c3ccccc3F)[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,8,group1-p,p,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL3623126,C[C@@]12C[C@@H](NS(=O)(=O)c3cccnc3)[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,8.15,group1-p,p,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL3623127,CCS(=O)(=O)N[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,7.8,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,2015
CHEMBL362566,N#Cc1ccc(N2C(=O)[C@H]3[C@@H]4C[C@@H](CN4C(=O)Oc4ccc(F)cc4)N3C2=O)cc1C(F)(F)F,5.41,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against mutant androgen receptor of LNCap cells,2004
CHEMBL363151,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(Cc4ccc(C)cc4)C3=CC[C@@]21C,5.19,group4-ia,ia,Androgen Receptor,Inhibition of human androgen receptor,2005
CHEMBL364393,CC(C)(C)OC(=O)N1C[C@H]2C[C@@H]1[C@H]1C(=O)N(c3ccc([N+](=O)[O-])cc3)C(=O)N12,5.62,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against mutant androgen receptor of LNCap cells,2004
CHEMBL365482,CCCCc1ccc(C(=O)N2C[C@@H]3C[C@H]2[C@@H]2C(=O)N(c4ccc([N+](=O)[O-])cc4)C(=O)N32)cc1,5.32,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against mutant androgen receptor of LNCap cells,2004
CHEMBL365650,O=C1[C@H]2[C@@H]3C[C@@H](CN3C(=O)c3ccccc3)N2C(=O)N1c1ccc([N+](=O)[O-])cc1,5.59,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against mutant androgen receptor of LNCap cells,2004
CHEMBL3658376,C[C@]12CCC3C4CCC(=O)C=C4CCC3C1C1CC1[C@@]21CCC(=O)O1,8.22,group1-p,p,Androgen Receptor,"Binding Assay: The test was carried out as in 1, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3658377,CC1CC2=CC(=O)CCC2C2CC[C@@]3(C)C(C4CC4[C@@]34CCC(=O)O4)C12,7.21,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3658378,CCC1CC2=CC(=O)CCC2C2CC[C@@]3(C)C(C4CC4[C@@]34CCC(=O)O4)C12,7.13,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3658379,C=CC1CC2=CC(=O)CCC2C2CC[C@@]3(C)C(C4CC4[C@@]34CCC(=O)O4)C12,7.26,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3658380,C[C@]12CCC3C4CCC(=O)C=C4CC(C4CC4)C3C1C1CC1[C@@]21CCC(=O)O1,7.11,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3658381,C[C@]12CCC3C4CCC(=O)C=C4[C@H](CO)CC3C1C1CC1[C@@]21CCC(=O)O1,5,group4-ia,ia,Androgen Receptor,"Binding Assay: The test was carried out as in 1, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3658382,C[C@]12CCC3C4CCC(=O)C=C4C4(CC4)CC3C1C1CC1[C@@]21CCC(=O)O1,7.58,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3658384,C[C@]12CCC3C4CCC(=O)C=C4C4CC4C3C1C1CC1[C@@]21CCC(=O)O1,6.48,group3-int,int,Androgen Receptor,"Binding Assay: The test was carried out as in 1, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL365921,N#Cc1ccc(N2C(=O)[C@H]3[C@@H]4C[C@@H](CN4C(=O)Oc4ccc(F)cc4)N3C2=O)c2ccccc12,5.73,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against mutant androgen receptor of LNCap cells,2004
CHEMBL3667040,C/C=C/C1=CC2=C(CO1)C(=O)[C@]1(C)OC(=O)[C@H](C(O)CCCCC)C1C2,4.92,group4-ia,ia,Androgen Receptor,"Inhibition Assay: To conduct the assays, the 250 uM monasuspiloin solution was further diluted with 10% DMSO to prepare 25 uM, and 5 uM monasuspiloin samples, and the final concentration of DMSO in the cell culture was 1%.The cell line used in glucocorticoid receptor (GR) assay was human A-549 cells (cultured in Ham's F12K medium (Gibco, USA), 10% FBS), the cell line used in progesterone receptor (PR) assay was human T-47D cells (cultured in RPMI 1640 medium (Gibco, USA), 10% FBS), and the cell line used in estrogen receptor (ER) assay was human MCF7 cells (cultured in MEM medium (Gibco, USA), 10% FBS). The cells in the exponential phase of growth were washed off with 1 ml of 0.05% trypsin, centrifuged and collected in a centrifuge tube. 1x107 cells were resuspended in 270 ul BES medium (5 mM BES in medium) and 8 to 10 ug of plasmid [pMMTV-SEAP plasmid was used for GR and PR (see FIG. 7), and pTA-ERE-SEAP plasmid (Clontech, USA) was used for ER (see FIG. 8)] were also added.",2015
CHEMBL366924,Cc1ccc(N2C(=O)[C@H]3C4C=CC(C4)[C@H]3C2=O)cc1C,7.02,group2-a,a,Androgen Receptor,Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation,2005
CHEMBL367364,O=C1[C@H]2C3CCC(C3)[C@H]2C(=O)N1c1cccc(C(F)(F)F)c1,6.9,group3-int,int,Androgen Receptor,Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay,2005
CHEMBL367375,O=C1[C@H]2C3C=CC([C@@H]4C[C@H]34)[C@H]2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,6.11,group3-int,int,Androgen Receptor,Inhibition of androgen receptor in human MDA-453 cells,2005
CHEMBL3682510,O[C@]1(C(F)(F)F)CCCc2c1[nH]c1cc(Cl)c(Cl)cc21,7.89,group2-a,a,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682511,O[C@]1(C(F)(F)F)CCCc2c1[nH]c1c(Cl)cc(Cl)cc21,7.7,group2-a,a,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682512,OC1(C(F)(F)F)c2[nH]c3cc(Cl)c(Cl)cc3c2CCC1F,6.85,group3-int,int,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682513,OC1(C(F)(F)F)CCCc2c1[nH]c1ccc(F)c(Cl)c21,6.28,group3-int,int,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682514,OC1c2[nH]c3ccc(Cl)c(Cl)c3c2C(C(F)(F)F)CC1F,7.16,group2-a,a,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682515,OC1(C(F)(F)F)CCCc2c1[nH]c1cc(Cl)c(F)cc21,7.7,group2-a,a,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682517,OC1(C(F)(F)F)c2[nH]c3cc(Cl)c(Cl)cc3c2CCC1(F)F,6.66,group3-int,int,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682519,CC1CCc2c([nH]c3ccc(Cl)c(Cl)c23)C1(O)C(F)(F)F,6.4,group3-int,int,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682520,OC1(C(F)(F)F)CCCc2c1[nH]c1cc(Cl)c(Cl)c(Cl)c21,6.39,group3-int,int,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682521,OC1(C(F)(F)F)CCCc2c1[nH]c1c(Cl)c(Cl)ccc21,6.89,group3-int,int,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682523,OC1(C(F)(F)F)CCc2c1[nH]c1cc(Cl)c(Cl)cc21,6.92,group3-int,int,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682524,OC1(C(F)(F)F)CCCc2c1[nH]c1c(F)cc(Cl)cc21,7.27,group2-a,a,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682525,OC1(C(F)(F)F)CCc2c1[nH]c1ccc(Cl)c(Cl)c21,6.76,group3-int,int,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3682526,N#Cc1cc(C(F)(F)F)c2[nH]c3c(c2c1)CCCC3(O)C(F)(F)F,6.41,group3-int,int,Androgen Receptor,"Biological Assay: In order to demonstrate the utility of the compounds of this invention, an androgen receptor binding assay was performed wherein many of the compounds of this invention are shown to demonstrate significant affinity for the androgen receptor. The assay was performed as specified by the manufacturer (Invitrogen, Madison, Wis.). Briefly, 1 ul of 10 mM compound was added to 500 ul of AR screening buffer in a 1.5 ml eppendorf tube to make a 2x10-5M stock. 10-fold serial dilutions of the test compounds were prepared ranging in concentration from 10-5M to 10-12M. Each dilution was added in triplicate to a black 384-microtiter plate. The test compounds will be diluted 2-fold in the final reaction. 2xAR-Fluormone complex was prepared with 2 nM Flourmone AL Green and 30 nM AR. 25 ul of 2x complex was aliquoted to each reaction well, such that the final reaction volume was 50 ul per well. The plate was sealed with a foil cover and incubated in the dark at room temperature.",2015
CHEMBL3687970,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]21C=CCO1,7.57,group2-a,a,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL368906,O=C1[C@H]2C3C=CC(C3)[C@H]2C(=O)N1c1ccc([N+](=O)[O-])c(C(F)(F)F)c1,6.92,group3-int,int,Androgen Receptor,Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay,2005
CHEMBL3692346,C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@@H]43)[C@@H]1CC[C@@]21C=CCO1,6.18,group3-int,int,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL3692347,C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34C=CCO4)[C@@H]21,7.35,group2-a,a,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL3692348,CC[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34C=CCO4)[C@@H]21,7.19,group2-a,a,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL3692349,C=C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34C=CCO4)[C@H]12,7.28,group2-a,a,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL3692350,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC1(CC1)[C@@]21C=CCO1,6.85,group3-int,int,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL3692351,CC[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]21C=CCO1,6.8,group3-int,int,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL3692352,CC[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@@H]43)[C@@H]1CC[C@@]21C=CCO1,6,group3-int,int,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL3692353,CC[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4C[C@@H](C)[C@H]3[C@@H]1CC[C@@]21C=CCO1,7.09,group2-a,a,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL3692354,CC[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]2CC[C@@]3(CC)[C@@H](CC[C@@]34C=CCO4)[C@@H]21,6,group3-int,int,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL3692355,C=C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]2CC[C@@]3(CC)[C@@H](CC[C@@]34C=CCO4)[C@H]12,5.89,group4-ia,ia,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL3692356,CC[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4C[C@@H](C4CC4)[C@H]3[C@@H]1CC[C@@]21C=CCO1,6.72,group3-int,int,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL3692357,CC[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4[C@H](CO)C[C@H]3[C@@H]1CC[C@@]21C=CCO1,6.85,group3-int,int,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL369509,O=C1[C@H]2C3C=CC(C3)[C@H]2C(=O)N1c1ccc(O)c2ncccc12,5.44,group4-ia,ia,Androgen Receptor,Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation,2005
CHEMBL369542,O=C1[C@H]2C3C=CC(CCC3)[C@H]2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,7.31,group2-a,a,Androgen Receptor,Inhibition of androgen receptor in human MDA-453 cells,2005
CHEMBL3695596,C[C@]12CCC3[C@@H](C4CC4C4=CC(=O)CC[C@@]43C)C1C1CC1[C@@]21CCC(=O)C1,6.2,group3-int,int,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695597,C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@@H]43)[C@@H]1CC[C@@]21C=CC(=O)O1,5,group4-ia,ia,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695598,C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34C=CC(=O)O4)[C@@H]21,6.96,group3-int,int,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695599,CC[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34C=CC(=O)O4)[C@@H]21,7.05,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695600,C=C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34C=CC(=O)O4)[C@H]12,6.89,group3-int,int,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695601,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC1(CC1)[C@@]21C=CC(=O)O1,6.51,group3-int,int,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695602,CC[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]21C=CC(=O)O1,7.55,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695603,CC[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@@H]43)[C@@H]1CC[C@@]21C=CC(=O)O1,5.58,group4-ia,ia,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695604,CC[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4C[C@@H](C)[C@H]3[C@@H]1CC[C@@]21C=CC(=O)O1,7.37,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695605,CC[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]2CC[C@@]3(CC)[C@@H](CC[C@@]34C=CC(=O)O4)[C@@H]21,7.12,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695606,C=C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]2CC[C@@]3(CC)[C@@H](CC[C@@]34C=CC(=O)O4)[C@H]12,7.3,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695607,CC[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4C[C@@H](C4CC4)[C@H]3[C@@H]1CC[C@@]21C=CC(=O)O1,7.03,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695608,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4C[C@@H](C4CC4)[C@H]3[C@@H]1CC[C@@]21C=CC(=O)O1,6.52,group3-int,int,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695609,CC[C@]12CC[C@@H]3[C@H]4CCC(=O)C(Cl)=C4CC[C@H]3[C@@H]1CC[C@@]21C=CC(=O)O1,6.77,group3-int,int,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695610,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C(Cl)=C4CC[C@H]3[C@@H]1CC[C@@]21C=CC(=O)O1,6.85,group3-int,int,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695611,CC[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4[C@H](CO)C[C@H]3[C@@H]1CC[C@@]21C=CC(=O)O1,6,group3-int,int,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695612,CC[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4C4(CC4)C[C@H]3[C@@H]1CC[C@@]21C=CC(=O)O1,7.38,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695613,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4[C@H](CO)C[C@H]3[C@@H]1CC[C@@]21C=CC(=O)O1,6,group3-int,int,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL3695614,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4C4(CC4)C[C@H]3[C@@H]1CC[C@@]21C=CC(=O)O1,7.43,group2-a,a,Androgen Receptor,"Binding Assay: The test was carried out as in 1., with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL369979,C=CC[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,5.75,group4-ia,ia,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL369991,CC/C=C\[C@]12CC[C@H](O)CC1=CCC1C3CC[C@H](O)[C@@]3(C)CCC12,5.42,group4-ia,ia,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL370236,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43/C=C/Cl)C1CC[C@@H]2O,5.84,group4-ia,ia,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL3706874,CCC1CCc2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2N1,7.85,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706875,CCCNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,7.5,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706876,Nc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,7.55,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706877,CNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,7.52,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706878,CCNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,7.46,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706879,CCCCNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,7.17,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706880,CC(C)Nc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,7.25,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706881,CC(C)CNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,7.13,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706882,CC(C)(C)CNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,7.01,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706883,CCC(C)(C)Nc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,6.68,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706884,C=CC(C)(C)Nc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,6.91,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706885,O=c1cc(C(F)(F)F)c2ccc(NC3CCC3)cc2[nH]1,7.37,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706886,O=c1cc(C(F)(F)F)c2ccc(NC3CCCC3)cc2[nH]1,6.83,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706887,O=c1cc(C(F)(F)F)c2ccc(NC3CCCCC3)cc2[nH]1,6.29,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706888,O=c1cc(C(F)(F)F)c2ccc(NCC(F)(F)F)cc2[nH]1,7.68,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706889,O=c1cc(C(F)(F)F)c2ccc(NCC(F)(F)C(F)(F)F)cc2[nH]1,7.24,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706891,O=c1cc(C(F)(F)F)c2ccc(NCc3ccccc3)cc2[nH]1,6.53,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706892,CN(C)c1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,5.94,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706893,CCN(CC)c1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,6.23,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706894,CCN(CC(F)(F)F)c1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,7.38,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706895,CCCN(CC(F)(F)F)c1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,6.26,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706896,Cc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1N,7.12,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706897,CCc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1N,7.64,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706898,CCCc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1N,7.72,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706899,CCC(C)c1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1N,7.85,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706900,CCCNc1cc2[nH]c(=O)cc(C(F)(F)F)c2cc1C,6.17,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706901,Cc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1NCC(C)C,6.52,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706902,CCc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1NC,6.3,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706903,CCc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1NCC(F)(F)F,6.67,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706904,O=c1cc(C(F)(F)F)c2ccc(NCC(F)(F)F)cc2o1,7.3,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706905,O=c1cc(C(F)(F)F)c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc2o1,7.2,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706906,CCNc1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,6.96,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706907,O=c1cc(C(F)(F)F)c2cc(NCC(F)(F)F)ccc2[nH]1,7.75,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706908,O=c1cc(C(F)(F)F)c2cc(NCC(F)(F)C(F)(F)F)ccc2[nH]1,7.77,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706909,O=c1cc(C(F)(F)F)c2cc(NC3CCCC3)ccc2[nH]1,7.38,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706910,CC(C)CNc1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,7.66,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706911,CC(C)(C)CNc1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,7.57,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells,2007
CHEMBL3706928,CCOC(=O)CN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,7.72,group2-a,a,Androgen Receptor,Antagonist activity at human AR,2007
CHEMBL3706929,O=C(N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1)C(F)(F)F,8.39,group1-p,p,Androgen Receptor,Antagonist activity at human AR,2007
CHEMBL371392,CCCCc1ccc(C(=O)N2C[C@@H]3C[C@H]2[C@@H]2C(=O)N(c4ccc(C#N)cc4)C(=O)N32)cc1,5.17,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against mutant androgen receptor of LNCap cells,2004
CHEMBL372390,C[C@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@H](C)CN1C(=O)Nc1ccc(C(F)(F)F)nc1,5.89,group4-ia,ia,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL373019,C=C[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,7.48,group2-a,a,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL373460,CCCCN(C)C(=O)CCCCCCCCCCC[C@@H]1CC2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]21,5.46,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL375107,BrCC(Br)C1CCC(Br)C(Br)C1,7.37,group2-a,a,Androgen Receptor,Activity against human androgen receptor expressed in HepG2 cells assessed as luciferase reporter gene activation,2006
CHEMBL375282,CCCN(C)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,6.52,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL375675,CCCCN(C)C(=O)CCCCCCCCCC[C@@H]1CC2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]21,5.72,group4-ia,ia,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL376182,CCN(CC)C(=O)CCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,6.48,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL378274,Oc1nnc(Cc2ccccc2Cl)c2ccccc12,4.07,group4-ia,ia,Androgen Receptor,Displacement of [3H]-DHT from human GST fused AR-LBD (627 to 919 amino acids) transfected in Escherichia coli HB 101 after 15 hrs by liquid scintillation counting assay,2015
CHEMBL3785926,Cc1cc(=O)oc2cc(OCC(=O)C(C)(C)C)ccc12,5.42,group4-ia,ia,Androgen Receptor,Antagonist activity against androgen receptor (unknown origin),2016
CHEMBL3787387,CCOC(=O)C(CC)Oc1ccc2c(C)cc(=O)oc2c1,5.3,group4-ia,ia,Androgen Receptor,Antagonist activity against androgen receptor (unknown origin),2016
CHEMBL3787517,Cc1cc(=O)oc2cc(OC(C)C(=O)c3ccccc3)ccc12,5.29,group4-ia,ia,Androgen Receptor,Antagonist activity against androgen receptor (unknown origin),2016
CHEMBL379441,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43/C=C\Br)C1CC[C@@H]2O,7.7,group2-a,a,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL379465,C[C@H]1CN(C(=O)Nc2ccc(N)nc2)[C@H](C)CN1c1ccc(C#N)c(C(F)(F)F)c1,6.43,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL380876,CO/C=C\[C@]12CC[C@H](O)CC1=CCC1C3CC[C@H](O)[C@@]3(C)CCC12,5.85,group4-ia,ia,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL381253,COc1ccc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)cn1,6.77,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL381358,CC(=O)c1ccc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)cn1,6.3,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL381558,COc1cncc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)c1,6.36,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL381566,C#C[C@]1(O)CCC2C3CC=C4C[C@@H](O)CC[C@]4(C=C)C3CC[C@@]21C,6.54,group3-int,int,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL381776,Cc1cncc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)c1,6.6,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL382097,CC[C@]12CC[C@H](O)CC1=CCC1C3CC[C@H](O)[C@@]3(C)CCC12,7.48,group2-a,a,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL3827008,CC(O)(CS(=O)(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,5.51,group4-ia,ia,Androgen Receptor,Antagonist activity at GAL4 DBD-fused androgen receptor LBD (unknown origin) transfected in UAS-bla GripTite 293 cells assessed as inhibition of R1881-induced receptor activation after 16 to 24 hrs by beta-lactamase reporter gene assay,2016
CHEMBL3828139,CC(O)(CSc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,6.15,group3-int,int,Androgen Receptor,Antagonist activity at GAL4 DBD-fused androgen receptor LBD (unknown origin) transfected in UAS-bla GripTite 293 cells assessed as inhibition of R1881-induced receptor activation after 16 to 24 hrs by beta-lactamase reporter gene assay,2016
CHEMBL383253,C/C=C\[C@]12CC[C@H](O)CC1=CCC1C3CC[C@H](O)[C@@]3(C)CCC12,6.14,group3-int,int,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL385509,Nc1ccc2nc(O)cc(C(F)(F)F)c2c1,7.58,group2-a,a,Androgen Receptor,Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay,2006
CHEMBL386437,CCCC(=O)Oc1ccc(COCC#CCN2C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1C(=O)NCN[C@H]1CC(OC2C[C@](O)(C(=O)CO)Cc3c(O)c4c(c(O)c32)C(=O)c2c(OC)cccc2C4=O)O[C@@H](C)[C@H]1O,7.2,group2-a,a,Androgen Receptor,Inhibition of [3H]mibolerone binding to human Androgen receptor of PC3/AR Cell Lysate,2004
CHEMBL386630,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,8.57,group1-p,p,Androgen Receptor,Binding affinity at AR,2007
CHEMBL387651,CCNC(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,6.03,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL387850,C[C@]12CCC(=O)CC1C[C@@H](CCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,6.02,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL389277,CN(C)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,6.58,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL3893153,Cc1cc(C(=O)NC[C@H]2CC[C@H](Oc3ccnc4c(C#N)cccc34)CC2)no1,6.19,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3893320,N#Cc1ccc(N2C[C@H]3[C@H]4CC[C@H](C4)[C@@]3(C(N)=O)S2(=O)=O)cc1C(F)(F)F,7.26,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,2016
CHEMBL3894825,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)OCCCCCC(=O)NO)c(F)c1,7.37,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) in membranes after 24 hrs by HAP adsorption assay,2016
CHEMBL3895477,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CCCC(=O)NC)cc3)C2=S)cc1C(F)(F)F,7.04,group2-a,a,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3895604,N#Cc1cccc2c(O[C@H]3CC[C@H](NC(=O)c4ccc(Cl)c(F)c4)CC3)ccnc12,7.21,group2-a,a,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL389631,CCCCN(C)C(=O)CCCCCCCC[C@@H]1CC2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]21,5.47,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL3898284,C[C@@]12[C@@H]3C=C[C@@H](C3)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,7.52,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,2016
CHEMBL3898984,Cc1nocc1C(=O)NC[C@H]1CC[C@H](Oc2ccnc3c(F)cccc23)CC1,6.68,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3899806,O=C(N[C@H]1CC[C@H](Oc2ccnc3c(Br)cccc23)CC1)c1ccc(F)cc1,6.32,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL390071,CCN(C)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,6.18,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells,2007
CHEMBL3900828,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)C2=S)cc1C(F)(F)F,6.86,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3902310,CNC(=O)[C@@]12[C@H]3C[C@H](C[C@@H]3F)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,7.24,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,2016
CHEMBL3903040,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccc(OC(=O)CCl)cc3)C2=S)cc1C(F)(F)F,6.88,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3903756,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)NCCCCCCNS(N)(=O)=O)c(F)c1,6.96,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) in membranes after 24 hrs by HAP adsorption assay,2016
CHEMBL3904234,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccc(N)cc3)C2=S)cc1C(F)(F)F,6.56,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3904554,O=C(N[C@H]1CC[C@H](Oc2ccnc3c(Br)cccc23)CC1)c1cccc(F)c1,7.03,group2-a,a,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3905727,O=C(NC[C@H]1CC[C@H](Oc2ccnc3c(F)cccc23)CC1)c1ccon1,6.13,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL390577,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OCCN3Cc1ccccc1,6.65,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,2007
CHEMBL3907028,N#Cc1cccc2c(O[C@H]3CC[C@H](NC(=O)c4ccc(F)c(Cl)c4)CC3)ccnc12,7.17,group2-a,a,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL390728,CCC1CCNc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,5.13,group4-ia,ia,Androgen Receptor,Antagonist activity against Human Androgen receptor expressed in CV-1 cells,1999
CHEMBL3907304,C[C@@]12[C@@H]3CC[C@@H](C3O)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,6.49,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,2016
CHEMBL390754,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OCCN3,6.53,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,2007
CHEMBL3908221,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)NCCCCCCc2ccc(C(=O)C(F)(F)F)s2)c(F)c1,7.17,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) in membranes after 24 hrs by HAP adsorption assay,2016
CHEMBL3910485,[C-]#[N+]c1ccc(N2C(=O)C3(CCCCC3)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,6.71,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3911299,O=C(NC[C@H]1CC[C@H](Oc2ccnc3c(F)cccc23)CC1)c1cc[nH]n1,6.38,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3912767,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)NCCCCCCn2cccc(O)c2=O)c(F)c1,6.6,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) in membranes after 24 hrs by HAP adsorption assay,2016
CHEMBL3913554,Cc1ccc(C(=O)N[C@H]2CC[C@H](Oc3ccnc4c(Br)cccc34)CC2)cc1F,7.17,group2-a,a,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3913672,N#Cc1ccc(C(=O)N[C@H]2CC[C@H](Oc3ccnc4c(Br)cccc34)CC2)cc1,6.58,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3914094,O=C(N[C@H]1CC[C@H](Oc2ccnc3ccccc23)CC1)c1cccc(F)c1,7.5,group2-a,a,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3915005,C[C@]12CCC3C4CCC(=O)C=C4[C@@H]4C[C@@H]4C3C1C1CC1[C@@]21CCC(=O)O1,6.38,group3-int,int,Androgen Receptor,"Binding Assay: The test was carried out as in 1, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.The results of the binding tests and the ratio of the competition factors CF(PR) and CR(MR) are shown in Table 1, which for comparison also shows receptor binding values of drospirenone as reference substance A.",2015
CHEMBL391548,N#Cc1ccc(-c2ccccc2O)cc1C(F)(F)F,10.7,group1-p,p,Androgen Receptor,Antagonist activity against human androgen receptor expressed in human MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced effect by luciferase receptor gene assay,2008
CHEMBL391549,N#Cc1ccc(-c2cccc(O)c2)cc1C(F)(F)F,6.64,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL391648,C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CCC(=O)C=C1C[C@H]3CCCCCCCCCC(=O)O,5.7,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,2007
CHEMBL3916504,O=C(NC[C@H]1CC[C@H](Oc2ccnc3ccccc23)CC1)c1ccc(F)c(F)c1,6.98,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3917362,O=C(NC[C@H]1CC[C@H](Oc2ccnc3c(F)cccc23)CC1)c1ccc(F)cc1,6.62,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3917372,N#Cc1ccc(N2C[C@H]3[C@H]4CC[C@H](C4)[C@H]3S2(=O)=O)cc1C(F)(F)F,6.89,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,2016
CHEMBL391795,CC[C@]12CC[C@H](O)CC1=CC[C@H]1[C@@H]3CC[C@H](O)[C@@]3(C)CC[C@@H]12,7.06,group2-a,a,Androgen Receptor,Binding affinity to androgen receptor,2007
CHEMBL391798,O=c1ccc2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,9,group1-p,p,Androgen Receptor,Antagonist activity at human AR,2007
CHEMBL3919228,[C-]#[N+]c1ccc(N2C(=O)C3(CCCC3)N(c3ccc([N+](=O)[O-])cc3)C2=S)cc1C(F)(F)F,6.3,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL392000,C=CC[C@@H]1C2=CC[C@@H]3[C@H](CC[C@]4(C)[C@@H](O)CC[C@@H]34)[C@@]2(C=C)CC[C@@H]1O,7.82,group2-a,a,Androgen Receptor,Binding affinity to androgen receptor,2007
CHEMBL392004,CCCc1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,7.44,group2-a,a,Androgen Receptor,Antagonist activity at human AR,2007
CHEMBL3920247,C[C@@]12[C@H]3C[C@H](C[C@@H]3O)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,6.97,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,2016
CHEMBL3920715,N#Cc1cccc2c(O[C@H]3CC[C@H](NC(=O)c4cccc(F)c4)CC3)ccnc12,7.28,group2-a,a,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3921315,CNC(=O)[C@@]12[C@@H]3CC[C@@H](C3)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,7.36,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,2016
CHEMBL3921830,N#Cc1ccc(C(=O)NC[C@H]2CC[C@H](Oc3ccnc4ccccc34)CC2)cc1,6.48,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3926358,C[C@@]12[C@@H]3CC[C@@H](C3)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,7.14,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,2016
CHEMBL3926496,C[C@@]12CCC(=O)C=C1[C@H]1C[C@H]1[C@H]1[C@H]2CC[C@]2(C)[C@@H]1[C@H]1C[C@H]1[C@]21CCC(=O)O1,6.2,group3-int,int,Androgen Receptor,"Receptor Binding Assay: Using cytosol from progesterone receptor-expressing insect cells (Hi5), competitive binding to the progesterone receptor was determined from the ability to displace 3H-progesterone as reference substance from the receptor. If a compound has an affinity corresponding to progesterone, this corresponds to a competition factor (CF) of 1. CF values greater than 1 are characterized by a lower affinity for the progesterone receptor, and CF values of less than 1 are characterized by higher affinity. The test was carried out as test above, with the following modifications: cytosol from androgen receptor-expressing insect cells (Hi5) was used, and the reference substance was 3H-testosterone.",2015
CHEMBL3927163,O=S(=O)(Nc1ccc(Oc2ccccc2)cc1)c1cccc(C(F)(F)F)c1,5.28,group4-ia,ia,Androgen Receptor,Antagonist activity at human AR expressed in HEK293 cells measured after 24 hrs by luciferase reporter gene assay,2016
CHEMBL3927231,O=C(N[C@H]1CC[C@H](Oc2ccnc3c(Br)cccc23)CC1)c1ccc(C(F)(F)F)c(F)c1,6.33,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3928026,N#Cc1cccc2c(O[C@H]3CC[C@H](NC(=O)c4cc(F)cc(F)c4)CC3)ccnc12,7.41,group2-a,a,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL392827,Cc1ccc(-c2ccc(C#N)c(C(F)(F)F)c2)cc1,6.7,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL3929024,O=C(N[C@H]1CC[C@H](Oc2ccnc3c(Br)cccc23)CC1)c1ccc(F)c(F)c1,6.77,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3930760,Cc1cc(C(=O)N[C@H]2CC[C@H](Oc3ccnc4c(C#N)cccc34)CC2)no1,7.75,group2-a,a,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3931647,[C-]#[N+]c1ccc(N2C(=O)C3(CCN(C)CC3)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,6.2,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL393278,C[C@]12CC[C@H]3[C@@H](CC[C@H]4[C@H]5CCC[C@]43CC[C@@H]5O)[C@@H]1CC[C@@H]2O,7.17,group2-a,a,Androgen Receptor,Binding affinity to androgen receptor,2007
CHEMBL3932783,N#Cc1cccc2c(O[C@H]3CC[C@H](NC(=O)c4ccc(F)cc4)CC3)ccnc12,6.85,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL393280,COc1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,7.82,group2-a,a,Androgen Receptor,Antagonist activity at human AR,2007
CHEMBL3932857,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccccc3C)C2=S)cc1C(F)(F)F,6.59,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL393319,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCC(=O)O)C[C@H]1CC(=O)CC[C@@]13C,6.04,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,2007
CHEMBL393320,CN(C)C(=O)CCCCCCC[C@@H]1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]21,6.72,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,2007
CHEMBL3933747,Cc1cc(C(=O)NC[C@H]2CC[C@H](Oc3ccnc4c(F)cccc34)CC2)no1,6.32,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3934779,[C-]#[N+]c1ccc(N2C(=O)C(CCl)(CCl)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,6.28,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3935242,C[C@@]12[C@@H]3CC[C@@H](C3=O)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,7.17,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,2016
CHEMBL3936716,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CCC(=O)NCCO)cc3)C2=S)cc1C(F)(F)F,6.13,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3936931,O=C(N[C@H]1CC[C@H](Oc2ccnc3c(Br)cccc23)CC1)c1ccc(F)c(Cl)c1,6.72,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3937441,O=C(N[C@H]1CC[C@H](Oc2ccnc3ccccc23)CC1)c1ccc(F)c(F)c1,7.35,group2-a,a,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3938351,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccc(C(F)(F)F)cc3)C2=S)cc1C(F)(F)F,6.84,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3938936,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CCC(N)=O)cc3)C2=S)cc1C(F)(F)F,6.65,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3939272,C[C@@]12[C@H]3C[C@H]([C@H](O)C3)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,6.37,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,2016
CHEMBL3940023,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,6.91,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3940304,[C-]#[N+]c1ccc(N2C(=S)N(c3ccc(O)cc3)C(C)(C)C2=S)cc1C(F)(F)F,6.56,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3941698,[C-]#[N+]c1ccc(N2C(=O)C(C)(CF)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,6.9,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL394392,N#Cc1ccc(-c2c(O)cccc2O)cc1C(F)(F)F,6,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL3947344,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(O)cc3)C2=S)cc1C(F)(F)F,6.79,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3948034,Cc1cc(C(=O)NC[C@H]2CC[C@H](Oc3ccnc4ccccc34)CC2)no1,6.68,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3948211,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CO)cc3)C2=S)cc1C(F)(F)F,6.51,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3948452,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(/C=C/C(=O)Nc2ccccc2N)c(F)c1,6.64,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) in membranes after 24 hrs by HAP adsorption assay,2016
CHEMBL3949176,C[C@@]12[C@H]3C[C@H](C[C@@H]3F)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,7.04,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,2016
CHEMBL3953928,O=C(NC[C@H]1CC[C@H](Oc2ccnc3c(Br)cccc23)CC1)c1ccon1,6.2,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3955013,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)Nc2ccccc2N)c(F)c1,6.48,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) in membranes after 24 hrs by HAP adsorption assay,2016
CHEMBL3955747,[C-]#[N+]c1ccc(N2C(=O)C3(CCCC3)N(c3ccc(C#N)cc3)C2=S)cc1C(F)(F)F,6.33,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3958249,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,6.9,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3958745,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CCCC(=O)OC)cc3)C2=S)cc1C(F)(F)F,6.37,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3959058,N#Cc1cccc2c(O[C@H]3CC[C@H](CNC(=O)c4ccon4)CC3)ccnc12,6.14,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3959936,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccccc3)C2=S)cc1C(F)(F)F,6.83,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3960255,N#Cc1cccc2c(O[C@H]3CC[C@H](NC(=O)c4ccc(F)c(F)c4)CC3)ccnc12,7.14,group2-a,a,Androgen Receptor,"Transactivation Assay: PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979) were plated out at a density of 10000 cells per well of a 96-well cell culture plate in RMPI 1640 medium (F1235, Biochrom AG, Berlin, Germany), which contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). On the next day the cells were transiently transfected with the pSG5-vector (#216201 Stratagene), which contained the sequence of the androgen receptor mutant W741C (Haapala et al., Lab Invest. 81(12): 1647-51, 2001), and with a reporter plasmid based on pGL4.14 (#E6691, Promega) with the luciferase-gene (from Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-8, 1987). The cells were treated with the test substances in concentrations from 1×10^−8 to 1×10^−10 M in the presence of 1×10^−10 M R1881 and were incubated overnight at 37° C. and 5% CO2. After 24 hours, 100 μl of Steady Glo Lysis and Detection reagent (E2550, Promega) was added per well and the luminescence was read in a Victor3 Luminometer (PerkinElmer) for 1 second per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3961165,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3cc(C)ccn3)C2=S)cc1C(F)(F)F,6.34,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3962284,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccccn3)C2=S)cc1C(F)(F)F,6.14,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3963614,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccccc3C(=O)O)C2=S)cc1C(F)(F)F,6.28,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3965705,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CCCC(N)=O)cc3)C2=S)cc1C(F)(F)F,6.95,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3966165,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)NCCOCCC(=O)NO)c(F)c1,7.11,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) in membranes after 24 hrs by HAP adsorption assay,2016
CHEMBL3966495,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(N4CCNCC4)cc3)C2=S)cc1C(F)(F)F,6.14,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL396656,N#Cc1ccc(-c2ccccc2C(F)(F)F)cc1C(F)(F)F,7.96,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL3966897,Cc1ccc(C(=O)N[C@H]2CC[C@H](Oc3ccnc4c(C#N)cccc34)CC2)cc1F,7.35,group2-a,a,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3967143,Cc1cc(C(=O)N[C@H]2CC[C@H](Oc3ccnc4c(Br)cccc34)CC2)no1,7.7,group2-a,a,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3967236,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CCC(=O)NC)cc3)C2=S)cc1C(F)(F)F,6.63,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3970563,O=C(NC[C@H]1CC[C@H](Oc2ccnc3ccccc23)CC1)c1cccc(F)c1,6.76,group3-int,int,Androgen Receptor,"Transactivation Assay: PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979) were plated out at a density of 10000 cells per well of a 96-well cell culture plate in RMPI 1640 medium (F1235, Biochrom AG Berlin, Germany) that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). On the next day the cells were transiently transfected with the pSG5-vector (#216201 Stratagene), which contained the sequence of the androgen receptor mutant E709Y (Georget et al., Mol. Endocrinol. 20(4): 724-734, 2006), and with the MMTV-luciferase plasmid (see above, transactivation assay for the androgen receptor mutant W741C). The cells were treated with the test substances in concentrations from 1×10^−8 to 1×10^−10 M in the presence of 1×10^−10 M R1881 and were incubated overnight at 37° C. and 5% CO2. After 24 hours, 100 μl of Steady Glo Lysis and Detection reagent (E2550, Promega) was added per well and the luminescence was read in a Victor3 Luminometer (PerkinElmer) for 1 second per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3972532,[C-]#[N+]c1ccc(N2C(=O)C3(CCCCCC3)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,6.63,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3973262,[C-]#[N+]c1ccc(N2C(=O)N(c3ccc(O)cc3)C(C)(C)C2=O)cc1C(F)(F)F,6.43,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL397343,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H]5CC[C@@]43CCO5)[C@@H]1CC[C@@H]2O,6.15,group3-int,int,Androgen Receptor,Binding affinity to androgen receptor,2007
CHEMBL3973563,O=C(NC[C@H]1CC[C@H](Oc2ccnc3c(F)cccc23)CC1)c1ccno1,6.34,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3974665,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)NCCCNS(N)(=O)=O)c(F)c1,6.46,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) in membranes after 24 hrs by HAP adsorption assay,2016
CHEMBL397563,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)N(CC1CC1)[C@H](c1ccccc1)CO3,7.35,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,2007
CHEMBL3976056,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(-c4ccccc4)cc3)C2=S)cc1C(F)(F)F,6.55,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3977051,[C-]#[N+]c1ccc(N2C(=O)C3(CCCC3)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,6.83,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL3982609,Cc1cc(C(=O)NC[C@H]2CC[C@H](Oc3ccnc4c(Br)cccc34)CC2)no1,6.16,group3-int,int,Androgen Receptor,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37° C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 μg/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Cölbe, Germany), 600 μg/ml Geneticin (G418-sulphate, Invitrogen) and 10 μg/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.12×10^−12 to 1×10^−5 M in the presence of 1×10^−1° R1881 (methyltrienolone). The test plates were incubated overnight at 37° C. and 5% CO2. After 16 hours, 15 μl of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",2016
CHEMBL3982650,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)NCCCn2cccc(O)c2=O)c(F)c1,6.25,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) in membranes after 24 hrs by HAP adsorption assay,2016
CHEMBL398431,CCCN(CC1CC1)c1cc(C(F)(F)F)c(C#N)cn1,9.1,group1-p,p,Androgen Receptor,Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells,2007
CHEMBL398432,N#Cc1cnc(N2CCCCC2)cc1C(F)(F)F,6.68,group3-int,int,Androgen Receptor,Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells,2007
CHEMBL398455,C=C[C@]12CC[C@](C)(O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,6.08,group3-int,int,Androgen Receptor,Binding affinity at AR,2007
CHEMBL398456,C=C[C@]12CCC(C)=CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,6.25,group3-int,int,Androgen Receptor,Binding affinity at AR,2007
CHEMBL3985131,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccc(O)cc3)C2=S)cc1C(F)(F)F,6.86,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL398634,C=C[C@]12CCC(C)=CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,6.28,group3-int,int,Androgen Receptor,Binding affinity at AR,2007
CHEMBL3987109,N#Cc1ccc(N2C[C@H]3[C@H]4C=C[C@H](C4)[C@H]3S2(=O)=O)cc1C(F)(F)F,6.66,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,2016
CHEMBL398840,C=C[C@]12CCC(c3ccccc3)=CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,5.5,group4-ia,ia,Androgen Receptor,Binding affinity at AR,2007
CHEMBL398841,C#C[C@]1(O)CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C=C)[C@H]3CC[C@@]21C,6.54,group3-int,int,Androgen Receptor,Binding affinity at AR,2007
CHEMBL399439,N#Cc1ccc(O[C@H]2CCCC[C@@H]2C#N)cc1C(F)(F)F,6.71,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced response in reporter gene assay,2007
CHEMBL399876,CC(c1ccccc1)N(C)c1cc(C(F)(F)F)c(C#N)cn1,6.91,group3-int,int,Androgen Receptor,Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells,2007
CHEMBL399887,N#Cc1ccc(O[C@@H]2CCCC[C@H]2C#N)cc1C(F)(F)F,7.92,group2-a,a,Androgen Receptor,Antagonist activity against human androgen receptor expressed in human MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced effect by luciferase receptor gene assay,2008
CHEMBL400098,C[C@@H](c1ccccc1)N(C)c1cc(C(F)(F)F)c(C#N)cn1,5.77,group4-ia,ia,Androgen Receptor,Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells,2007
CHEMBL400480,C=C[C@]12CCC(=C)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,6.48,group3-int,int,Androgen Receptor,Binding affinity at AR,2007
CHEMBL401458,CC(C)C(O)(c1nc2cc(Cl)c(Cl)cc2[nH]1)C(F)(F)F,8.7,group1-p,p,Androgen Receptor,Binding affinity at androgen receptor expressed in COS cells by whole cell binding assay,2007
CHEMBL401629,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C(F)(F)F)c3c1CO2,7.85,group2-a,a,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL401711,Cc1cc(=O)[nH]c2ccc3c4c(C(=O)OC(C)(C)C)cccc4oc(=O)c3c12,8.72,group1-p,p,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL402063,C/C=C1/C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,6.66,group3-int,int,Androgen Receptor,Inhibitory concentration against Androgen receptor,2005
CHEMBL402136,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C(F)(F)F)c3c1OC2,6.32,group3-int,int,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL402930,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1ccc(Br)c2ccccc12,6.17,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL403039,CC12CCC(C)(O1)[C@@H]1C(=O)N(c3ccc([N+](=O)[O-])c4c(Br)cccc34)C(=O)[C@@H]12,7.4,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL403061,COc1cc(N2C(=O)[C@H]3[C@@H](C2=O)C2(C)CCC3(C)O2)ccc1-c1cnco1,7.7,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL403213,CC12CCC(C)(O1)[C@@H]1C(=O)N(c3cnc(C#N)c(Cl)c3)C(=O)[C@@H]12,7.42,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL403214,CC12CCC(C)(O1)[C@@H]1C(=O)N(c3ccc([N+](=O)[O-])c(C(F)(F)F)c3)C(=O)[C@@H]12,7.96,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL403219,COc1cccc2c(=O)oc3c(ccc4[nH]c(=O)cc(C(F)(F)F)c43)c12,7.05,group2-a,a,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL403668,CC12CCC(C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(I)c3)C(=O)[C@@H]12,8.15,group1-p,p,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL403669,CC12CCC(C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,8.15,group1-p,p,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL404222,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@H](c1ccccc1)N3CC(F)(F)F,6.47,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,2008
CHEMBL404315,CC(C)(C)OC(=O)N1CC2CC1[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)N21,6.11,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL404506,CC12CCC(O1)[C@H]1C(=O)N(c3cccc(C(F)(F)F)c3)C(=O)[C@H]12,6.46,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL404512,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@@H](CO)N3CC(F)(F)F,7.22,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,2008
CHEMBL404568,COC[C@H]1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,7.77,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,2008
CHEMBL405835,CCCNc1ccc2nc(O)cc(C(F)(F)F)c2c1,7.56,group2-a,a,Androgen Receptor,Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay,2006
CHEMBL4059588,CC[C@H]1[C@@H](O)CC(=O)N1c1ccc(C#N)c(OC)c1,8.04,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4059979,COc1ccc(-c2csc(N3C(=O)c4ccc(F)cc4C3=O)n2)cc1,5.09,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL4060271,Cc1c(N2CC[C@](C)(O)[C@@H]2C)ccc(C#N)c1Cl,9.31,group1-p,p,Androgen Receptor,Displacement of [17-alpha-methyl-H-3] mibolerone from wild-type androgen receptor (unknown origin) expressed in Freestyle293F cells measured after 3 hrs dextran/charcoal based method,2017
CHEMBL4060340,CCn1c(C#N)ccc1-c1ccc(O)cc1F,6.9,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4060981,Cc1ccc(-c2csc(N3C(=O)c4ccc(F)cc4C3=O)n2)cc1,4.59,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL4061510,Cn1c(C#N)ccc1-c1ccc(O)c2c1CCC2,8.09,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4062016,Cn1c(C#N)ccc1-c1ccc(O)c(Cl)c1,7.32,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4063939,C[C@H]1[C@@H](O)C(F)(F)C(=O)N1c1ccc(C#N)c(Cl)c1,8.96,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4064645,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1ccccc1,4.64,group4-ia,ia,Androgen Receptor,Displacement of [3H]-DHT from recombinant human androgen receptor expressed in CHO cells,2017
CHEMBL4065842,Cc1cc(-c2ccc(C#N)n2C)ccc1O,8.54,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4066319,Cn1c(C#N)ccc1-c1ccc(O)cc1C#N,8.17,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4067691,CC[C@H]1[C@H](O)CC(=O)N1c1ccc(C#N)c(Cl)c1,8.47,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4068008,CCOc1nccc2c1[C@H](c1ccc(C#N)cc1OC)C(C#N)=C(C)N2,5.55,group4-ia,ia,Androgen Receptor,Antagonist activity at GAL4-fused human AR LBD (667 to 919 residues) expressed in CHO-K1 cells assessed as inhibition of dihydrotestosterone-induced transactivation activity after 5 to 6 hrs by luciferase reporter gene assay,2017
CHEMBL4068562,Cn1c(C#N)ccc1-c1ccc(O)c(F)c1,7.23,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4068946,C[C@@H]1N(c2ccc(C#N)c(Cl)c2)CC[C@]1(C)O,9.28,group1-p,p,Androgen Receptor,Displacement of [17-alpha-methyl-H-3] mibolerone from wild-type androgen receptor (unknown origin) expressed in Freestyle293F cells measured after 3 hrs dextran/charcoal based method,2017
CHEMBL4069026,Cn1c(C#N)ccc1-c1ccc(O)c(F)c1F,7.43,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4069656,O=C1c2ccc(F)cc2C(=O)N1c1nc(-c2ccc(F)cc2)cs1,4.67,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL4070425,Cc1ccc(-c2csc(N3C(=O)c4ccccc4C3=O)n2)cc1,4.54,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL4071751,C[C@H]1[C@@H](O)CC(=O)N1c1ccc(C#N)c(Cl)c1,8.11,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4072533,CC[C@H]1[C@@H](O)CC(=O)N1c1ccc(C#N)c(Cl)c1,8.41,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4072730,Cc1c(O)ccc(-c2ccc(C#N)n2C)c1C,8.31,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4073161,O=C1c2ccccc2C(=O)N1c1nc(-c2ccccc2)cs1,4.43,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL4073399,Cn1c(C#N)ccc1-c1ccc(O)cc1C(F)(F)F,7.83,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4073869,Cn1c(C#N)cc(Br)c1-c1ccc(O)cc1,6.78,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4074501,C[C@@H]1C(=O)N(c2ccc(C#N)c(Cl)c2)[C@@H](C)[C@H]1O,8.89,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4074555,Cn1c(C#N)ccc1-c1c(Cl)cc(O)cc1Cl,7.54,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4074927,Cn1c(C#N)ccc1-c1ccc(O)cc1S(C)(=O)=O,5.83,group4-ia,ia,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4077666,C[C@H]1[C@@H](O)C(C)(C)C(=O)N1c1ccc(C#N)c(Cl)c1,7.85,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL407848,Cn1c(C#N)ccc1-c1cc(F)c2c(c1)C(C)(C)C(=O)N2,6.71,group3-int,int,Androgen Receptor,Antagonist activity at human AR ligand binding domain expressed in african green monkey COS7 cells in presence of 5-alpha-dihydrotestosterone by Gal4 hybrid assay,2008
CHEMBL4079171,O=C1c2ccccc2C(=O)N1c1nc(-c2ccc([N+](=O)[O-])cc2)cs1,4.88,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL4079377,Cc1cc(O)ccc1-c1ccc(C#N)n1C,8.43,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4080698,N#CCn1c(C#N)ccc1-c1ccc(O)cc1F,5.22,group4-ia,ia,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4082265,C[C@@H]1[C@H](O)C(C)(C)C(=O)N1c1ccc(C#N)c(Cl)c1,5.18,group4-ia,ia,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4082860,O=C1c2ccc(F)cc2C(=O)N1c1nc(-c2ccc(Cl)cc2)cs1,4.55,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL4083012,N#CC[C@H]1[C@@H](O)CC(=O)N1c1ccc(C#N)c(Cl)c1,7.85,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4085241,CC1(C)C[C@](O)(C(F)(F)F)[C@@H](Nc2cccc3c(=O)[nH]ccc23)c2ccc(F)c(O)c21,6.5,group3-int,int,Androgen Receptor,Binding affinity to recombinant human androgen receptor expressed in baculovirus infected sf9 cells,2017
CHEMBL4085514,C[C@@H]1N(c2ccc(C#N)c(Cl)c2)C(=O)C[C@]1(C)O,7.82,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4087256,Cn1c(C#N)ccc1-c1ccc(O)cc1,8.2,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4087674,COC(=O)c1cc(O)ccc1-c1ccc(C#N)n1C,6.48,group3-int,int,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4087902,CC[C@H]1[C@@H](O)CC(=O)N1c1ccc(C#N)c(Cl)c1C,8.05,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4088158,Cn1c(C#N)ccc1-c1ccc(O)cc1Cl,8.85,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4088224,N#Cc1ccc(-c2csc(N3C(=O)c4ccc(F)cc4C3=O)n2)cc1,5.22,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL4088572,Cn1c(-c2ccc(O)cc2)cc(C(F)(F)F)c1C#N,7.96,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4088914,CC[C@H]1[C@@H](O)CC(=O)N1c1ccc(C#N)c(C(F)(F)F)c1,8.44,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL409,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.4,group3-int,int,Androgen Receptor,In vitro antagonistic activity against mutant androgen receptor of LNCap cells,2004
CHEMBL4090028,Cc1c(N2CC[C@H](O)[C@@H]2C)ccc(C#N)c1Cl,9.14,group1-p,p,Androgen Receptor,Displacement of [17-alpha-methyl-H-3] mibolerone from wild-type androgen receptor (unknown origin) expressed in Freestyle293F cells measured after 3 hrs dextran/charcoal based method,2017
CHEMBL4090670,O=C1c2ccc(F)cc2C(=O)N1c1nc(-c2ccccc2)cs1,4.65,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL4090771,N#Cc1ccc(N2C(=O)C3Cc4ccccc4N3C2=S)cc1C(F)(F)F,4.73,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in African green monkey COS7 cells assessed as inhibition of R1881-induced protein activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4091358,COc1ccc(-c2csc(N3C(=O)c4ccccc4C3=O)n2)cc1,4.86,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL4091403,Cn1c(C#N)ccc1-c1cc(F)c(O)cc1F,7.07,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4092066,CC1(C)C[C@](O)(C(F)(F)F)[C@@H](Nc2cccc3[nH]c(=O)ccc23)c2ccc(F)c(O)c21,6.1,group3-int,int,Androgen Receptor,Binding affinity to recombinant human androgen receptor expressed in baculovirus infected sf9 cells,2017
CHEMBL4092535,Cc1c(N2CC[C@](C)(O)[C@@H]2C)ccc(C#N)c1F,9.54,group1-p,p,Androgen Receptor,Agonist activity at androgen receptor (unknown origin) expressed in African green monkey COS7 cells after 24 hrs by MMTV-promoter driven luciferase reporter gene assay,2017
CHEMBL4093265,CC(C)C[C@H]1[C@@H](O)CC(=O)N1c1ccc(C#N)c(Cl)c1,8.26,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4095364,Cn1c(C#N)ccc1-c1c(F)cc(O)cc1F,8.8,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4095883,Cn1c(C#N)ccc1-c1ccc(O)cc1F,8.49,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4096901,CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C#N)=C(C)N2,5.62,group4-ia,ia,Androgen Receptor,Antagonist activity at GAL4-fused human AR LBD (667 to 919 residues) expressed in CHO-K1 cells assessed as inhibition of dihydrotestosterone-induced transactivation activity after 5 to 6 hrs by luciferase reporter gene assay,2017
CHEMBL4098395,O=C1c2ccc(F)cc2C(=O)N1c1nc(-c2ccc([N+](=O)[O-])cc2)cs1,5.11,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL4100251,Cn1c(C#N)ccc1-c1ccc(O)cc1[N+](=O)[O-],7.19,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4100278,Cc1c(N2C(=O)C[C@H](O)[C@@H]2C)ccc(C#N)c1Cl,7.96,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4100995,CC[C@H]1[C@@H](O)[C@H](C)C(=O)N1c1ccc(C#N)c(Cl)c1,8.74,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4101232,CC[C@@H]1C(=O)N(c2ccc(C#N)c(Cl)c2)[C@@H](C)[C@H]1O,8.49,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4101935,C[C@H]1[C@@H](O)[C@H](Cc2ccccc2)C(=O)N1c1ccc(C#N)c(Cl)c1,8.22,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human AR after 3 hrs,2017
CHEMBL4103425,N#Cc1ccc(-c2csc(N3C(=O)c4ccccc4C3=O)n2)cc1,4.96,group4-ia,ia,Androgen Receptor,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,2017
CHEMBL4103641,CCc1cc(-c2ccc(C#N)n2C)ccc1O,8.15,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4104046,Cn1c(C#N)ccc1-c1c(F)cc(O)cc1C#N,7.17,group2-a,a,Androgen Receptor,Displacement of [3H]mibolerone from human androgen receptor expressed in African green monkey COS cells after 3.5 hrs by scintillation and luminescene counting,2017
CHEMBL4105484,[2H]C([2H])([2H])NC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,7.81,group2-a,a,Androgen Receptor,Displacement of [3H]-R1881 from AR in human LNCaP cells preincubated for 30 mins followed by [3H]-R1881 addition measured after 30 mins by microbeta scintillation counter method,2017
CHEMBL410683,C/C=C1\C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,6.18,group3-int,int,Androgen Receptor,Inhibitory concentration against Androgen receptor,2005
CHEMBL4114736,[C-]#[N+]c1ccc(N2C(=S)N(c3ccc(C)cc3)C(C)(C)/C2=N/C(=S)NCC)cc1C(F)(F)F,6.8,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL4114783,[C-]#[N+]c1ccc(N2C(=S)N(c3ccc(C)cc3)C3(CCC3)/C2=N/C(=S)Nc2ccc(C#N)c(C(F)(F)F)c2)cc1C(F)(F)F,6.84,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL4114801,[C-]#[N+]c1ccc(N2C(=S)N(c3ccc(C)cc3)C3(CCC3)/C2=N/C)cc1C(F)(F)F,6.65,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL4115695,[C-]#[N+]c1ccc(N2C(=S)N(c3ccc(C)cc3)C3(CCC3)/C2=N/C(=S)Nc2ccccc2)cc1C(F)(F)F,6.75,group3-int,int,Androgen Receptor,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",2015
CHEMBL413309,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1c(F)cccc1-3,6.05,group3-int,int,Androgen Receptor,Inhibition of human androgen receptor at 10e-12 to 10e-5 M,2003
CHEMBL414845,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)N21,6.19,group3-int,int,Androgen Receptor,In vitro antagonistic activity against androgen receptor of MDA-453 cells,2004
CHEMBL415289,CC1CCNc2cc3oc(=O)cc(C(F)(F)F)c3cc21,9,group1-p,p,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL4159987,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@@H]23)cc1,6.78,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL4161754,CC(C)N(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@@H]23)cc1,6.32,group3-int,int,Androgen Receptor,Antagonist activity at AR (unknown origin) expressed in human LNCaP cells assessed as reduction in R1881-induced response incubated for 20 hrs by luciferase reporter gene assay,2018
CHEMBL4161910,CCOC(=O)Nc1cc2c(cc1F)CC1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=S)N1C2,5.13,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in African green monkey COS7 cells assessed as inhibition of R1881-induced protein activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4163069,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,6.89,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL41632,O=C(O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1,4.46,group4-ia,ia,Androgen Receptor,Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis,2011
CHEMBL4173799,Cc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc2c3ccc(F)cc3c(=O)n(C)c12,6.52,group3-int,int,Androgen Receptor,Antagonist activity at human CMX-AR expressed in HEK293 cells assessed as reduction in dihydrotestosterone-induced transactivation activity after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4174074,CC(C)c1ccc2c(c1)C(=O)C[C@H]1[C@@](C)(CNC(=O)c3ccccc3)CCC[C@]21C,4.08,group4-ia,ia,Androgen Receptor,Binding affinity to androgen receptor (unknown origin),2018
CHEMBL4175249,Cc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc2c1[nH]c(=O)c1cc(F)ccc12,5.75,group4-ia,ia,Androgen Receptor,Antagonist activity at human CMX-AR expressed in HEK293 cells assessed as reduction in dihydrotestosterone-induced transactivation activity after 24 hrs by luciferase reporter gene assay,2018
CHEMBL417729,C=C1CCCC(C)(C)[C@H]1Cc1cc(OC)c(Br)cc1O,6.42,group3-int,int,Androgen Receptor,Inhibitory activity against human Androgen receptor,1996
CHEMBL418198,CCC1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC[C@@H]1C,5.57,group4-ia,ia,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,1999
CHEMBL418684,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(F)cc1-3,6.19,group3-int,int,Androgen Receptor,Inhibition of antagonist activity towards human Androgen receptor,2003
CHEMBL418971,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1,5.23,group4-ia,ia,Androgen Receptor,Antagonist activity at human pSG5-AR assessed as inhibition of dihydrotestosterone-induced effect by reporter gene assay,2013
CHEMBL419633,Cc1c(NS(C)(=O)=O)cccc1N(Cc1ccccc1)Cc1ccccc1,6.77,group3-int,int,Androgen Receptor,Displacement of [3H]dexamethasone from human androgen receptor,2004
CHEMBL4225186,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1ccc(C(=O)NCCOCCOCCOCCNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](O)[C@H](N)Cc2ccccc2)cc1,7.57,group2-a,a,Androgen Receptor,Displacement of [17-alpha-methyl-H-3] mibolerone from wild-type androgen receptor (unknown origin) expressed in human Freestyle293F cells measured after 3 hrs,2018
CHEMBL4225339,CC(O)(CS(=O)(=O)c1ccc(C(=O)O)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7.27,group2-a,a,Androgen Receptor,Binding affinity to androgen receptor (unknown origin),2018
CHEMBL4226259,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1ccc(C(=O)O)cc1,8.85,group1-p,p,Androgen Receptor,Binding affinity to androgen receptor (unknown origin),2018
CHEMBL4226314,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1CCc1ccc(C(=O)NCCOCCOCCOCCNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](O)[C@H](N)Cc2ccccc2)cc1,6.72,group3-int,int,Androgen Receptor,Displacement of [17-alpha-methyl-H-3] mibolerone from wild-type androgen receptor (unknown origin) expressed in human Freestyle293F cells measured after 3 hrs,2018
CHEMBL4226575,COC(=O)c1ccc(Cc2c(C)n[nH]c2C)cc1,5.82,group4-ia,ia,Androgen Receptor,Binding affinity to androgen receptor (unknown origin),2018
CHEMBL4226844,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1CCc1ccc(C(=O)O)cc1,7.28,group2-a,a,Androgen Receptor,Binding affinity to androgen receptor (unknown origin),2018
CHEMBL4226899,Cc1nn(-c2ccc(C#N)c(C(F)(F)F)c2)c(C)c1Cc1ccc(C(=O)NCCOCCOCCOCCNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](O)[C@H](N)Cc2ccccc2)cc1,6.72,group3-int,int,Androgen Receptor,Displacement of [17-alpha-methyl-H-3] mibolerone from wild-type androgen receptor (unknown origin) expressed in human Freestyle293F cells measured after 3 hrs,2018
CHEMBL422707,CCC1(C)CCc2cc3c(C(F)(F)F)cc(=O)n(C)c3cc2N1,7.32,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL4227287,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(=O)NCCOCCOCCOCCNC(=O)c1ccc(S(=O)(=O)CC(C)(O)C(=O)Nc2ccc(C#N)c(C(F)(F)F)c2)cc1,5.96,group4-ia,ia,Androgen Receptor,Displacement of [17-alpha-methyl-H-3] mibolerone from wild-type androgen receptor (unknown origin) expressed in human Freestyle293F cells measured after 3 hrs,2018
CHEMBL4227715,Cc1nn(-c2ccc(C#N)c(C(F)(F)F)c2)c(C)c1Cc1ccc(C(=O)O)cc1,8.85,group1-p,p,Androgen Receptor,Binding affinity to androgen receptor (unknown origin),2018
CHEMBL423620,CC1(C)CCC[C@]2(C)c3cc4c(C(F)(F)F)cc(O)nc4cc3N[C@H]12,7.29,group2-a,a,Androgen Receptor,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,1998
CHEMBL426623,O=C1[C@H]2[C@@H]3C[C@@H](CN3C(=O)Oc3ccc(F)cc3)N2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,4.52,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against mutant androgen receptor of LNCap cells,2004
CHEMBL427078,CNC(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,6.32,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL42710,C=CCc1ccc(O)c(OC)c1,4.72,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human MDA-kb2 cells co-transfected with MMTV-luc assessed as decrease in DHT-induced luciferase activity by reporter gene assay,2010
CHEMBL427243,C[C@]12CC[C@H]3[C@@H](C(CCCCCCCC(=O)N4CCCC4)C[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,6.52,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,2007
CHEMBL427502,Cc1cc(N2C(=O)[C@H]3C4C=CC([C@@H](O)[C@H]4O)[C@H]3C2=O)ccc1Br,5.28,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor in human MDA-453 cells,2005
CHEMBL427678,COc1cccc(OC)c1-c1ccc(C#N)c(C(F)(F)F)c1,7.83,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL427721,N#Cc1ccc(N2C(=O)[C@@H]3C4CCC(O4)[C@@H]3C2=O)cc1C(F)(F)F,5.54,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL427731,COc1c(O)ccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1CO2,8.92,group1-p,p,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL4278241,COc1ccc2oc(-c3ccccc3OC)cc(=O)c2c1,5.21,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4278637,O=C1c2ccccc2C(=Cc2cccc(O)c2)c2ccccc21,6.5,group3-int,int,Androgen Receptor,Inhibition of R1881-induced full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct after 72 hrs by fluorescence assay,2018
CHEMBL427898,COc1c(O)ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c12,9.7,group1-p,p,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL4279318,O=C1CC(c2ccccc2O)Oc2ccc(Cl)cc21,5.78,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4279841,CC(C)Oc1ccccc1/C=C/C(=O)c1cc(Br)ccc1O,5.04,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced cell growth treated for every 2 days for 4 days by hemocytometry,2018
CHEMBL428021,C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CCC(=O)C=C1C[C@H]3CCCc1ccc(OCCCC(=O)O)cc1,6.18,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,2007
CHEMBL4282772,O=C1CC(c2ccccc2O)Oc2c(Br)cc(Br)cc21,5.45,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4283232,COc1ccccc1/C=C/C(=O)c1cc(Br)ccc1O,5.31,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced cell growth treated for every 2 days for 4 days by hemocytometry,2018
CHEMBL4284351,CCCOc1ccccc1/C=C/C(=O)c1cc(Br)ccc1O,5.4,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4285137,COc1ccccc1/C=C/C(=O)c1cc(F)ccc1O,5.3,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4285568,COc1cc(/C=C/C(=O)c2cc(Cl)ccc2O)ccc1O,5.22,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4286655,COc1ccccc1/C=C/C(=O)c1cc(I)ccc1O,5.76,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4287759,CCOc1ccccc1/C=C/C(=O)c1cc(Br)ccc1O,5.28,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4290001,O=C1CC(c2ccccc2O)Oc2ccc(Br)cc21,5.75,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4290022,O=C(/C=C/c1ccc2c(c1)OCO2)c1cc(Cl)ccc1O,5.36,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4292968,O=C(/C=C/c1ccccc1O)c1cc(F)ccc1O,5.85,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4293380,O=C1CC(c2ccccc2O)Oc2ccc(I)cc21,5.37,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4293816,O=C(/C=C/c1ccccc1O)c1cc(Br)ccc1O,5.06,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4294564,O=C(/C=C/c1ccccc1O)c1cc(I)ccc1O,5.79,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4294994,O=C(/C=C/c1ccccc1O)c1cc(Br)cc(Br)c1O,5.54,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL4297185,CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,7.58,group2-a,a,Androgen Receptor,Inhibition of androgen receptor (unknown origin),2020
CHEMBL430855,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cccc(Br)c1)Oc1ccccc1-3,6.4,group3-int,int,Androgen Receptor,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,1998
CHEMBL435651,CN1c2cc3c(cc2CCC1(C)C)c(C(F)(F)F)cc(=O)n3C,7.72,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL436644,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@H](CO)N3CC(F)(F)F,6.78,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,2008
CHEMBL437065,C#C[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,5.75,group4-ia,ia,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL437214,Cc1ccc(N2C(=O)[C@@H]3C4CCC(O4)[C@@H]3C2=O)cc1Cl,5.64,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL439685,C[C@H]1CN(C(=O)Nc2cccnc2)[C@H](C)CN1c1ccc(C#N)c(C(F)(F)F)c1,6.92,group3-int,int,Androgen Receptor,Inhibition of AR mediated transcriptional activation using reporter assay,2006
CHEMBL440283,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,6.67,group3-int,int,Androgen Receptor,Inhibitory activity against AR,2006
CHEMBL443579,COc1cccc(-c2ccc(C#N)c(C(F)(F)F)c2)c1,6.02,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells,2007
CHEMBL4436972,C[C@](O)(CN1CCc2ccc(F)cc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7.41,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4438211,C[C@](O)(CN1CCc2c(F)cccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7.23,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4439327,Oc1ccc2c(O)ncc(-c3cc(F)c(F)c(F)c3)c2c1,5.68,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in human HeLa cells harboring AR3A-PSA-(ARE)4-Luc13 in presence of DHT by BrightGlo luciferase assay,2020
CHEMBL443970,CCCSc1ccc(C#N)c(OC)c1,7.4,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL4441215,Cc1ccc(-c2c(C)noc2C)cc1Nc1ccc(C#N)c(Cl)c1,6.19,group3-int,int,Androgen Receptor,Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay,2019
CHEMBL4442857,Cc1cn(C[C@](C)(O)C(=O)Nc2ccc(C#N)c(C(F)(F)F)c2)c2ccc(F)cc12,6.8,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4443566,C[C@](O)(CN1CCc2ccccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.85,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4444904,C[C@](O)(Cn1ccc2cc(F)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7.07,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4446471,C[C@](O)(Cn1ccc2ccccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7.19,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4447539,CC1(C)CCc2cc3c(cc2N1)NC(C#N)C=C3C(F)(F)F,8.05,group1-p,p,Androgen Receptor,Inhibition of human androgen receptor,2018
CHEMBL4447959,C[C@](O)(Cn1ccc2cc(F)c(-c3ccccc3)cc21)C(=O)Nc1ccc(C#N)c(Cl)c1,6.69,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4448048,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(-n4cccc4)cc3)C[C@@]21C,6.45,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL4448937,CCOC(=O)c1cn(C[C@](C)(O)C(=O)Nc2ccc(C#N)c(C(F)(F)F)c2)c2ccccc12,6.01,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL444991,Cc1cc(C)cc(Nc2cc(C(=O)N3CCCC3)n(C)c2)c1,4.82,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL4449952,C[C@](O)(CN1CCc2cc(Br)ccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,6.08,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4451795,C[C@](O)(Cn1cc(-c2ccccc2)c2cc(F)ccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,5.99,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4452917,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N(C)C(C)C)cc3)C[C@@]21C,5.65,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL4453035,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N4CCCC4)cc3)C[C@@]21C,5.5,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL445429,COc1cc(SC(C)C)ccc1C#N,7.54,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL4456765,C[C@](O)(Cn1ccc2c(F)cccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.9,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4456781,C[C@](O)(Cn1ccc2cc(Br)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.04,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4460554,CCC(C)(C)C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,6.76,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL4460567,C[C@](O)(Cn1ccc2cc(F)c(-c3ccccc3)cc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.67,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL446191,O=c1cc(C(F)(F)F)c2cc(N3CCCC3)ccc2[nH]1,7.6,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor by luciferase reporter gene assay,2007
CHEMBL4463558,CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4Cc5c(c(C)nc6[nH]c7ccccc7c56)[C@@]4(C)CC[C@@H]32)C1,6.5,group3-int,int,Androgen Receptor,Inhibition of R1881 induced-AR transcriptional activity in AR-positive human 22Rv1 cells harboring ARE14 construct after 24 hrs by luciferase assay,2019
CHEMBL4465426,CC1(C)NC(=O)N(c2ccc(F)c(C(F)(F)F)c2)C1=O,5.36,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL446626,CC12CCC(C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c4nsnc34)C(=O)[C@@H]12,7.8,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,2008
CHEMBL4469605,C[C@](O)(CN1CCc2cc(F)c(F)cc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL447184,CCCCc1ccc(C(=O)N2C[C@@H]3C[C@H]2[C@@H]2C(=O)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)N32)cc1,4.75,group4-ia,ia,Androgen Receptor,In vitro antagonistic activity against androgen receptor of MDA-453 cells,2004
CHEMBL4474096,C[C@](O)(Cn1ccc2ccc(F)cc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7.07,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4474118,C[C@](O)(Cn1ccc2cc(F)ccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,7.03,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4475563,C[C@](O)(Cn1ccc2c(F)cc(-c3ccc(F)cc3)cc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.05,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4475765,C[C@@](O)(Cn1ccc2cc(F)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.22,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL447604,COc1cc(C#N)ccc1Oc1cccc(C)c1,6.45,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL4476493,CCC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,5.53,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL4483408,CC(C)(C)C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](c3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)C[C@@]21C,6.45,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL4483663,C[C@](O)(Cn1ccc2c(F)cccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,6.85,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4483697,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(F)(F)F)[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@H]23)cc1,6.19,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL448454,COc1cc(Sc2c(C)cccc2C)ccc1C#N,7.52,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay,2009
CHEMBL448978,CC(C)(C)Sc1ccc(C#N)c(C(F)(F)F)c1,6.5,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL449371,N#Cc1ccc(SC2CCC2)cc1C(F)(F)F,6.78,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay,2009
CHEMBL449804,CCOc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,7.33,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response,2009
CHEMBL449867,COc1cc(C#N)ccc1Oc1ccccc1C,7.32,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay,2009
CHEMBL450334,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)-c1ccccc1CO3,7.4,group2-a,a,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL450933,COc1cccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c12,7.68,group2-a,a,Androgen Receptor,Activity at androgen receptor in human Saos2 cells assessed as IL6 repression,2008
CHEMBL451153,COc1ccc(CO)cc1Oc1ccc(C#N)c(C(F)(F)F)c1,6.67,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL4515467,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(OC)cc3)C[C@@]21C,6.25,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL4520679,C[C@](O)(Cn1ccc2c(F)c(-c3ccccc3)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,5.99,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4521365,C[C@](O)(CN1CCc2cc(F)c(F)cc21)C(=O)Nc1ccc(C#N)c(Cl)c1,7.5,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL452153,c1ccc2nc(-c3ccncc3)ccc2c1,5.38,group4-ia,ia,Androgen Receptor,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,2014
CHEMBL4527176,C[C@](O)(CN1CCc2ccc(F)cc21)C(=O)Nc1ccc(C#N)c(Cl)c1,7.43,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4527241,C[C@](O)(CN1CCc2c(F)cccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,6.9,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4527872,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC3CC3)[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@H]23)cc1,5.84,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL4528089,c1ccc2c(c1)CC(c1c[nH]c3ccccc13)N2,6.51,group3-int,int,Androgen Receptor,Inhibition of AR transcriptional activity in human ARR2PB-eGFP expressing LNCaP cells after 3 days by fluorescence assay,2016
CHEMBL453244,COc1cc(SCC2CCC2)ccc1C#N,6.36,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL4534324,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](OCc3ccc(Cl)cc3)C[C@@]21C,7.07,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL453623,N#Cc1ccc(SCC2CC2)cc1C(F)(F)F,7.46,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL453624,N#Cc1ccc(SCC2CCC2)cc1C(F)(F)F,6.15,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay,2009
CHEMBL453740,CC(C)Sc1ccc(C#N)c(C(F)(F)F)c1,7.05,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay,2009
CHEMBL4539953,C[C@](O)(CN1CCc2cc(F)c(-c3ccccc3)cc21)C(=O)Nc1ccc(C#N)c(Cl)c1,6.61,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL454138,CC(C)OC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21,5,group4-ia,ia,Androgen Receptor,Antagonist activity at gal-AR expressed in african green monkey CV1 cells co-expressing MH100 with GRIP1 co-factor by luciferase reporter gene assay,2009
CHEMBL4542153,C[C@](O)(CN1CCc2cc(F)ccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,6.89,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4542693,C[C@](O)(Cn1ccc2cc(I)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.01,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4545820,CC(C)(C)C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](c3ccc(N4CCOCC4)cc3)C[C@@]21C,6.68,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL4548397,CC1(C)CCc2cc3c(cc2N1)NC(F)C=C3C(F)(F)F,7.66,group2-a,a,Androgen Receptor,Inhibition of human androgen receptor,2018
CHEMBL4554646,C[C@](O)(Cn1ccc2ccc([N+](=O)[O-])cc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7.24,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL455566,CCCCSc1ccc(C#N)c(OC)c1,7.08,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL4562338,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N(C)CCOC)cc3)C[C@@]21C,5.89,group4-ia,ia,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL456237,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,5.64,group4-ia,ia,Androgen Receptor,Displacement of radiolabeled mibolerone from human androgen receptor by filter paper assay,2008
CHEMBL4567476,C[C@](O)(Cn1cc(F)c2ccccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,7.35,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL457036,CC#C[C@@]1(O)CC[C@@]2(CC)c3ccc(OCc4cccnc4C)cc3CC[C@@H]2C1,6.06,group3-int,int,Androgen Receptor,Binding affinity to human androgen receptor,2009
CHEMBL4571052,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,6.04,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL4571680,CC(O)(CCc1ccc(N)cc1)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,6.41,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4572306,CC(C)(NC(=O)Nc1ccc(F)c(C(F)(F)F)c1)C(=O)O,5.51,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4576596,CCN(CC)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@@H]23)cc1,6.58,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL458084,N#Cc1ccc([C@H]2CCCC[C@H]2O)cc1C(F)(F)F,7.37,group2-a,a,Androgen Receptor,Antagonist activity against human androgen receptor expressed in human MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced effect by luciferase receptor gene assay,2008
CHEMBL4583465,C[C@](O)(Cn1ccc2nc(C#N)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.16,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4584527,CN(C[C@](C)(O)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1)c1ccc(C#N)c(-c2ccccc2)c1,7.32,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL458506,N#Cc1ccc([C@@H]2CCCC[C@@H]2O)cc1C(F)(F)F,5.8,group4-ia,ia,Androgen Receptor,Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells,2008
CHEMBL4585987,C[C@](O)(Cn1ccc2cccc(F)c21)C(=O)Nc1ccc(C#N)c(Cl)c1,6.63,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4586748,C[C@](O)(Cn1ccc2cc([N+](=O)[O-])ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7.06,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4590504,C[C@](O)(Cn1ccc2ccc(F)cc21)C(=O)Nc1ccc(C#N)c(Cl)c1,7,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,2019
CHEMBL4591353,CN1CCN(c2ccc([C@H]3C[C@@]4(C)[C@@H](CC[C@@]4(O)C#CC(C)(C)C)[C@@H]4CCC5=CC(=O)CC[C@@H]5[C@@H]34)cc2)CC1,6,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,2019
CHEMBL462022,COc1cc(Sc2c(C)cc(C)cc2C)ccc1C#N,7.41,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL462025,Cc1ccccc1Sc1ccc(C#N)c(C(F)(F)F)c1,6.65,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL462026,COc1ccccc1Sc1ccc(C#N)c(C(F)(F)F)c1,7.25,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL462027,Cc1cccc(C)c1Sc1ccc(C#N)c(C(F)(F)F)c1,6.39,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL462234,Cc1cc(C)c(Sc2ccc(C#N)c(C(F)(F)F)c2)c(C)c1,5.87,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL462663,COc1cc(SCCC(C)C)ccc1C#N,5.76,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL462664,CCCSc1ccc(C#N)c(C(F)(F)F)c1,7.96,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay,2009
CHEMBL462665,CCCCSc1ccc(C#N)c(C(F)(F)F)c1,6.08,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay,2009
CHEMBL4634960,N=c1oc2c(O)cccc2cc1C(=O)Nc1cccc(F)c1,5.48,group4-ia,ia,Androgen Receptor,Antagonistic activity at AR in human 22Rv1 cells assessed as reduction in cell number by CCK8 assay,2020
CHEMBL4640248,N=c1oc2c(O)cccc2cc1C(=O)Nc1ccccc1Cl,5.48,group4-ia,ia,Androgen Receptor,Antagonistic activity at AR in human 22Rv1 cells assessed as reduction in cell number by CCK8 assay,2020
CHEMBL4641012,CCc1ccc(NC(=O)c2cc3cccc(O)c3oc2=N)cc1,5.44,group4-ia,ia,Androgen Receptor,Antagonistic activity at AR in human 22Rv1 cells assessed as reduction in cell number by CCK8 assay,2020
CHEMBL4642187,CCc1ccccc1NC(=O)c1cc2cccc(O)c2oc1=N,5.09,group4-ia,ia,Androgen Receptor,Antagonistic activity at AR in human 22Rv1 cells assessed as reduction in cell number by CCK8 assay,2020
CHEMBL4642678,N=c1oc2c(O)cccc2cc1C(=O)Nc1ccccc1F,5.36,group4-ia,ia,Androgen Receptor,Antagonistic activity at AR in human 22Rv1 cells assessed as reduction in cell number by CCK8 assay,2020
CHEMBL4644092,N=c1oc2c(O)cccc2cc1C(=O)Nc1ccc(F)cc1,5.19,group4-ia,ia,Androgen Receptor,Antagonistic activity at AR in human 22Rv1 cells assessed as reduction in cell number by CCK8 assay,2020
CHEMBL4646593,CCc1cccc(NC(=O)c2cc3cccc(O)c3oc2=N)c1,5.24,group4-ia,ia,Androgen Receptor,Antagonistic activity at AR in human 22Rv1 cells assessed as reduction in cell number by CCK8 assay,2020
CHEMBL464764,Cc1cccc(Oc2ccc(C#N)c(C(F)(F)F)c2)c1,5.78,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL4648793,Cc1ccc(NC(=O)c2cc3cccc(O)c3oc2=N)cc1,5.62,group4-ia,ia,Androgen Receptor,Antagonistic activity at AR in human 22Rv1 cells assessed as reduction in cell number by CCK8 assay,2020
CHEMBL464929,COc1cc(C#N)ccc1Oc1ccc(C)cc1,5.28,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL465539,Cc1ccc(Oc2ccc(C#N)c(C(F)(F)F)c2)cc1,5.27,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL469333,COc1cccc(OC)c1Oc1ccc(C#N)c(C(F)(F)F)c1,6.8,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL469334,COc1cc(C)ccc1Oc1ccc(C#N)c(C(F)(F)F)c1,6.52,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response,2009
CHEMBL469380,COc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,7.08,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL469602,CCCc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,6.7,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL469982,Cc1ccc(O)c(Oc2ccc(C#N)c(C(F)(F)F)c2)c1,6.09,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response,2009
CHEMBL469983,COc1cccc(F)c1Oc1ccc(C#N)c(C(F)(F)F)c1,6.8,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL470204,Cc1ccccc1Oc1ccc(C#N)c(Cl)c1,7.52,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL470395,CCSc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,6.26,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response,2009
CHEMBL470629,N#Cc1ccc(Oc2ccccc2Cl)cc1C(F)(F)F,6.91,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL470841,N#Cc1ccc(Oc2cccc(Cl)c2)cc1C(F)(F)F,5.57,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL470842,N#Cc1ccc(Oc2ccc(Cl)cc2)cc1C(F)(F)F,5.18,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL471644,Cc1cccc(C)c1Oc1ccc(C#N)c(C(F)(F)F)c1,8,group1-p,p,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL471645,N#Cc1ccc(Oc2ccccc2O)cc1C(F)(F)F,7.01,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response,2009
CHEMBL471876,N#Cc1ccc(Oc2ccccc2-c2ccccc2)cc1C(F)(F)F,6.37,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL4739997,C[C@](O)(Cn1cc(C#N)c(Br)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.74,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4740374,C[C@](O)(Cn1ccc(F)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.66,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4740742,N#Cc1ccc(NC(=O)CS(=O)(=O)c2ccc(F)cc2)cc1C(F)(F)F,6.61,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4740944,CC1(C)C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)N1S(C)(=O)=O,5.2,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4741021,C[C@](O)(Cn1cc(F)cn1)C(=O)Nc1ccnc(Cl)c1,5.61,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4741569,C[C@](O)(Cn1ccc(C(F)(F)F)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.69,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4741767,COC(=O)Nc1ccc(-c2cnn(C[C@](C)(O)C(=O)Nc3ccc(C#N)c(C(F)(F)F)c3)c2)cc1,6.08,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4742694,CC(=O)c1cnn(C[C@](C)(O)C(=O)Nc2ccc(C#N)c(C(F)(F)F)c2)c1,6.12,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4743145,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc2c(c1)COC2=O,6.83,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4743302,CN1Cc2cc(N3C(=S)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)C3(C)C)ccc2C1=O,6.23,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4743529,CC1(C)NC(=O)N(Cc2ccc(F)c(C(F)(F)F)c2)C1=O,5.38,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4745209,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc2c(c1)CCOC2=O,6.71,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4745855,N#Cc1ncc(N2C(=O)C3(COC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,4.57,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4746345,C[C@](O)(Cn1cc(Br)c(F)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7.08,group2-a,a,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4746443,CN(C)C(=O)c1cc(N2C(=O)NC(C)(C)C2=O)ccc1F,5.04,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4746653,N#Cc1ncc(N2C(=O)C3(CCCC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,7.2,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4746814,C[C@](O)(Cn1cc(-c2ccc(F)cc2)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.01,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4746960,CC(Cn1cc(F)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.33,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4747056,N#Cc1ccc(NC(=O)CCn2cc(F)cn2)cc1C(F)(F)F,5.67,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4747499,O=C1NC2(CCCCC2)C(=O)N1c1ccc(F)c(C(F)(F)F)c1,5.38,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4747667,Cc1cnn(C[C@](C)(O)C(=O)Nc2ccc(C#N)c(C(F)(F)F)c2)c1,5.09,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4748422,CC1(C)NC(=O)N(c2ccnc(C(F)(F)F)c2)C1=O,5.35,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4748557,CC1(C)C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)N1S(=O)(=O)c1ccccc1,5.37,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4750103,CC1(C)NC(=O)N(c2ccc(Cl)c(C(F)(F)F)c2)C1=O,5.89,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4750351,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5ccccc5)ccc4N3C2=S)cc1C(F)(F)F,5.46,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4750503,N#Cc1ccc(N2C(=O)C3CCc4cc(Br)ccc4N3C2=S)cc1C(F)(F)F,5.36,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4751646,C[C@](O)(Cn1cc(C(F)(F)F)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7.15,group2-a,a,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4752477,Cc1cn(C[C@](C)(O)C(=O)Nc2ccc(C#N)c(C(F)(F)F)c2)nc1Cl,6.48,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4752689,N#Cc1ccc(N2C(=O)C3(CCCC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,7.09,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4752893,CC(C)(C)OC(=O)Nc1ccc(-c2cnn(C[C@](C)(O)C(=O)Nc3ccc(C#N)c(C(F)(F)F)c3)c2)cc1,5.94,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4752991,C[C@](O)(Cn1cc(Cl)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.87,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4753877,C[C@](O)(Cn1cc([N+](=O)[O-])cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7.44,group2-a,a,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4754074,N#Cc1ccc(N2C(=O)C3CNc4cc(Br)ccc4N3C2=S)cc1C(F)(F)F,5.01,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4754309,N#Cc1ncc(N2C(=O)C3(CCCCC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,7.03,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4755665,O=C1NC2(CCCC2)C(=O)N1c1ccc(F)c(C(F)(F)F)c1,6,group3-int,int,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4755743,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5cnc(Cl)nc5)ccc4N3C2=S)cc1C(F)(F)F,5.09,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4756685,N#Cc1ncc(N2C(=O)C3(CCCC3)N(c3cnc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,5.65,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4756936,CCOC(=O)Nc1cc2c(cc1F)CC1C(=O)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=S)N1C2,5.21,group4-ia,ia,Androgen Receptor,Antagonist activity at Androgen receptor (unknown origin) expressed in COS7 cells by dual luciferase reporter gene assay relative to control,2020
CHEMBL4757339,CC(C)(c1ccc(OCc2ccnc(NS(C)(=O)=O)n2)cc1)c1cc(F)c(OCCCl)c(Cl)c1,6.3,group3-int,int,Androgen Receptor,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,2020
CHEMBL4757702,C[C@](O)(Cn1cc(Cl)c(Br)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.86,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4757852,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5ccc(C(F)(F)F)nc5)ccc4N3C2=S)cc1C(F)(F)F,5.66,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4758119,C[C@](O)(Cn1cc(-c2ccccc2)c(C#N)n1)C(=O)Nc1cnc(C#N)c(C(F)(F)F)c1,6.24,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4758277,CC1(C)C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)N1CC#N,6.54,group3-int,int,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4758685,C[C@](O)(Cn1cc(-c2ccccc2)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,5.94,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4759470,CC1(C)C(=O)N(c2cnc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc2c(c1)COC2=O,6.03,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4759623,c1ccc(C2Nc3ccc4ccccc4c3C3C4CCC(C4)C23)cc1,5.25,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,2020
CHEMBL4759704,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5cnc6ccccc6c5)ccc4N3C2=S)cc1C(F)(F)F,5.05,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4759832,N#Cc1ccc(N2C(=O)C3(CCOC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,6.62,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4759841,N#Cc1ccc(N2C(=O)C3(CCC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,6.66,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4760141,Brc1ccc(C2Nc3ccc4ccccc4c3C3C=CCC32)cc1,6.82,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,2020
CHEMBL4761957,CC(C)S(=O)(=O)Nc1nc(COc2ccc(C(C)(C)c3cc(Cl)c(OCCCl)c(C#N)c3)cc2)co1,6.3,group3-int,int,Androgen Receptor,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,2020
CHEMBL4762417,N#Cc1ccc(N2C(=O)C3(CC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,6.17,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL476292,COc1ccc2c(c1)C(=O)CC(c1ccccc1)O2,4.4,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,2009
CHEMBL4763136,O=C1N[C@H](c2ccccc2)C(=O)N1c1ccc(F)c(C(F)F)c1,5.28,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4763876,CC1(C)NC(=O)N(c2cccnc2)C1=O,5.02,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4764992,N#Cc1ncc(N2C(=O)C3(CCOC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,6.29,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4776221,CC(C)(C)OC(=O)Nc1cnn(C[C@](C)(O)C(=O)Nc2cnc(C#N)c(C(F)(F)F)c2)c1,5.21,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4776248,C[C@](O)(Cn1cc(C#N)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,7.37,group2-a,a,Androgen Receptor,Antagonist activity at recombinant human AR F876L mutant expressed in COS cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4777133,CC1(C)CNC(=O)N(c2ccc(F)c(C(F)(F)F)c2)C1=O,5.16,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4777511,CC1(C)CN(c2ccc(F)c(C(F)(F)F)c2)C(=O)N1,5.09,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4778019,C[C@](O)(Cn1ccc(-c2ccccc2)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,5.32,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4778185,O=C1C2CCCN2C(=O)N1c1ccc(F)c(C(F)(F)F)c1,5.46,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4778298,CC1(C)NC(=O)N(c2ccnc3ccccc23)C1=O,5.89,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4778550,CCOC(=O)c1ccc(NC(=O)c2cccc(S(=O)(=O)N3CCCc4ccccc43)c2)s1,5.69,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant androgen receptor (unknown origin) transfected in human LNCaP cells co-transfected with PSA and luciferase incubated for 24 hrs by dual luciferase reporter gene assay,2019
CHEMBL4778795,C[C@](O)(Cn1cc(C#N)cn1)C(=O)Nc1cnc(C#N)c(C(F)(F)F)c1,7.23,group2-a,a,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4778974,CN1C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)C1(C)C,5.89,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4779474,C[C@](O)(Cn1cccn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,5.84,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4779527,C[C@](O)(Cn1cc(F)cn1)C(=O)Nc1ccc(C#N)c(Cl)c1,6.37,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4780549,N#Cc1ccc(N2C(=O)C3(CCCOC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,6.85,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4781335,C[C@](O)(Cn1cc(F)cn1)C(=O)Nc1cnc(C#N)c(C(F)(F)F)c1,7.2,group2-a,a,Androgen Receptor,Antagonist activity at recombinant human AR F876L mutant expressed in COS cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4781708,CC1(C)NC(=O)N(c2cccc(C(F)(F)F)c2)C1=O,5.22,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4781726,N#Cc1ccc(N2C(=O)C3CCc4ccccc4N3C2=S)cc1C(F)(F)F,5.55,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4782426,CC1(C)NC(=O)N(c2ccncc2)C1=O,5.42,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4782786,Clc1ccc(C2Nc3ccc4ccccc4c3C3C4CCC(C4)C23)cc1,5.13,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,2020
CHEMBL4782924,C[C@@](Cn1cc(N)cn1)(OC(=O)CCl)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.04,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4782992,C[C@](O)(Cn1cc(-c2ccc(F)cc2)c(F)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.54,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4783581,C[C@](O)(Cn1cc(F)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.7,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4784244,C[C@](O)(Cn1cc(C#N)c(Br)n1)C(=O)Nc1cnc(C#N)c(C(F)(F)F)c1,5.26,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4786505,CC1(C)C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)N1CCc1ccccc1,5.62,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4786811,CC1(C)C(=O)NC(=O)N1c1ccc(F)c(C(F)(F)F)c1,5.55,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4787221,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5ccn(C6CC6)n5)ccc4N3C2=S)cc1C(F)(F)F,5.34,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4787631,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1cnc2c(c1)COC2=O,5.64,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4787997,CC1(C)CC(=O)N(c2ccc(F)c(C(F)(F)F)c2)C1=O,6.04,group3-int,int,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4788710,N#Cc1ccc(N2C(=O)C3CSc4cc(Br)ccc4N3C2=S)cc1C(F)(F)F,4.74,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4788869,Cc1noc(C)c1-c1ccc2c(c1)CCC1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=S)N21,5.22,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4790160,CCOC(=O)C1Nc2ccc3ccccc3c2C2C=CCC12,6.09,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,2020
CHEMBL4790269,CC1(C)OC(=O)N(c2ccc(F)c(C(F)(F)F)c2)C1=O,5.68,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4790541,C[C@](O)(Cn1cc(C(F)(F)F)cn1)C(=O)Nc1cnc(C#N)c(C(F)(F)F)c1,6.68,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4792484,N#Cc1ccc(N2C(=O)C3(CCCC3)N(c3ccc4c(c3)CCOC4=O)C2=S)cc1C(F)(F)F,6.87,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4792938,C[C@@](O)(Cn1cc(F)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.72,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4793070,O=C1CNC(=O)N1c1ccc(F)c(C(F)(F)F)c1,6.58,group3-int,int,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4793158,CC1(CO)NC(=O)N(c2ccc(F)c(C(F)(F)F)c2)C1=O,5.32,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4793442,C[C@](O)(Cn1ccc(-c2ccc(F)cc2)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,5.97,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4794197,C#Cc1ccc(-c2cnn(C[C@](C)(O)C(=O)Nc3ccc(C#N)c(C(F)(F)F)c3)c2)cc1,6.56,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4794467,C[C@](O)(Cn1cc(Br)c(F)n1)C(=O)Nc1cnc(C#N)c(C(F)(F)F)c1,7.46,group2-a,a,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4794639,N#Cc1ccc(N2C(=O)C3(CCCCC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,7.02,group2-a,a,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4796332,Clc1ccc(C2Nc3ccc4ccccc4c3C3C=CCC32)cc1,5.72,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,2020
CHEMBL4797334,C[C@](O)(Cn1cc(Br)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.37,group3-int,int,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4797715,Clc1ccccc1C1Nc2ccc3ccccc3c2C2C=CCC21,5.4,group4-ia,ia,Androgen Receptor,Displacement of fluormone-AL green from GST-tagged androgen receptor LBD (unknown origin) measured after 4 hrs by fluorescence polarization assay,2020
CHEMBL4798254,Clc1ccc(C2Nc3ccc4ccccc4c3C3OCCCC23)c(Cl)c1,4.69,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,2020
CHEMBL4798606,Fc1ccccc1C1Nc2ccc3ccccc3c2C2C=CCC21,6.66,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,2020
CHEMBL4798843,C[C@](O)(Cn1cc(I)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,5.69,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4798945,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5cccnc5)ccc4N3C2=S)cc1C(F)(F)F,5.41,group4-ia,ia,Androgen Receptor,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,2021
CHEMBL4799175,CCN1C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)C1(C)C,6.85,group3-int,int,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL4799429,CC1(C)NC(=O)N(c2ccc(F)c(C#N)c2)C1=O,5.43,group4-ia,ia,Androgen Receptor,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,2016
CHEMBL479988,CC(=O)c1ccc(N(Cc2ccccc2)c2cc(C(=O)N3CCCC3)n(C)c2)cc1,5.7,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL4800363,C[C@](O)(Cn1cc(F)cn1)C(=O)Nc1cc(C(F)(F)F)c(C#N)cc1I,5.26,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL4800572,C[C@@]1(Cn2cc(F)cn2)OC(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C1=O,5.95,group4-ia,ia,Androgen Receptor,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,2020
CHEMBL480162,Cn1cc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])cc2)cc1C(N)=O,5.71,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL480182,O=C1ON=C(c2ccc(Cl)cc2)/C1=C/c1ccc(N2CCCC2)cc1,6.4,group3-int,int,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL480183,Cc1cc(C)cc(N(C)c2cc(C(=O)N3CCCC3)n(C)c2)c1,4.58,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL480934,Cn1cc(N(Cc2ccc(O)cc2)c2ccc([N+](=O)[O-])cc2)cc1C(=O)N1CCCC1,5.32,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL480955,Cn1cc(N(Cc2ccccc2)c2ccc(C#N)cc2)cc1C(=O)N1CCCC1,6.21,group3-int,int,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL480959,COC(=O)c1ccc(N(Cc2ccccc2)c2cc(C(=O)N3CCCC3)n(C)c2)cc1,5.21,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL480960,Cn1cc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])cc2)cc1CO,5.68,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL480982,CCN(CC)c1ccc(/C=C2\C(=O)ON=C2C)cc1,6.22,group3-int,int,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL481107,Cn1cc(N(Cc2ccc(F)cc2)c2ccc([N+](=O)[O-])cc2)cc1C(=O)N1CCCC1,5.4,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL481139,CCN(CC)C(=O)c1cc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])cc2)cn1C,6,group3-int,int,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL481152,CCN(c1cc(C)cc(C)c1)c1cc(C(=O)N2CCCC2)n(C)c1,4.65,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL481302,CCCCN(CCCC)C(=O)c1cc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])cc2)cn1C,5.21,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL481355,CCN(c1ccc([N+](=O)[O-])cc1)c1cc(C(=O)N2CCCC2)n(C)c1,4.81,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL481356,CC(C)N(c1ccc([N+](=O)[O-])cc1)c1cc(C(=O)N2CCCC2)n(C)c1,4.84,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL481515,Cc1cc(C)cc(N(Cc2ccc(O)cc2)c2cc(C(=O)N3CCCC3)n(C)c2)c1,5.18,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL481686,Cc1cc(C)cc(N(Cc2ccc(CO)cc2)c2cc(C(=O)N3CCCC3)n(C)c2)c1,5.24,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL481746,Cn1cc(N(Cc2ccc(CO)cc2)c2ccc([N+](=O)[O-])cc2)cc1C(=O)N1CCCC1,5.26,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL481924,Cn1cc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)cc1C(=O)N1CCCC1,5.6,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL481939,Cc1ccc(CN(c2ccc([N+](=O)[O-])cc2)c2cc(C(=O)N3CCCC3)n(C)c2)cc1,5.33,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL482063,O=C(c1ccc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])cc2)cc1)N1CCCC1,5.43,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL482064,O=C(c1cccc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])cc2)c1)N1CCCC1,5.31,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL483246,Cn1c(C#N)ccc1-c1ccc2c(c1)C(c1ccco1)(c1ccco1)OCC(=O)N2,6.13,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor by Gal4-DNA binding domain-hormone receptor LBD one-hybrid assay,2008
CHEMBL484662,O=c1cc(-c2ccc(O)cc2)oc2cccc(O)c12,6.07,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay,2013
CHEMBL485349,O=C1CC(c2ccccc2O)Oc2ccc(O)cc21,5.56,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL489788,Cn1c(C#N)ccc1-c1ccc2c(c1)C(C)(c1ccco1)OCC(=O)N2,6.67,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor by Gal4-DNA binding domain-hormone receptor LBD one-hybrid assay,2008
CHEMBL490955,Cc1ccccc1Oc1ccc(C#N)cc1Cl,7.34,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay,2009
CHEMBL490956,Cc1ccccc1Sc1ccc(C#N)cc1Cl,7.11,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay,2009
CHEMBL490957,COc1cc(Oc2cccc(C)c2)ccc1C#N,7.24,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL491,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,7.82,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL491493,COc1cc(Oc2ccccc2C)ccc1C#N,7.62,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL499137,Cc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,6.27,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL50023,C=C1C=C(C)CC(C)(C)C1Cc1ccc([N+](=O)[O-])cc1,6.6,group3-int,int,Androgen Receptor,Inhibitory activity against human Androgen receptor,1996
CHEMBL501080,CCC1(c2ccco2)OCC(=O)Nc2ccc(-c3cc(F)cc(C#N)c3)cc21,6.16,group3-int,int,Androgen Receptor,Antagonist activity at cloned androgen receptor-ligand binding domain expressed in african green monkey COS7 cells by two hybrid luciferase assay,2008
CHEMBL501627,N#Cc1ccc(C2CCCCC2O)cc1C(F)(F)F,7.05,group2-a,a,Androgen Receptor,Antagonist activity against human androgen receptor expressed in human MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced effect by luciferase receptor gene assay,2008
CHEMBL501649,COc1cc(Oc2ccc(C)cc2)ccc1C#N,6.7,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL503575,COc1cc(-c2ccccc2O)ccc1C#N,7.43,group2-a,a,Androgen Receptor,Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells,2008
CHEMBL503676,Cn1cc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])cc2)cc1C(=O)N1CCc2ccccc21,6,group3-int,int,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL503687,CC(C)CCSc1ccc(C#N)c(C(F)(F)F)c1,6.29,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL504110,COc1cc(SCC2CC2)ccc1C#N,6.77,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells,2009
CHEMBL504179,CSc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,7.66,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response,2009
CHEMBL507267,CC(C)c1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,5.64,group4-ia,ia,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL507671,N#Cc1ccc(Sc2ccccc2F)cc1C(F)(F)F,6.74,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human AR expressed in baculovirus Sf9 cells system by scintillation counting,2010
CHEMBL510145,COc1cc(Sc2ccccc2OC)ccc1C#N,7.46,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay,2009
CHEMBL510289,CCOc1cc(C)ccc1Oc1ccc(C#N)c(C(F)(F)F)c1,6.59,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL51093,C=C1CC[C@@H](Br)C(C)(C)[C@H]1Cc1cc(OC)c(Br)cc1O,6.35,group3-int,int,Androgen Receptor,Inhibitory activity against human Androgen receptor,1996
CHEMBL511145,Cc1ccc(Oc2ccc(C#N)c(C(F)(F)F)c2)c(O)c1,6.45,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL512837,COc1ccc(C)cc1Oc1ccc(C#N)c(C(F)(F)F)c1,6.32,group3-int,int,Androgen Receptor,Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response,2009
CHEMBL513195,CCc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,7.7,group2-a,a,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL513768,Cc1cc(C)c(Oc2ccc(C#N)c(C(F)(F)F)c2)c(C)c1,6.7,group3-int,int,Androgen Receptor,Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system,2009
CHEMBL51639,C=C1CC[C@@H](Br)C(C)(C)[C@@H]1Cc1cc(OC)c(Br)cc1O,6.62,group3-int,int,Androgen Receptor,Inhibitory activity against human Androgen receptor,1996
CHEMBL516610,Cn1cc(Nc2ccc([N+](=O)[O-])cc2)cc1C(=O)N1CCCC1,4.83,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL516752,Cc1cc(C)cc(N(c2cc(C(=O)N3CCCC3)n(C)c2)C(C)C)c1,5,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL518945,Cn1cc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])cc2)cc1C(=O)N1CCCC1,6.36,group3-int,int,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL519112,Cn1cc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])cc2)cc1C(=O)O,5.21,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL519292,Cn1cc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])cc2)cc1C(=O)N1C[C@H](O)[C@@H](O)C1,4.86,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL519780,Cn1cc(N(CC2CCCCC2)c2ccc([N+](=O)[O-])cc2)cc1C(=O)N1CCCC1,6.06,group3-int,int,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL52,CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1,4.41,group4-ia,ia,Androgen Receptor,Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis,2011
CHEMBL520169,Cn1c(C#N)ccc1-c1ccc2c(c1)C(c1cccs1)(c1cccs1)OCC(=O)N2,6.11,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor by Gal4-DNA binding domain-hormone receptor LBD one-hybrid assay,2008
CHEMBL520428,Cn1cc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])cc2)cc1C(=O)N1CCCCC1,5.77,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL521249,Cn1cc(N(Cc2ccccc2)c2ccc(C(F)(F)F)cc2)cc1C(=O)N1CCCC1,5.77,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL521251,CCOC(=O)c1cc(N(Cc2ccccc2)c2ccc([N+](=O)[O-])cc2)cn1C,6.02,group3-int,int,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL522432,Cn1c(C#N)ccc1-c1ccc2c(c1)C(C)(c1ccsc1)OCC(=O)N2,6.49,group3-int,int,Androgen Receptor,Antagonist activity at androgen receptor by Gal4-DNA binding domain-hormone receptor LBD one-hybrid assay,2008
CHEMBL538137,C[C@@H]1C[C@H]2[C@@H]3CC[C@H]4N(C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]2(C)[C@H]1O,7.51,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL538877,COC[C@@H]1C[C@H]2[C@@H]3CC[C@H]4N(C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]2(C)[C@H]1O,7.62,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL549375,Cc1ncc(/C=C2\C[C@H]3[C@@H]4CC[C@H]5N(C)C(=O)C=C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2O)cn1,7.37,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL549725,CC(C(=O)N(C)C)N(CC(F)(F)F)c1ccc(C#N)c(C(F)(F)F)c1,5.8,group4-ia,ia,Androgen Receptor,Binding affinity to AR by fluorescence polarization based competition binding assay,2009
CHEMBL551269,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5cncnc5)[C@@H]4O)[C@@H]3CC[C@@H]12,7.23,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL551270,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5cnc(C6CC6)nc5)[C@@H]4O)[C@@H]3CC[C@@H]12,7.29,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL556229,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](O)[C@H](Cc5cccc(F)c5)C[C@H]4[C@@H]3CC[C@@H]12,7.64,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL556431,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5cc(F)cc(F)c5)[C@@H]4O)[C@@H]3CC[C@@H]12,7.39,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL556848,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5ccncc5)[C@@H]4O)[C@@H]3CC[C@@H]12,6.89,group3-int,int,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL557116,C/C=C1\C[C@H]2[C@@H]3CC[C@H]4N(C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]2(C)[C@H]1O,7.46,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL558664,CN1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,6.6,group3-int,int,Androgen Receptor,Binding affinity to AR by fluorescence polarization based competition binding assay,2009
CHEMBL559246,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CC[C@@H]12,8.15,group1-p,p,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL559485,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5ccccn5)[C@@H]4O)[C@@H]3CC[C@@H]12,6.54,group3-int,int,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL559878,COc1ncc(/C=C2\C[C@H]3[C@@H]4CC[C@H]5N(C)C(=O)C=C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2O)cn1,7.96,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL560935,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5ccccc5)[C@@H]4O)[C@@H]3CC[C@@H]12,6.94,group3-int,int,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL562394,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5cnc(-c6ccccn6)nc5)[C@@H]4O)[C@@H]3CC[C@@H]12,6.15,group3-int,int,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL562471,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5cccc(F)c5)[C@@H]4O)[C@@H]3CC[C@@H]12,7.57,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL562780,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5cccnc5)[C@@H]4O)[C@@H]3CC[C@@H]12,7.21,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL563341,CN1CC[C@@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,6.6,group3-int,int,Androgen Receptor,Binding affinity to androgen receptor,2009
CHEMBL563597,CNc1ncc(/C=C2\C[C@H]3[C@@H]4CC[C@H]5N(C)C(=O)C=C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2O)cn1,7.51,group2-a,a,Androgen Receptor,Displacement of [3H]methyltrienolone from androgen receptor in human MDA-MB-453 cells,2009
CHEMBL570708,Cc1c(C#N)c(Cl)nc2c3c(sc12)NC(=O)CC3c1ccccc1Cl,5.7,group4-ia,ia,Androgen Receptor,Binding affinity to androgen receptor,2009
CHEMBL570897,O=[N+]([O-])c1ccc(N2CCCC2)c2ccccc12,8.6,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL570898,N#Cc1ccc(N2CCCC2)c2ccccc12,8.6,group1-p,p,Androgen Receptor,Displacement of [3H]mibolerone from androgen receptor (unknown origin) after 3 hrs,2015
CHEMBL589158,Cc1cccc(SCc2cc(=O)oc3cc(O)ccc23)n1,4.3,group4-ia,ia,Androgen Receptor,Antagonist activity at AR by reporter gene assay,2010
CHEMBL591628,CCOc1cc(C2Nc3cccc4cccc(c34)N2)ccc1O,4.96,group4-ia,ia,Androgen Receptor,Inhibition of human AR AF2 site expressed in human LNCap cells coexpressing eGFP -ARR2PB assessed as inhibition of transcriptional activity,2011
CHEMBL592043,O=c1oc2cc(O)ccc2c(C(F)(F)F)c1Cc1ccccc1,5.22,group4-ia,ia,Androgen Receptor,Antagonist activity at AR by reporter gene assay,2010
CHEMBL594854,COc1ccccc1/C=C/C(=O)c1ccccc1O,5.46,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,2018
CHEMBL62227,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(C#N)cc1-3,7.22,group2-a,a,Androgen Receptor,Inhibition of antagonist activity towards Androgen receptor,2003
CHEMBL62700,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/Br)Oc1ccc(F)cc1-3,6.6,group3-int,int,Androgen Receptor,Antagonist activity against Androgen receptor,2003
CHEMBL62761,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(Br)cc1-3,7.05,group2-a,a,Androgen Receptor,Inhibition of antagonist activity towards Androgen receptor,2003
CHEMBL62981,CC/C(C)=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,6.6,group3-int,int,Androgen Receptor,Antagonist activity against human Androgen receptor,2003
CHEMBL63560,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,6.57,group3-int,int,Androgen Receptor,Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method,2008
CHEMBL63788,CC1CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(F)cc1-3,6.83,group3-int,int,Androgen Receptor,Inhibition of antagonist activity towards human androgen receptor,2003
CHEMBL63870,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(Br)cc1-3,6.4,group3-int,int,Androgen Receptor,Inhibition of antagonist activity towards Androgen receptor,2003
CHEMBL64123,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(Cl)cc1-3,6.1,group3-int,int,Androgen Receptor,Inhibition of antagonist activity towards Androgen receptor,2003
CHEMBL64294,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc([N+](=O)[O-])cc1-3,7.22,group2-a,a,Androgen Receptor,Inhibition of antagonist activity towards Androgen receptor,2003
CHEMBL65021,COc1cccc2c1-c1ccc(NS(C)(=O)=O)cc1C(c1ccccc1)O2,5.18,group4-ia,ia,Androgen Receptor,Displacement of [3H]mibolerone from human Androgen receptor,2004
CHEMBL65079,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(F)cc1-3,5.9,group4-ia,ia,Androgen Receptor,Inhibition of antagonist activity towards Androgen receptor,2003
CHEMBL65221,CS(=O)(=O)Nc1ccc2c(c1)C(c1ccccc1)Oc1cccc(OC(F)F)c1-2,5.06,group4-ia,ia,Androgen Receptor,Displacement of [3H]mibolerone from human Androgen receptor,2004
CHEMBL6530,CCC1CCN(C)c2cc3oc(=O)cc(C(F)(F)F)c3cc21,6.56,group3-int,int,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL65743,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(Cl)cc1-3,6.37,group3-int,int,Androgen Receptor,Inhibition of antagonist activity towards human Androgen receptor,2003
CHEMBL65929,CC1=CC(C)(C)Nc2ccc3c(c21)C(=C1SCCCS1)Oc1ccc(F)cc1-3,6.75,group3-int,int,Androgen Receptor,Antagonist activity against human Androgen receptor,2003
CHEMBL6654,CCC1Nc2cc3oc(=O)cc(C(F)(F)F)c3cc2CC1C,8.15,group1-p,p,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL66761,O=c1[nH]nc(Cc2ccccc2)c2ccccc12,5.27,group4-ia,ia,Androgen Receptor,Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay,2015
CHEMBL6689,CC[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2CC1(C)C,7.38,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL6721,CCC1CC(CC)c2cc3c(C(F)(F)F)cc(=O)oc3cc2N1,8.15,group1-p,p,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL6843,CCC1CCNc2cc3oc(=O)cc(C(F)(F)F)c3cc21,9,group1-p,p,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL6855,CCCC1CCNc2cc3oc(=O)cc(C(F)(F)F)c3cc21,8.3,group1-p,p,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL6874,CC1(C)CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,7.57,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,1998
CHEMBL6983,C[C@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1C,7.48,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL70381,Cc1c(NS(C)(=O)=O)cccc1N(Cc1ccccc1)Cc1ccc(Cl)cc1F,6.52,group3-int,int,Androgen Receptor,Displacement of [3H]dexamethasone from human androgen receptor,2004
CHEMBL7058,C[C@@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1C,7.13,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL7089,CC[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2C[C@H]1C,7.82,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL717,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,8.21,group1-p,p,Androgen Receptor,Inhibition of human androgen receptor at 10e-12 to 10e-5 M,2003
CHEMBL7177,CC[C@@H]1CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,7.96,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL7289,CC1(C)CCc2cc3c(C(F)(F)F)cc(=O)oc3cc2N1,9,group1-p,p,Androgen Receptor,In vitro binding affinity at human androgen receptor transfected into COS cells.,1999
CHEMBL7373,CC[C@@H]1C[C@H](C)c2cc3c(C(F)(F)F)cc(O)nc3cc2N1,6.86,group3-int,int,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL7455,CC[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2C[C@@H]1C,7.96,group2-a,a,Androgen Receptor,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,1999
CHEMBL75897,O=C1CC(c2ccccc2O)Oc2ccccc21,5.19,group4-ia,ia,Androgen Receptor,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced cell growth treated for every 2 days for 4 days by hemocytometry,2018
CHEMBL806,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,5.7,group4-ia,ia,Androgen Receptor,Antiandrogenic activity in human MDA-MB-453 cells expressing androgen receptor assessed as inhibition of DHT-induced androgen-dependent transcription by luciferase reporter gene assay,2009
CHEMBL9337,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)N1CCCCO,7.51,group2-a,a,Androgen Receptor,Antagonist activity at human androgen receptor expressed in MDA-MB-453 cells,2007
